

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis - An OA Trial Bank protocol for a systematic review and individual patient data meta-analysis

| | |
|-------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2019-035302 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 27-Oct-2019 |
| Complete List of Authors: | Jin, Xingzhong; Southern Medical University, Zhujiang Hospital; The University of Sydney, The Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders Antony, Benny; University of Tasmania, Menzies Institute for Medical Research Wang, Xia; The University of Sydney, Institute of Bone and Joint Research Persson, Monica; University of Nottingham Faculty of Medicine and Health Sciences McAlindon, Timothy; Tufts Medical Center, Arden, Nigel; Nuffield Department of Orthopaedics, ; Srivastava, Sudeepti; King George Medical College Srivastava, Rajeshwar; King George Medical University van Middelkoop, Marienke; Erasmus MC Bierma-Zeinstra, Sita; Erasmus MC Zhang, Weiya; University of Nottingham, Academic Rheumatology Cicuttini, Flavia; Monash University, Department of Epidemiology and Preventative Medicine Ding, Changhai; University of Tasmania, Menzies Institute for Medical Research |
| Keywords: | PREVENTIVE MEDICINE, RHEUMATOLOGY, GENERAL MEDICINE (see Internal Medicine) |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis

An OA Trial Bank protocol for a systematic review and individual patient data meta-analysis

Xingzhong Jin^{1,2}, Benny Antony³, Xia Wang⁴, Monica SM Persson^{5,6}, Timothy McAlindon⁷, Nigel Arden⁸, Sudeepti Ratan Srivastava⁹, Rajeshwar Nath Srivastava⁹, Marienke van Middelkoop¹⁰, Sita Biermsa-Zeinstra¹⁰, Weiya Zhang^{5,6}, Flavia Cicuttini¹¹, Changhai Ding^{1,3,11}.

Author Affiliations

¹ ZhuJiang Hospital, Southern Medical University, China

² The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, the University of Sydney, Australia.

³ Menzies Institute for Medical Research, University of Tasmania, Australia.

⁴ Institute of Bone & Joint Research, the University of Sydney, Australia.

⁵ Academic Rheumatology, Division of Rheumatology, Orthopaedics, and Dermatology, University of Nottingham, United Kingdom.

⁶ Arthritis Research UK Pain Centre, United Kingdom.

⁷ Tufts Medical Center, United States.

⁸ Nuffield Department Orthopaedic, Rheumatology and musculoskeletal sciences, University of Oxford, United Kingdom.

⁹ King George Medical University, India.

¹⁰ Erasmus MC, University Medical Center Rotterdam, Netherland.

¹¹ Department of Epidemiology and Preventive Medicine, Monash University, Australia

Correspondence to

Xingzhong Jin, The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, Level 2 Charles Perkins Centre (D17), John Hopkins Drive, The University of Sydney, NSW 2006, Australia; xingzhong.jin@sydney.edu.au.

Keywords

Systematic Review; Meta-analysis; Individual Patient Data; Osteoarthritis; Vitamin D; Knee.

Abstract

Introduction

Observational data suggest vitamin D deficiency is associated with the onset and progression of knee osteoarthritis (OA). Vitamin D supplementation may be a promising cost-effective treatment. However, randomized clinical trials (RCTs) to date investigating the efficacy of vitamin D supplementation in knee OA have reported conflicting results. Recent systematic reviews with aggregate data from these RCTs suggest that further research is needed to clarify the effects on patient-reported outcomes and determine whether there are OA patient subgroups who may benefit from vitamin D. The aim of this study is to identify patient-level predictors of treatment response to vitamin D supplementation on pain and physical function. A systematic literature search will be conducted for RCTs comparing vitamin D supplementation with other control treatments in individuals with knee OA. Authors of original trials will be contacted to obtain individual patient data (IPD) from each study.

Methods and analysis

The primary outcomes will include long-term (≥ 12 months) pain and physical function. Secondary outcomes will include medium-term (≥ 6 months and < 12 months) and short-term (< 6 months) pain and physical function, as well as patient global assessment and quality of life. Potential treatment effect modifiers to be examined in the subgroup analyses include age, gender, body mass index, baseline knee pain severity and physical function, baseline vitamin D level, radiographic stage, presence of bone marrow lesions on MRI, presence of clinical signs of local inflammation, and concomitant depressive symptoms. Both one-step and two-step modelling methods will be used to determine the possible modifiable effect of each subgroup of interest.

Discussion

This study will be the first meta-analysis of vitamin D supplementation for knee OA using IPD from RCTs. This study will clarify the effect of vitamin D supplementation on clinical symptoms in different subgroups of patients with knee OA.

Systematic review registration

This systematic review is registered on PROSPERO (CRD42018107740).

Article Summary

This article is a protocol for a systematic review and IPD meta-analysis of RCTs studying the effects of vitamin D supplementation on joint pain and physical function in patients with symptomatic knee OA.

Strengths and limitations of this study

- This study protocol is endorsed by the OA Trial Bank, an international collaboration that initiates meta-analyses on predefined subgroups of OA patients.
- This study is the first IPD meta-analysis to identify OA patient subgroups that may benefit from vitamin D supplementation.
- IPD meta-analysis offer greater statistical power and precision than subgroup analysis in a single trial and conventional meta-analysis using aggregate data.
- Analysis may be limited to the variables that have been collected across included RCTs.

Introduction

Osteoarthritis (OA) is the most common joint disorder worldwide. OA is ranked as the 13th highest contributor of 310 diseases to global disability in 2015¹. In Australia, OA affects over 2.1 million people (9% of the population), costing the healthcare system over \$2.1 billion in 2015². This cost is forecasted to increase by 41% in 2030³.

Knee OA accounts for 83% of the disease burden of OA⁴ and is characterized by pain, gradual loss of articular cartilage, and structural changes such as subchondral remodelling and effusion-synovitis⁵. Currently, there are no effective disease-modifying treatments to reverse the progression of knee OA once the disease is established. A majority of patients with knee OA eventually progress to advanced stage and undergo total knee replacement⁶. There is clearly an urgent need for innovative and cost-effective approaches to slow the progression of knee OA.

Emerging observational data suggest that vitamin D insufficiency is associated with the onset and progression of knee OA⁷. The association between low serum vitamin D levels and knee OA symptoms may be explained by a direct effect of vitamin D on chondrocytes in osteoarthritic cartilage⁸, as well as indirect effects on subchondral bone, synovium, and periarticular muscle⁹. For example, vitamin D deficiency could impair the ability of bone to respond optimally to pathological bone marrow lesions (BMLs) and altered bone mineral density, therefore predisposing the knees to disease progression¹⁰. Vitamin D also may reduce synovitis in affected knees by regulating cytokine levels in the joint, leading to a reduction in the amount of effusion-synovitis in magnetic resonance images (MRI)¹¹. In addition, depressive symptoms is interrelated to joint pain in OA¹², and maintaining sufficient serum vitamin D may improve depression symptoms in patients with knee OA¹³.

However, evidence from randomized controlled trials (RCTs) have been conflicting¹⁴⁻¹⁷. A pilot RCT in India found a small but statistically significant clinical benefit for 12-month vitamin D treatment on pain and function in patients with knee OA, compared with placebo¹⁶. In contrast, a subsequent RCT from the US showed that vitamin D supplementation did not reduce knee pain or cartilage volume loss over 24 months¹⁵. Subsequently, data from RCTs in Australia¹⁷ and UK¹⁴ did not find significant clinical benefits of vitamin D supplementation for knee OA. However, a there was a non-significant trend of symptom reduction (e.g. knee pain and physical function) in these RCTs. Two systematic reviews of aggregate data from these RCTs concluded that, although current evidence does not support vitamin D supplementation for reducing structural disease progression, further research is needed to clarify the effects on patient-reported outcomes^{18,19}.

1
2
3 The null results of these RCTs could be due to a low prevalence of vitamin D deficiency in the
4 study subjects or low statistical power secondary to small sample sizes. Another possible
5 reason is that vitamin D may have an effect only in some OA phenotypes, such as those with
6 BMLs (predominant bone abnormality)²⁰, effusion-synovitis (inflammatory)²¹ or depressive
7 symptoms (psychological distress)¹³. Post hoc analyses within these RCTs were frequently
8 underpowered, and hence unreliable to determine the effect of vitamin D treatment on
9 subgroups of knee OA patients. A meta-analysis using individual patient data (IPD) can
10 increase the power by combining individual trials²² and hence can quantify the vitamin D
11 treatment effects in these subgroups.
12
13
14
15
16
17
18

19 **Methods and analysis**

20 We will conduct a systematic review and IPD meta-analysis of RCTs studying the effects of
21 vitamin D supplementation in patients with symptomatic knee OA. The primary aim is to
22 identify patient-level predictors of treatment response to vitamin D supplementation, including
23 the status of vitamin D deficiency, MRI-detected bone marrow abnormalities and effusion-
24 synovitis, and clinical signs of local inflammation. The protocol of this review is registered on
25 the PROSPERO database (CRD42018107740).
26
27
28
29
30

31 **Literature search**

32 A systematic literature search for articles published from January 1990 until November 2019
33 will be performed in the following electronic databases:
34
35

- 36 • Cochrane Central Register of Controlled Trials (CENTRAL);
- 37 • MEDLINE (Ovid);
- 38 • EMBASE;

39 The search strategies used for each database are listed in *Appendix 1*. All retrieved articles will
40 be exported to the reference manager *EndNote*, in which duplicates will be removed. The
41 remaining records will be exported to an online systematic review management tool *Covidence*
42 (*Veritas Health Innovation, Melbourne, Australia*) and the articles will be assessed for
43 eligibility for inclusion. In addition to the electronic search, we will check the reference lists
44 of included trials and previous systematic reviews to identify any trials that are not retrieved
45 from the electronic search. Review authors and collaborating authors will be asked if they are
46 aware of further relevant studies not yet included. We will also search the WHO International
47 Clinical Trial Registration Platform Search Portal (www.who.int/trialsearch) to identify any
48 relevant trials that are completed but did not published the results.
49
50
51
52
53
54
55
56
57
58
59
60

Study selection

Two review authors (XJ, BA) will independently conduct study screening by assessing the article titles and abstracts. Full texts of the articles will be further assessed if the information from the abstract suggests that a study is eligible for inclusion. When information contained in the full text is not sufficient to make a judgement on its eligibility, we will make efforts to contact the corresponding authors to obtain further details. If a corresponding author is not contactable after two email attempts and one phone call, the study will be deemed ineligible. Any disagreement regarding the inclusion of a study will be discussed between the two review authors (XJ, BA). If no consensus can be reached, a third review author will be consulted (XW) to make a final decision.

Type of studies

Published RCTs that reported the efficacy of vitamin D in participants with knee OA will be included. Cross-over design will also be eligible and only the first phase data will be included in the analysis. Both open-labelled and blinded studies will be eligible. There will be no language or geographical restrictions applied to study selection.

Participants

Men and women who have a diagnosis of knee OA, either according to the American College of Rheumatology criteria, or on the basis of detailed clinical and/or radiographic information, will be included. Studies with a subgroup of knee OA patients will also be included, provided that IPD can be collected separately for the OA subgroup.

Interventions

Only studies investigating oral supplementation of vitamin D will be included. Vitamin D treatments administered subcutaneously, intraperitoneally or intravenously will not be included. Both ergocalciferol (vitamin D₂) and cholecalciferol (vitamin D₃) will be eligible, irrespective of preparations (tablet or capsule), dosage, regimen, and length of treatment.

Comparators

Oral vitamin D supplementation will be compared with control treatment including placebo or usual conservative care (pain medication and/or exercise therapy if they are used in both treatment and control groups).

Outcomes

The minimum criterion for inclusion of trial in the systematic review is reporting pain or physical function as either primary or secondary outcomes. There will be no restrictions on the

1
2
3 duration of follow-up. Data on other outcomes (e.g. patient's global assessment, quality of life,
4 and adverse events) will be analysed when feasible but will not be required for study selection.
5
6

7 **Baseline assessments**

8 As a minimum, included studies should have measured knee pain, physical function, serum
9 levels of vitamin D, and basic patient characteristics including age, gender, and body mass
10 index (BMI) at baseline.
11
12

13 **Extraction of aggregate data**

14 Study data extraction will be performed independently by two review authors (BA, XW).
15 Discrepancies will be resolved by a third reviewer (XJ). We will extract the following study
16 data from the included studies:
17
18
19

- 20 • General information: article title, bibliographic details, published language, and
21 funding source.
- 22 • Participants: inclusion criteria, exclusion criteria, number of participants in total and in
23 each study arm, study settings, and baseline participant characteristics (e.g. age, gender,
24 BMI).
- 25 • Intervention: type of vitamin D preparation, dose, regimen, treatment duration, type of
26 control, and co-interventions (if any).
- 27 • Outcomes: primary and secondary outcomes at the end of treatment and/or the end of
28 follow-up. Number of withdrawals and loss to follow-up. Adverse events recorded.
- 29 • Data analysis: statistical models used for data analysis, confounding factors adjusted in
30 the models, and methods used for addressing missing values.

31 **Risk of bias assessment**

32 The methodological quality of the included studies will be assessed using a modified version
33 of the Cochrane's risk of bias tool²³. The modified version includes all the seven domains of
34 the original tool, but further separates performance bias assessment into 'blinding of
35 participants' and 'blinding of study personnel', as well as pre-specifies other sources of bias as
36 'balance in baseline covariates', 'treatment compliance', and 'timely outcome assessment'
37 (Table 1). Each domain will be scored as 'low risk', 'high risk' or 'unclear' according to the
38 criteria described in the Appendix 2. The overall rating of study quality is based on the number
39 of domains with a 'high-risk' score. The overall rating is intended to inform readers of the
40 study quality and will not be used to weight the studies in the meta-analysis. Two review
41 authors (XJ, XW) will independently evaluate the quality of an individual study. Any
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 disagreement will be settled by further discussion until a consensus is reached between the two
4 review authors.
5

6 7 **IPD collection and transfer**

8 The primary or corresponding authors of included trials will be invited to collaborate on the
9 project and contribute their raw data. When we cannot reach a corresponding author after
10 sending two emails and making two telephone calls, we will contact the co-authors listed in
11 the article. If none of the co-author can be contacted, we will approach the institutes, in which
12 the trial has been conducted. All data custodians will be asked to sign a data delivery
13 agreement, which includes items regarding IPD delivery, obligations, ownership of data, terms
14 and conditions of the use of the data, authorship, and publications. If needed, the project
15 coordinator (XJ) will visit the institutes of the data deliverers to retrieve the data and to sign
16 the data delivery agreement on behalf of the OA Trial Bank. De-identified datasets will be
17 accepted in any electronic format (for example, SPSS, Stata, SAS, Excel) or in paper form,
18 provided that variables and categories are adequately labelled within the dataset or within a
19 separate codebook. The IPD files received by the coordinator will be kept in their original
20 version and saved on a secured password-protected server at Erasmus MC Medical University
21 in Rotterdam. The datasets will not be used for any other research apart from that described in
22 the license agreement.
23
24
25
26
27
28
29
30
31
32
33

34 To ensure the quality of the data, the coordinator will independently check for data consistency
35 by comparing the summary statistics derived from the IPD received against the summary
36 results reported in the published articles. In the case of differences, the project coordinator will
37 communicate with the data deliverer via email or teleconference to resolve the discrepancy.
38
39
40
41

42 **Variables of interest**

43 The following IPD variables will be obtained (where available):

44 **Primary outcome variables**

45 The primary outcomes for this meta-analysis will be pain and physical function at long-term
46 follow-up (12 months or more).
47
48
49

- 50
51 • Knee pain will be evaluated using visual analogue scale (VAS) if available, otherwise the
52 pain subscales of the Western Ontario and McMaster Universities Osteoarthritis Index
53 (WOMAC)²⁴ or the Knee injury and Osteoarthritis Outcome Score (KOOS)²⁵ will be used.
54 The pain data will be converted into a 0-100 common scale as recommended by the
55 WOMAC manual²⁶.
56
57
58
59
60

- 1
2
3
4
5
6
7
8
- Physical function will be evaluated using a validated instrument specific to knee OA, such as the physical function subscales of the WOMAC or the KOOS subscales. The scores will be standardised into a 0-100 scale.

9 **Secondary outcome variables**

10 Secondary outcomes will include:

- 11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- Medium-term (more than 6 months but less than 12 months) pain and physical function;
 - Short-term (less than 6 months) pain and physical function;
 - Patient global assessment at the end of study follow-up, as recommended by the OMERACT-OARSI Initiative²⁷.
 - Quality of life evaluated using a validated instrument, such as EQ-5D²⁸, osteoarthritis Knee and Hip Quality of Life (OAKHQOL)²⁹, or original instrument used in the included studies;
 - Adverse events if reported, including all major and minor events such as hypocalcaemia, fractures, and depression.

29 **Potential treatment effect moderators**

30 If data are available, we will analyse potential treatment effect modification for the following
31 variables measured at baseline:

- 32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Radiographic stage of knee OA (mild/moderate or severe). Radiographic knee OA should be staged at baseline using either the Kellgren-Lawrence (KL)³⁰ or Osteoarthritis Research Society International (OARSI) joint space narrowing (JSN) grading system³¹. The results from the two grading systems have been shown to be highly correlated³². Mild to moderate disease will be defined as a KL score ≤ 3 or an OARSI JSN score ≤ 2 , and severe disease will be a KL score of 4, or an OARSI score of 3.
 - Vitamin D level (deficiency, insufficiency, or sufficiency). Vitamin D deficiency is defined as serum levels of 25(OH)D less than 30 nmol/L at baseline. Insufficiency is defined as serum 25(OH)D levels from 30 to <50 nmol/L. Serum 25(OH)D levels ≥ 50 nmol/L is considered as vitamin D sufficiency³³.
 - Presence of BMLs (yes or no). BMLs at the patella-femoral and femoro-tibial joints should be measured by MRI using a validated scoring system, such as BLOKS (Boston Leeds Osteoarthritis Knee Score)³⁴, WORMS (Whole-Organ Magnetic Resonance Imaging Score)³⁵, or KOSS (Knee Osteoarthritis Scoring System)³⁶.

- Clinical signs of local inflammation or the presence of effusion-synovitis (yes or no). Clinical signs of local inflammation should be assessed by physical examination - tumor (swelling), dolor (pain), rubor (redness), calor (heat), and functio laesa (disturbance of function) - or by additional laboratory testing (e.g. serum c-reactive protein and erythrocyte sedimentation rate). Effusion-synovitis should be measured on either ultrasound or MRI.
- Presence of depressive symptoms or comorbid depression. Depressive symptoms are measured using a validated questionnaire, such as the Patient Health Questionnaire (PHQ-9)³⁷ and the Geriatric Depression Scale (GDS)³⁸.

Statistical analysis

All statistical analysis will be conducted in R version 3.3.2 and RStudio (version 1.0.136, RStudio, Inc., Boston, MA).

Conventional meta-analysis

An aggregate data meta-analysis, using a random-effects model, will be performed to estimate the treatment effect of vitamin D over control. The results will be compared with the IPD meta-analysis findings as sensitivity analyses.

Heterogeneity will be assessed by inspecting the forest plots. In addition, heterogeneity will be tested by both Chi^2 test and I^2 test. A result of $\text{Chi}^2 > 25\%$ and $p < 0.10$ will be defined as evidence of significant heterogeneity across studies. I^2 test will be used to estimate the extent of variability across studies that is due to heterogeneity. A result of over 30% and 50% represents moderate and substantial heterogeneity, respectively. Sources of heterogeneity will be explored by excluding individual trials causing an I^2 score below 50%.

If 10 trials or more trials are available³⁹, funnel plots of treatment effect against its standard error will be used to explore publication bias and 'small-study effects'. Asymmetry in the funnel plots will imply possible small-study effects. A modified 'Egger' regression test will be conducted to detect such asymmetry. $P < 0.10$ will be deemed to have considerable small-study effects.

IPD meta-analysis

IPD from included trials will be recoded and formatted in a consistent way to permit re-analysis. A new variable will be created to indicate the trial in which the IPD are collected. The method used to handle missing data will depend on the mechanism causing the missingness. If no explanation is known for the reason of missing data, they will be assumed to be missing at random. We will use the R MICE package⁴⁰ for multiple imputation and the

1
2
3 imputation model will include all available patient variables to help predict missing data for
4 the variables of interest within each study dataset. The imputation procedure will use 20
5 imputed datasets. A sensitivity analyses will be performed restricting to participants without
6 missing data (complete case analysis).
7
8
9

10 Both the treatment effect of vitamin D supplementation and the effect of potential moderators
11 will be studied in the IPD meta-analyses. The treatment effect of vitamin D will be measured
12 using the mean difference in knee pain and physical function between treatment and control
13 based on the intention-to-treat principle. The interaction between the treatment and a potential
14 moderator will be used to identify the effect of the moderator. Interaction effects with $P < 0.05$
15 will be considered statistically significant. The IPD meta-analyses will be undertaken using
16 both the one-stage and two-stage approaches. We will use the one-stage approach as the
17 primary analysis to avoid assumption of within-study normality and known within-study
18 variance⁴¹. We will and compare the results to the two-stage approach to assess consistency in
19 a sensitivity analysis.
20
21
22
23
24
25
26
27

28 ***One-stage modelling***

29 The one-stage mixed-effects IPD meta-analysis approach will take into account both study
30 level and subject-level covariates. Subject -level covariates will be centred to the mean of the
31 covariate in each trial to avoid ecological bias. Two multilevel regression models will be built,
32 one to examine the summary treatment effect (difference between vitamin D and control) and
33 the other to evaluate different moderators on treatment effect.
34
35
36
37

38 The first model will include outcome measure (e.g. pain score at follow-up) as a dependent
39 variable, treatment (vitamin D or control), baseline subject-level covariate (e.g. pain score) and
40 confounders (age, gender and BMI) as fixed-effect independent variables, adjusted for study
41 identifier (random intercept). The partial regression coefficient of the treatment will be used to
42 compare to the conventional meta-analysis.
43
44
45
46
47

48 The second model will further add the moderator of interest (e.g. radiographic stage of the
49 disease) and interaction term between the treatment and study-centred values of the moderator
50 in the fixed-effect of the first model. The regression coefficient of the interaction term will be
51 used to quantify the impact of the moderator on treatment effect.
52
53
54

55 ***Two-stage modelling***

56 In the first stage, treatment effect and variance are derived from separate analysis in each study.
57 An analysis of covariance (ANCOVA) model adjusted for baseline covariates (age, gender,
58
59
60

1
2
3 BMI, as well as knee pain or function), will be used to obtain the treatment effect and variance
4 within each study separately. The effect of a moderator and its variance within each study will
5 be obtained by adding the interaction term between treatment effect and the moderator into the
6 model. In the second stage, the treatment effect and its variances obtained from the first stage
7 will be pooled across studies using a fixed-effect model based on the inverse-variance
8 approach. The result of this model is a summary estimate of the treatment effect of vitamin D
9 versus control. The effect of a moderator will be calculated by pooling the regression
10 coefficient and variance of the interaction term between the treatment and the moderator using
11 a similar model.
12
13
14
15
16
17
18

19 **Discussion**

20 Vitamin D supplementation may improve pain and function in patients with knee OA; however,
21 the evidence from observational studies and RCTs are controversial^{7,18}. In a few existing RCTs
22 in patients with symptomatic knee OA^{27,14,16,17}, small to modest improvement in knee pain and
23 physical function were observed in participants receiving vitamin D supplementation, but the
24 treatment response varies considerably and the effects were not statistically significant when
25 compared to placebo. The broad variation in treatment response could be a result of the fact
26 that knee OA is a highly heterogenous disease with multiple aetiologies. Vitamin D may
27 therefore be more effective in a subset of patients with specific characteristics than others. The
28 purpose of the proposed IPD meta-analysis is to evaluate the treatment response of vitamin D
29 supplementation on pain and physical function for knee OA in specific subsets of patients
30 according to disease severity, vitamin D levels, presence of BMLs, inflammatory signs and
31 depressive symptoms, over both short- and long-term follow-up.
32
33
34
35
36
37
38
39
40
41

42 An IPD meta-analysis is an integrated part of precision medicine⁴². It is a cost-effective
43 approach to identify potential moderators of treatment response at a patient level, which is not
44 possible with subgroup analyses in a single trial or conventional meta-analysis with aggregate
45 data. Subgroup analyses within individual trials are often underpowered to generate reliable
46 findings. In contrast, IPD meta-analysis techniques increase the statistical power of the study
47 by combining multiple trials with the same treatment. This offers greater precision in analysing
48 moderators of treatment response and offers the potential to analyse a greater number of
49 moderators. In conventional meta-analysis, meta-regression analysis may be used to examine
50 differences in the types of patients enrolled in individual trials, but is potentially problematic.
51 Meta-regression analysis may make incorrect inferences about individual characteristics based
52 upon aggregate baseline statistics reported in trial publications. This is also known as
53
54
55
56
57
58
59
60

1
2
3 ecological fallacy, where the relationship between the effect estimate and average patient
4 characteristics across trials may not be the same as the relationship within individual trials.
5
6

7 Identifying different phenotypes of knee OA is currently a popular subject of research in the
8 field. Different phenotyping strategies have been proposed based on risk factors from
9 epidemiological studies⁴³, anatomical abnormalities on modern imaging⁴⁴, or molecular
10 abnormalities related to pathological mechanisms⁴⁵. While there is currently no standardised
11 classification system for knee OA phenotypes⁵, we believe that disease phenotypes are most
12 meaningful when they reflect differential treatment effects. IPD meta-analysis provides an
13 opportunity to assess the effect of treatments on subtypes or phenotypes of patients with knee
14 OA according to predefined set of characteristics. The current proposed IPD meta-analysis
15 attempts to differentiate subgroups by identifying subtypes of patients that respond better to
16 vitamin D supplementation on pain and physical function.
17
18
19
20
21
22
23
24

25 **Strengths and limitations**

26 Several challenges may present when conducting an IPD meta-analysis. First, although IPD
27 meta-analyses usually offer sufficient statistical power to examine moderators of treatment
28 response, not all RCTs measure potential moderators of interest or measure them in the same
29 way. This may limit the analysis to only exploring moderators that have been collected across
30 studies. The current protocol attempts to minimise this risk by including moderators that are
31 commonly reported in OA research. In addition, there are expected barriers to accessing data,
32 such as the authors of included trials not being able to be contacted, or the authors losing access
33 to raw data or not choosing to collaborate, may introduce selection bias into the IPD meta-
34 analysis. However, this will be examined in sensitivity analyses by comparing the results to
35 the conventional meta-analysis.
36
37
38
39
40
41
42
43

44 The benefits of using IPD meta-analysis techniques greatly outweigh the challenges of using
45 this intensive method. Previous RCTs and systematic reviews have not had sufficient power to
46 thoroughly examine the differential treatment response of vitamin D supplementation in
47 different subsets of patients with knee OA.
48
49
50

51 The results of this project have a high potential to provide important evidence to guide
52 subgroup-specific treatment decisions in clinical practice to improve therapeutic effectiveness.
53
54

55 **Status of project**

56 Currently, literature search in the electronic databases has been commenced.
57
58
59
60

Abbreviations

OA: osteoarthritis; IPD: individual patient data; RCT: randomised controlled trial; BMI: body mass index; MRI: magnetic resonance imaging; BMLs: bone marrow lesions; JSN: joint space narrowing; OARSI: Osteoarthritis Research Society International.

For peer review only

Additional Information

Acknowledgement

We acknowledge the University of Sydney China Study Centre for providing short-term travel support to establish international collaboration for this project.

Ethics approval and consent to participate

Research ethical or governance approval is exempt for this study as no new data are being collected.

Consent for publication

All authors have given consent for publication of the manuscript.

Availability of data and material

Not applicable.

Authors contributions

All authors were involved in the study design and all will contribute to the interpretation of the results. CD, BA and XJ conceived this study. WZ and MP provided methodological support for statistical analysis. XJ and BA will contact the potential data delivers and will coordinate the project. CD, TM, NA and RNS will deliver relevant data from their completed trials. SBZ and MM will facilitate legal agreement for data transfer and provide database management at the OA Trial Bank. XJ, BA and XW will perform the study selection, risk of bias assessment, data collection and analysis. All authors contributed to writing of this manuscript and approved the final submission.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors declare that they have no competing interests.

Patient and public involvement

We do not directly include patient and public involvement in this study, but the design of included randomised controlled trials may involve patients.

Word count

Abstract: 294

Main text: 3718

References: 45

References

1. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* 2016;388(10053):1545–602.
2. Australian Bureau of Statistics. 2014-15 National Health Survey. Canberra: Australian Bureau of Statistics; 2017.
3. Ackerman IN, Pratt C, Gorelik A, Liew D. Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population-Level Analysis. *Arthritis Care Res* 2018;70(6):877–83.
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012;380(9859):2163–96.
5. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for Standardized Definitions of Osteoarthritis and Risk Stratification for Clinical Trials and Clinical Use. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2015;23(8):1233–41.
6. Australian Orthopaedic Association National Joint Replacement Registry. Annual Report 2012. Adelaide, Australia: AOA; 2012.
7. Cao Y, Winzenberg T, Nguo K, Lin J, Jones G, Ding C. Association between serum levels of 25-hydroxyvitamin D and osteoarthritis: a systematic review. *Rheumatology* 2013;ket132.
8. Garfinkel RJ, Dilisio MF, Agrawal DK. Vitamin D and Its Effects on Articular Cartilage and Osteoarthritis. *Orthop J Sports Med* [Internet] 2017 [cited 2018 Oct 12];5(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480771/>
9. Zhang FF, Driban JB, Lo GH, et al. Vitamin D Deficiency Is Associated with Progression of Knee Osteoarthritis. *J Nutr* 2014;144(12):2002–8.
10. Bellido M, Lugo L, Roman-Blas JA, et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. *Osteoarthritis Cartilage* 2011;19(10):1228–36.
11. Wang X, Cicutinni F, Jin X, et al. Effect of vitamin D on effusion-synovitis in knee osteoarthritis: a randomized controlled trial. *Arthritis Rheumatol* 2015;67:439–40.
12. Sharma A, Kudesia P, Shi Q, Gandhi R. Anxiety and depression in patients with osteoarthritis: impact and management challenges. *Open Access Rheumatol Res Rev* 2016;8:103–13.
13. Zheng S, Tu L, Cicutinni F, et al. Effect of Vitamin D Supplementation on Depressive Symptoms in Patients With Knee Osteoarthritis. *J Am Med Dir Assoc* 2018;

14. Arden NK, Cro S, Sheard S, et al. The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial. *Osteoarthritis Cartilage* 2016;24(11):1858–66.
15. McAlindon T, LaValley M, Schneider E, et al. Effect Of Vitamin D Supplementation On Progression Of Knee Pain And Cartilage Volume Loss In Patients With Symptomatic Osteoarthritis. A Randomized Controlled Trial. *JAMA J Am Med Assoc* 2013;309(2):155–62.
16. Sanghi D, Mishra A, Sharma AC, et al. Does Vitamin D Improve Osteoarthritis of the Knee: A Randomized Controlled Pilot Trial. *Clin Orthop Relat Res* 2013;471(11):3556–62.
17. Jin X, X J, G J, et al. Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial. 2016; Available from: <http://doi.org/10.1001/jama.2016.1961>
18. Hussain S, Singh A, Akhtar M, Najmi AK. Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials. *Rheumatol Int* 2017;37(9):1489–98.
19. Diao N, Yang B, Yu F. Effect of vitamin D supplementation on knee osteoarthritis: A systematic review and meta-analysis of randomized clinical trials. *Clin Biochem* 2017;50(18):1312–6.
20. Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. *Radiol Clin* 2004;42(1):1–9.
21. Wang X, Cicuttini F, Jin X, et al. Knee effusion-synovitis volume measurement and effects of vitamin D supplementation in patients with knee osteoarthritis. *Osteoarthritis Cartilage* 2017;25(8):1304–1312.
22. Groenwold RHH, Donders ART, Heijden GJMG van der, Hoes AW, Rovers MM. Confounding of Subgroup Analyses in Randomized Data. *Arch Intern Med* 2009;169(16):1532–4.
23. Jørgensen L, Paludan-Müller AS, Laursen DRT, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. *Syst Rev [Internet]* 2016 [cited 2018 Oct 11];5. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862216/>
24. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. *Arthritis Care Res* 2001;45(5):453–61.
25. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) - validation and comparison to the WOMAC in total knee replacement. *Health Qual Life Outcomes* 2003;1:17.
26. Bellamy N. WOMAC osteoarthritis index: user guide IV. 2000.

- 1
- 2
- 3
- 4 27. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2004;12(5):389–99.
- 5
- 6
- 7
- 8 28. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res* 2013;22(7):1717–27.
- 9
- 10
- 11
- 12 29. Rat A-C, Coste J, Pouchot J, et al. OAKHQOL: a new instrument to measure quality of life in knee and hip osteoarthritis. *J Clin Epidemiol* 2005;58(1):47–55.
- 13
- 14
- 15 30. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. *Ann Rheum Dis* 1957;16(4):494–502.
- 16
- 17
- 18 31. Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised. *Osteoarthritis Cartilage* 2007;15 Suppl A:A1-56.
- 19
- 20
- 21 32. Gudbergsen H, Lohmander LS, Jones G, et al. Correlations between radiographic assessments and MRI features of knee osteoarthritis – a cross-sectional study. *Osteoarthritis Cartilage* 2013;21(4):535–43.
- 22
- 23
- 24
- 25 33. Scragg R. Emerging Evidence of Thresholds for Beneficial Effects from Vitamin D Supplementation. *Nutrients* 2018;10(5).
- 26
- 27
- 28 34. Hunter DJ, Lo GH, Gale D, Grainger AJ, Guermazi A, Conaghan PG. The reliability of a new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion assessment: BLOKS (Boston Leeds Osteoarthritis Knee Score). *Ann Rheum Dis* 2008;67(2):206–11.
- 29
- 30
- 31 35. Peterfy CG, Guermazi A, Zaim S, et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. *Osteoarthritis Cartilage* 2004;12(3):177–90.
- 32
- 33
- 34 36. Kornaat PR, Ceulemans RYT, Kroon HM, et al. MRI assessment of knee osteoarthritis: Knee Osteoarthritis Scoring System (KOSS)--inter-observer and intra-observer reproducibility of a compartment-based scoring system. *Skeletal Radiol* 2005;34(2):95–102.
- 35
- 36
- 37 37. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med* 2001;16(9):606–13.
- 38
- 39
- 40 38. Montorio I, Izal M. The Geriatric Depression Scale: a review of its development and utility. *Int Psychogeriatr* 1996;8(1):103–12.
- 41
- 42
- 43 39. Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002.
- 44
- 45
- 46 40. Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *J Stat Softw* 2011;45(3).
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 41. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage
- 5 and two-stage approaches, and why they may differ. *Stat Med* 2017;36(5):855–75.
- 6
- 7 42. Cahan A, Cimino JJ. Improving precision medicine using individual patient data from
- 8 trials. *CMAJ Can Med Assoc J* 2017;189(5):E204–7.
- 9
- 10 43. Felson DT. Identifying Different Osteoarthritis Phenotypes through Epidemiology.
- 11 *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2010;18(5):601–4.
- 12
- 13 44. Deveza LA, Melo L, Yamato TP, Mills K, Ravi V, Hunter DJ. Knee osteoarthritis
- 14 phenotypes and their relevance for outcomes: a systematic review. *Osteoarthritis*
- 15 *Cartilage* 2017;25(12):1926–41.
- 16
- 17 45. van Spil WE, Jansen NWD, Bijlsma JWJ, et al. Clusters within a wide spectrum of
- 18 biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals
- 19 with very early symptomatic osteoarthritis. *Osteoarthritis Cartilage* 2012;20(7):745–54.
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Table 1. Modified risk of bias assessment

| Source of bias [#] | Low risk | High risk | Unclear | Comments |
|-------------------------------------|--------------------------|--------------------------|--------------------------|----------|
| 1. Random sequence generation | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Allocation concealment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 3. Blinding of participants | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 4. Blinding of key study personnel | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 5. Blinding of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 6. Incomplete outcome data | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 7. Selective outcome reporting | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 8. Imbalance in baseline covariates | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 9. Treatment compliance | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 10. Timing of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Overall risk of bias | Low | Moderate | High | |
| | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |

[#]See *Appendix 2* for criteria for different levels of risk.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 1. Search strategy

Cochrane CENTRAL

- #1. MeSH descriptor Osteoarthritis explode all trees
- #2. (osteoarthritis* or osteo-arthritis* or osteoarthrotic or osteoarthros*):ti,ab,kw
- #3. (degenerative near/2 arthritis):ti,ab,kw
- #4. coxarthrosis:ti,ab,kw
- #5. (#1 OR #2 OR #3 OR #4)
- #6. MeSH descriptor vitamin D explode all trees
- #7. (vitamin D):ti,ab,kw
- #8. (vitamin D2):ti,ab,kw
- #9. (vitamin D3):ti,ab,kw
- #10. (1-alpha hydroxyvitamin D3):ti,ab,kw
- #11. (1-alpha-hydroxy-vitamin D3):ti,ab,kw
- #12. (1-alpha hydroxycalciferol):ti,ab,kw
- #13. (1-alpha-hydroxy-calciferol):ti,ab,kw
- #14. (1,25 dihydroxyvitamin D3):ti,ab,kw
- #15. (1,25-dihydroxy-vitamin D3):ti,ab,kw
- #16. (1,25 dihydroxycholecalciferol):ti,ab,kw
- #17. (1,25-dihydroxycholecalciferol):ti,ab,kw
- #18. (25-hydroxycholecalciferol):ti,ab,kw
- #19. (25 hydroxycholecalciferol):ti,ab,kw
- #20. (25 hydroxyvitamin D):ti,ab,kw
- #21. (25-hydroxy-vitamin D):ti,ab,kw
- #22. (alfacalcidol):ti,ab,kw
- #23. (calcidiol):ti,ab,kw
- #24. (calcitriol):ti,ab,kw
- #25. (calcifediol):ti,ab,kw
- #26. (calciferol):ti,ab,kw
- #27. (ergocalciferol):ti,ab,kw
- #28. (cholecalciferol):ti,ab,kw
- #29. (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)
- #30. #5 AND #29

MEDLINE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthritis* or osteo-arthritis* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. randomized controlled trial.pt.
31. controlled clinical trial.pt.
32. randomized controlled trials.sh.
33. random allocation.sh.
34. double blind method.sh.

- 1
- 2
- 3 35. single-blind method.sh.
- 4
- 5 36. clinical trial.pt.
- 6
- 7 37. clinical trials.sh.
- 8
- 9 38. clinical trial.tw.
- 10 39. ((singl\$ or doubl\$ or trebl\$ or tripl\$) and (mask\$ or blind\$)).tw.
- 11
- 12 40. placebos.sh.
- 13
- 14 41. placebo\$.tw.
- 15
- 16 42. random\$.tw.
- 17 43. Research Design/
- 18 44. comparative study.sh.
- 19
- 20 45. evaluation studies.sh.
- 21
- 22 46. follow-up studies.sh.
- 23
- 24 47. prospective studies.sh.
- 25
- 26 48. control\$.tw.
- 27
- 28 49. prospectiv\$.tw.
- 29
- 30 50. volunteer\$.tw.
- 31
- 32 51. or/30-50
- 33 52. (animal not human).mp.
- 34
- 35 53. 46 not 47
- 36
- 37 54. 5 and 29 and 53
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

EMBASE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. random\$.tw.
31. factorial\$.tw.
32. crossover\$.tw.
33. cross over\$.tw.
34. cross-over\$.tw.

- 1
- 2
- 3 35. placebo\$.tw.
- 4
- 5 36. (doubl\$ adj blind\$.tw.
- 6
- 7 37. (singl\$ adj blind\$.tw.
- 8
- 9 38. assign\$.tw.
- 10
- 11 39. allocat\$.tw.
- 12
- 13 40. volunteer\$.tw.
- 14
- 15 41. Crossover Procedure/
- 16
- 17 42. double-blind procedure.tw.
- 18
- 19 43. Randomized Controlled Trial/
- 20
- 21 44. Single Blind Procedure/
- 22
- 23 45. or/30-44
- 24
- 25 46. (animal/ or nonhuman/) not human/
- 26
- 27 47. 45 not 46
- 28
- 29 48. 5 and 29 and 47
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 2. Modified risk of bias assessment

1. Random sequence generation

Criteria for a judgement of “Low risk”:

The investigators describe a random component in the sequence generation process such as:

- Referring to a random number table;
- Using a computer random number generator;
- Coin tossing;
- Shuffling cards or envelopes;
- Throwing dice;
- Drawing of lots;
- Minimisation. ^*Minimization may be implemented without a random element, and this is considered to be equivalent to being random.

Criteria for a judgement of “High risk”:

Sequence generation process involves some systematic, non-random approach, for example:

- sequence generated by odd or even date of birth;
- sequence generated by some rule based on date (or day) of admission;
- sequence generated by some rule based on hospital or clinic record number.

Sequence generation process involves judgement or some method of non-random categorisation of participants, for example:

- Allocation by judgement of the clinician;
- Allocation by preference of the participant;
- Allocation based on the results of a laboratory test or a series of tests;
- Allocation by availability of the intervention.

Criteria for a judgement of “Unclear risk”:

Insufficient information about sequence generation process

2. Allocation concealment

Criteria for a judgement of “Low risk”:

Participants and investigators enrolling participants could not foresee assignment because a successful method of allocation concealment, for example:

- Central allocation (including telephone, web-based, and pharmacy-controlled, randomisation);
- Sequentially numbered drug containers of identical appearance;
- Sequentially numbered, opaque, sealed envelopes.

Criteria for a judgement of “High risk”:

Participants and investigator enrolling participants could possibly foresee assignments and thus introduce selection bias, for example:

- Using an open random allocation schedule (e.g. a list of random numbers);
- Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered);
- Alternation or rotation;
- Date of birth;
- Case record number;
- Any other explicitly unconcealed procedure.

Criteria for a judgement of “Unclear risk”:

Insufficient detail to permit judgement of “Low risk” or “High risk”.

3. Blinding of participants**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of participants ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”,
- The study did not address this outcome.

4. Blinding of key study personnel**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of key study personnel (physicians/pharmacists/care givers/trial coordinators) ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

5. Blinding of outcome assessment

Criteria for a judgement of “Low risk”:

Any one of the following:

- No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;
- Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcome assessment is likely to be influenced by lack of blinding;
- Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Criteria for a judgement of “Unclear”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

6. Incomplete outcome data

Criteria for a judgement of “Low risk”:

Any one of the following:

- No missing outcome data;
- Reasons for missing outcome data unlikely to be related to true outcome;
- Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;
- The percentage of withdrawal and drop-outs does not exceed 20% with reasons documented and missing data have been imputed using appropriate methods.

Criteria for a judgement of “High risk”:

Any one of the following:

- Reason for missing outcome data is likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;
- ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation;

- Potentially inappropriate application of simple imputation.

Criteria for a judgement of “Unclear”:

- Insufficient reporting of attrition/exclusions to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

7. Selective outcome reporting:

Criteria for a judgement of “Low risk”:

Any of the following:

- The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
- The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).

Criteria for a judgement of “High risk”:

Any one of the following:

- Not all of the study’s pre-specified primary outcomes have been reported;
- One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified;
- One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);
- One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;
- The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Criteria for a judgement of “Unclear”:

Insufficient information to permit judgement of “Low risk” or “High risk”.

8. Imbalance in baseline covariates

Criteria for a judgement of “Low risk”:

Groups are similar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “High risk”:

Groups are obviously dissimilar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “Unclear”:

If baseline characteristics are described in the text but data are not presented.

9. Treatment compliance

Criteria for a judgement of “Low risk”:

Participants’ compliance with the treatment allocation was measured or documented. The level of treatment compliance based on reported dosage, duration and frequency is acceptable. Analyses were performed on an intention-to-treat basis.

Criteria for a judgement of “High risk”:

Any one of the following:

- Participants' compliance with the treatment allocation was not measured;
- Over 50% of participants did not comply with the allocated treatment;
- Participants were excluded from analysis for variety of reasons, or only per protocol analysis was performed as the primary analysis.

Criteria for a judgement of “Unclear”:

Insufficient reporting in treatment compliance to permit judgement of “Low risk” or “High risk”.

10. Timly outcome assessment

Criteria for a judgement of “Low risk”:

Timing of outcome assessment is identical or closely similar for all treatment groups and for all important outcomes.

Criteria for a judgement of “High risk”:

Timing of outcome assessment is obviously different among participants due to variety reasons.

Criteria for a judgement of “Unclear”:

Insufficient reporting to permit judgement of “Low risk” or “High risk”.

Overall risk of bias

A - low risk of bias:

Low risk for all sources of bias (1-10).

B - moderate risk of bias:

One of more high risk in other sources of bias (8-10). Low risk or unclear risk for key sources of bias (1-7).

C - high risk of bias:

High risk for one or more key sources of bias (1-7).

PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted – Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 5:15

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|-----------------------------------|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| ADMINISTRATIVE INFORMATION | | | | | |
| Title | | | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Registration | 2 | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 2 |
| Authors | | | | | |
| Contact | 3a | Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Support | | | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Role of sponsor/funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| INTRODUCTION | | | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 4-5 |

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|---|-----|---|-------------------------------------|-------------------------------------|---------------------|
| | | | Yes | No | |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| METHODS | | | | | |
| Eligibility criteria | 8 | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Information sources | 9 | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5, Appendix 1. |
| STUDY RECORDS | | | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7-8 |
| Selection process | 11b | State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Data collection process | 11c | Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8 |
| Data items | 12 | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-10 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-9 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7, Appendix 2 |
| DATA | | | | | |
| Synthesis | 15a | Describe criteria under which study data will be quantitatively synthesized | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15c | Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|--|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (e.g., GRADE) | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

For peer review only

BMJ Open

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis (OA) - An OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2019-035302.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 19-Dec-2019 |
| Complete List of Authors: | Jin, Xingzhong; Southern Medical University, Zhujiang Hospital; The University of Sydney, The Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders Antony, Benny; University of Tasmania, Menzies Institute for Medical Research Wang, Xia; The University of Sydney, Institute of Bone and Joint Research Persson, Monica; University of Nottingham Faculty of Medicine and Health Sciences McAlindon, Timothy; Tufts Medical Center, Arden, Nigel; Nuffield Department of Orthopaedics, ; Srivastava, Sudeepti; King George Medical College Srivastava, Rajeshwar; King George Medical University van Middelkoop, Marienke; Erasmus MC Bierma-Zeinstra, Sita; Erasmus MC Zhang, Weiya; University of Nottingham, Academic Rheumatology Cicuttini, Flavia; Monash University, Department of Epidemiology and Preventative Medicine Ding, Changhai; University of Tasmania, Menzies Institute for Medical Research |
| Primary Subject Heading: | Rheumatology |
| Secondary Subject Heading: | Complementary medicine |
| Keywords: | PREVENTIVE MEDICINE, RHEUMATOLOGY, GENERAL MEDICINE (see Internal Medicine) |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis (OA)

An OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis

Xingzhong Jin^{1,2}, Benny Antony³, Xia Wang⁴, Monica SM Persson^{5,6}, Timothy McAlindon⁷, Nigel Arden⁸, Sudeepti Ratan Srivastava⁹, Rajeshwar Nath Srivastava⁹, Marienke van Middelkoop¹⁰, Sita M.A. Biermsa-Zeinstra¹⁰, Weiya Zhang^{5,6}, Flavia Cicuttini¹¹, Changhai Ding^{1,3,11}.

Author Affiliations

¹ ZhuJiang Hospital, Southern Medical University, China

² The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, the University of Sydney, Australia.

³ Menzies Institute for Medical Research, University of Tasmania, Australia.

⁴ Institute of Bone & Joint Research, the University of Sydney, Australia.

⁵ Academic Rheumatology, Division of Rheumatology, Orthopaedics, and Dermatology, University of Nottingham, United Kingdom.

⁶ Arthritis Research UK Pain Centre, United Kingdom.

⁷ Tufts Medical Center, United States.

⁸ Nuffield Department Orthopaedic, Rheumatology and musculoskeletal sciences, University of Oxford, United Kingdom.

⁹ King George Medical University, India.

¹⁰ Erasmus MC, University Medical Center Rotterdam, Netherland.

¹¹ Department of Epidemiology and Preventive Medicine, Monash University, Australia

Correspondence to

Xingzhong Jin, The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, Level 2 Charles Perkins Centre (D17), John Hopkins Drive, The University of Sydney, NSW 2006, Australia; xingzhong.jin@sydney.edu.au.

Keywords

Systematic Review; Meta-analysis; Individual Patient Data; Osteoarthritis; Vitamin D; Knee.

Abstract

Introduction

Observational data suggest vitamin D deficiency is associated with the onset and progression of knee OA. However, randomized controlled trials (RCTs) to date investigating the efficacy of vitamin D supplementation in knee OA have reported conflicting results. Further research is needed to clarify the effects of vitamin D on patient-reported outcomes and determine whether there are patient subgroups who may benefit from the supplementation. The aim of this IPD meta-analysis is to identify patient-level predictors of treatment response to vitamin D supplementation on pain and physical function.

Methods and analysis

A systematic literature search will be conducted for RCTs of vitamin D supplementation on knee OA. Authors of original RCTs will be contacted to obtain the IPD. The primary outcomes will include long-term (≥ 12 months) pain and physical function. Secondary outcomes will include medium-term (≥ 6 months and <12 months) and short-term (<6 months) pain and physical function, as well as patient global assessment, quality of life and adverse events. Potential treatment effect modifiers to be examined in the subgroup analyses include age, gender, body mass index (BMI), baseline knee pain severity and physical function, baseline vitamin D level, radiographic stage, presence of bone marrow lesions on magnetic resonance images (MRI), presence of clinical signs of local inflammation, and concomitant depressive symptoms. Both one-step and two-step modelling methods will be used to determine the possible modifiable effect of each subgroup of interest.

Ethics and dissemination

Separate ethics committee approval because this study involves analysis of de-identified data that have already been collected in individual RCTs. This study will be the first IPD meta-analysis to clarify the effect of vitamin D supplementation on clinical symptoms in different subgroups of patients with knee OA. The findings will be disseminated through peer-review publications and conference presentations.

Systematic review registration

This systematic review is registered on PROSPERO (CRD42018107740).

Article Summary

This article is a protocol for a systematic review and IPD meta-analysis of RCTs studying the effects of vitamin D supplementation on joint pain and physical function in patients with symptomatic knee OA.

Strengths and limitations of this study

- This study protocol is endorsed by the OA Trial Bank, an international collaboration that initiates meta-analyses on predefined subgroups of OA patients.
- This study is the first IPD meta-analysis to identify OA patient subgroups that may benefit from vitamin D supplementation.
- IPD meta-analysis offer greater statistical power and precision than subgroup analysis in a single trial and conventional meta-analysis using aggregate data.
- Analysis may be limited to the variables that have been collected across included RCTs.

Introduction

OA is the most common joint disorder worldwide. OA is ranked as the 13th highest contributor of 310 diseases to global disability in 2015¹. In Australia, OA affects over 2.1 million people (9% of the population), costing the healthcare system over \$2.1 billion in 2015². This cost is forecasted to increase by 41% in 2030³.

The majority (83%) of the disease burden of OA is attributable to knee OA⁴, which is characterized by pain, gradual loss of articular cartilage, and structural changes such as subchondral remodelling and effusion-synovitis⁵. Currently, there are no effective disease-modifying treatments to reverse the progression of knee OA once the disease is established. A majority of patients with knee OA eventually progress to advanced stage and undergo total knee replacement⁶. There is clearly an urgent need for innovative and cost-effective approaches to slow the progression of knee OA.

Emerging observational data suggest that vitamin D insufficiency is associated with the onset and progression of knee OA⁷. The association between low serum vitamin D levels and knee OA symptoms may be explained by a direct effect of vitamin D on chondrocytes in osteoarthritic cartilage⁸, as well as indirect effects on subchondral bone, synovium, and periarticular muscle⁹. For example, vitamin D deficiency could impair the ability of bone to respond optimally to pathological bone marrow lesions (BMLs) and altered bone mineral density, therefore predisposing the knees to disease progression¹⁰. Vitamin D also may reduce synovitis in affected knees by regulating cytokine levels in the joint, leading to a reduction in the amount of effusion-synovitis in MRI¹¹. In addition, depressive symptoms is interrelated to joint pain in OA¹², and maintaining sufficient serum vitamin D may improve depression symptoms in patients with knee OA¹³.

However, evidence from RCTs have been conflicting¹⁴⁻¹⁷. A pilot RCT in India found a small but statistically significant clinical benefit for 12-month vitamin D treatment on pain and function in patients with knee OA, compared with placebo³⁹¹⁶. In contrast, a subsequent RCT from the US showed that vitamin D supplementation did not reduce knee pain or cartilage volume loss over 24 months¹⁵. Subsequently, data from RCTs in Australia¹⁷ and UK¹⁴ did not find significant clinical benefits of vitamin D supplementation for knee OA. However, there was a non-significant trend for symptom reduction (e.g. knee pain and physical function) in these RCTs. Two systematic reviews using aggregate data from these RCTs concluded that, although current evidence does not support vitamin D supplementation for reducing structural

1
2
3 disease progression, further research is needed to clarify the effects on patient-reported
4 outcomes^{18,19}.

5
6
7 The null results of these RCTs could be due to a low prevalence of vitamin D deficiency in the
8 study subjects or low statistical power secondary to small sample sizes. Another possible
9 reason is that vitamin D may have an effect only in some OA phenotypes, such as those with
10 BMLs (predominant bone abnormality)²⁰, effusion-synovitis (inflammatory)²¹ or depressive
11 symptoms (psychological distress)¹³. Post hoc analyses within these RCTs^{15,21} were frequently
12 underpowered, and hence unreliable to determine the effect of vitamin D treatment on
13 subgroups of knee OA patients. A meta-analysis using IPD can increase the power of subgroup
14 analysis by combining individual data from included trials²² and therefore can quantify
15 potential effect modifier of vitamin D treatment in subgroups.
16
17
18
19
20
21
22

23 **Methods and analysis**

24 We will conduct a systematic review and IPD meta-analysis of RCTs studying the effects of
25 vitamin D supplementation in patients with symptomatic knee OA. The primary aim is to
26 identify patient-level predictors of treatment response to vitamin D supplementation, including
27 the status of vitamin D deficiency, MRI-detected bone marrow abnormalities and effusion-
28 synovitis, and clinical signs of local inflammation. The protocol of this review is registered on
29 the PROSPERO database (CRD42018107740).
30
31
32
33
34
35

36 **Study eligibility**

37 This systematic review will include studies that meet the following inclusion criteria:

38 **Type of studies**

39 RCTs that have been published in journals and reported the efficacy of vitamin D in participants
40 with knee OA will be included. Cross-over design will also be eligible and only the first phase
41 data will be included in the analysis. Both individually randomised trials and cluster
42 randomised trials will be eligible. Both open-labelled and blinded studies will be eligible. There
43 will be no language or geographical restrictions applied to study selection.
44
45
46
47
48

49 **Participants**

50 Men and women who have a diagnosis of knee OA, either according to the American College
51 of Rheumatology criteria, or on the basis of detailed clinical and/or radiographic information,
52 will be included. Studies with a subgroup of knee OA patients will also be included, provided
53 that IPD can be collected separately for the OA subgroup.
54
55
56
57

58 **Interventions**

1
2
3 Only studies investigating oral supplementation of vitamin D will be included. Vitamin D
4 treatments administered subcutaneously, intraperitoneally or intravenously will not be
5 included. Both ergocalciferol (vitamin D₂) and cholecalciferol (vitamin D₃) will be eligible,
6
7 irrespective of preparations (tablet or capsule), dosage, regimen, and length of treatment.
8
9

10 **Comparators**

11 Oral vitamin D supplementation will be compared with control treatment including placebo or
12 usual conservative care (pain medication and/or exercise therapy if they are used in both
13 treatment and control groups).
14
15

16 **Outcomes**

17 The minimum criterion for inclusion is reporting pain or physical function as either primary or
18 secondary outcomes. There will be no restrictions on the duration of follow-up. Data on other
19 outcomes (e.g. patient's global assessment, quality of life, and adverse events) will be analysed
20 when feasible but will not be required for study selection.
21
22
23
24
25

26 **Baseline assessments**

27 As a minimum, included studies should have measured knee pain, physical function, serum
28 levels of vitamin D at baseline, and included basic patient characteristics such as age, gender,
29 and BMI.
30
31
32

33 **Literature search**

34 A systematic literature search for articles published from 1 January 1990 until 31 December
35 2019 will be performed by a trained review author (XJ) in the following electronic databases:
36
37

- 38 • Cochrane Central Register of Controlled Trials (CENTRAL);
- 39 • MEDLINE (Ovid);
- 40 • EMBASE;
- 41
- 42
- 43

44 The search strategies used for each database are listed in *Appendix 1*. All retrieved articles will
45 be exported to the reference manager *EndNote*, in which duplicates will be removed
46 electronically and manually. The remaining records will be exported to an online systematic
47 review management tool *Covidence* (Veritas Health Innovation, Melbourne, Australia) and the
48 articles will be assessed for eligibility for inclusion. In addition to the electronic search, we
49 will check the reference lists of included trials and previous systematic reviews to identify any
50 trials that are not retrieved from the electronic search. Review authors and collaborating authors
51 will be asked if they are aware of further relevant studies not yet included. We will also search
52 the WHO International Clinical Trial Registration Platform Search Portal
53
54
55
56
57
58
59
60

1
2
3 (www.who.int/trialsearch) to identify any relevant trials that are completed but did not
4 published the results.
5
6

7 **Study selection**

8 Two review authors (XJ, BA) will independently conduct study screening by assessing the
9 article titles and abstracts. Full texts of the articles will be further assessed if the information
10 from the abstract suggests that a study is eligible for inclusion. When information contained in
11 the full text is not sufficient to make a judgement on its eligibility, we will make efforts to
12 contact the corresponding authors to obtain further details. If a corresponding author is not
13 contactable after two email attempts and one phone call, the study will be deemed ineligible.
14 Any disagreement regarding the inclusion of a study will be discussed between the two review
15 authors (XJ, BA). If no consensus can be reached, a third review author will be consulted (XW)
16 to make a final decision.
17
18
19
20
21
22
23

24 **Extraction of aggregate data**

25 Study data extraction will be performed independently by two review authors (BA, XW).
26 Discrepancies will be resolved by a third reviewer (XJ). We will extract the following study
27 data from the included studies:
28
29
30

- 31 • General information: article title, bibliographic details, published language, and
32 funding source.
- 33 • Participants: inclusion criteria, exclusion criteria, number of participants in total and in
34 each study arm, study settings, and baseline participant characteristics (e.g. age, gender,
35 BMI).
- 36 • Intervention: type of vitamin D preparation, dose, regimen, treatment duration, type of
37 control, and co-interventions (if any).
- 38 • Outcomes: primary and secondary outcomes at the end of treatment and/or the end of
39 follow-up. Number of withdrawals and loss to follow-up. Adverse events recorded.
- 40 • Data analysis: statistical models used for data analysis, confounding factors adjusted in
41 the models, and methods used for addressing missing values.
42
43
44
45
46
47
48
49
50
51
52

53 **Risk of bias assessment**

54 The methodological quality of the included studies will be assessed using a modified version
55 of the Cochrane's risk of bias tool²³. The modified version includes all the seven domains of
56 the original tool, but further separates performance bias assessment into 'blinding of
57 participants' and 'blinding of study personnel', as well as pre-specifies other sources of bias as
58
59
60

1
2
3 ‘balance in baseline covariates’, ‘treatment compliance’, and ‘timely outcome assessment’
4 (*Appendix 2*). Each domain will be scored as ‘low risk’, ‘high risk’ or ‘unclear’ according to
5 the criteria described in the *Appendix 3*. The overall rating of risk of bias is based on the number
6 of domains with a ‘high-risk’ score. The overall rating is intended to inform readers of the risk
7 of bias across individual studies and will not be used to weight the studies in the meta-analysis.
8 Two review authors (XJ, XW) will independently evaluate the quality of an individual study.
9 Any disagreement will be settled by further discussion until a consensus is reached between
10 the two review authors.
11

12 **IPD collection and transfer**

13 The primary or corresponding authors of included trials will be invited to collaborate on the
14 project and contribute their raw data. When we cannot reach a corresponding author after
15 sending two emails and making two telephone calls, we will contact the co-authors listed in
16 the article. If none of the co-authors can be contacted, we will approach the institutes, in which
17 the trial has been conducted. All data custodians will be asked to sign a data delivery
18 agreement, which includes items regarding IPD delivery, obligations, ownership of data, terms
19 and conditions of the use of the data, authorship, and publications. If needed, the project
20 coordinator (XJ) will visit the institutes of the data deliverers to retrieve the data and to sign
21 the data delivery agreement on behalf of the OA Trial Bank. De-identified datasets will be
22 accepted in any electronic format (for example, SPSS, Stata, SAS, Excel) or in paper form,
23 provided that variables and categories are adequately labelled within the dataset or within a
24 separate codebook. The IPD files received by the coordinator will be kept in their original
25 version and saved on a secured password-protected server at Erasmus MC Medical University
26 in Rotterdam. The datasets will not be used for any other research apart from that described in
27 the license agreement.
28

29 To ensure the quality of the data, the coordinator will independently check for data consistency
30 by comparing the summary statistics derived from the IPD received against the summary
31 results reported in the published articles. In the case of differences, the project coordinator will
32 communicate with the data deliverer via email or teleconference to resolve the discrepancy.
33

34 **Variables of interest**

35 The following IPD variables will be obtained (where available):

36 **Primary outcome variables**

37 The primary outcomes for this meta-analysis will be pain and physical function at long-term
38 follow-up (12 months or more).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Knee pain will be evaluated using visual analogue scale (VAS) if available, otherwise the pain subscales of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)²⁴ or the Knee injury and Osteoarthritis Outcome Score (KOOS)²⁵ will be used. The pain data will be converted into a 0-100 common scale as recommended by the WOMAC manual²⁶.
- Physical function will be evaluated using a validated instrument specific to knee OA, such as the physical function subscales of the WOMAC or the KOOS subscales. The scores will be standardised into a 0-100 scale.

Secondary outcome variables

Secondary outcomes will include:

- Medium-term (more than 6 months but less than 12 months) pain and physical function;
- Short-term (less than 6 months) pain and physical function;
- Patient global assessment at the end of study follow-up, as recommended by the OMERACT-OARSI Initiative²⁷.
- Quality of life evaluated using a validated instrument, such as EQ-5D²⁸, osteoarthritis Knee and Hip Quality of Life (OAKHQOL)²⁹, or original instrument used in the included studies;
- Adverse events if reported, including all major and minor events such as hypocalcaemia, fractures, and depression.

Potential treatment effect moderators

If data are available, we will analyse potential treatment effect modification for the following variables measured at baseline:

- Radiographic stage of knee OA (mild/moderate or severe). Radiographic knee OA should be staged at baseline using either the Kellgren-Lawrence (KL)³⁰ or Osteoarthritis Research Society International (OARSI) joint space narrowing (JSN) grading system³¹. The results from the two grading systems have been shown to be highly correlated³². Mild to moderate disease will be defined as a KL score ≤ 3 or an OARSI JSN score ≤ 2 , and severe disease will be a KL score of 4, or an OARSI score of 3.
- Vitamin D level (deficiency, insufficiency, or sufficiency). Vitamin D deficiency is defined as serum levels of 25(OH)D less than 30 nmol/L at baseline. Insufficiency is defined as serum 25(OH)D levels from 30 to <50 nmol/L. Serum 25(OH)D levels ≥ 50 nmol/L is considered as vitamin D sufficiency³³.

- Presence of BMLs (yes or no). BMLs at the patella-femoral and femoro-tibial joints should be measured by MRI using a validated scoring system, such as BLOKS (Boston Leeds Osteoarthritis Knee Score)³⁴, WOMMS (Whole-Organ Magnetic Resonance Imaging Score)³⁵, or KOSS (Knee Osteoarthritis Scoring System)³⁶.
- Clinical signs of local inflammation or the presence of effusion-synovitis (yes or no). Clinical signs of local inflammation should be assessed by physical examination - tumor (swelling), dolor (pain), rubor (redness), calor (heat), and functio laesa (disturbance of function) - or by additional laboratory testing (e.g. serum c-reactive protein and erythrocyte sedimentation rate). Effusion-synovitis should be measured on either ultrasound or MRI.
- Presence of depressive symptoms or comorbid depression. Depressive symptoms are measured using a validated questionnaire, such as the Patient Health Questionnaire (PHQ-9)³⁷ and the Geriatric Depression Scale (GDS)³⁸.

Data synthesis and statistical methods

All statistical analysis will be conducted using R version 3.5.0 and RStudio (version 1.0.136, RStudio, Inc., Boston, MA), with R extension package ‘metafor’ for the conventional meta-analysis and two-stage IPD meta-analysis, and ‘lme4’ for the one-stage IPD meta-analysis.

Conventional meta-analysis

An aggregate data meta-analysis, using a random-effects model based on the ‘DerSimonian and Laird’ method³⁹, will be performed to estimate the treatment effect of vitamin D over control. The results will be compared with the IPD meta-analysis findings as sensitivity analyses.

Heterogeneity will be assessed by inspecting the forest plots and tested by χ^2 test. A result of $p < 0.10$ will be defined as evidence of significant heterogeneity across studies. I^2 test will be used to estimate the extent of inconsistency across studies that is due to heterogeneity⁴⁰. A result of over 30% and 50% represents moderate and substantial heterogeneity, respectively⁴¹. Sources of heterogeneity will be explored by excluding individual trials causing an I^2 score below 50%.

If 10 trials or more trials are available, we will use a Doi plot (normal quantile versus effect size plot) explore publication bias and ‘small-study effects’⁴². Asymmetry in the Doi plot will be detected and quantified by the LFK index. A value beyond +/- 1 will be deemed consistent with asymmetry, thus having considerable small-study effects⁴².

IPD meta-analysis

1
2
3 IPD from included trials will be recoded and formatted in a consistent way to permit re-
4 analysis. A new variable will be created to indicate the trial in which the IPD are collected.
5 The method used to handle missing data will depend on the mechanism causing the
6 missingness. If no explanation is known for the reason of missing data, they will be assumed
7 to be missing at random. We will use the R MICE package⁴³ for multiple imputation and the
8 imputation model will include all available patient variables to help predict missing data for
9 the variables of interest within each study dataset. The imputation procedure will use 20
10 imputed datasets. A sensitivity analyses will be performed restricting to participants without
11 missing data (complete case analysis).
12
13
14
15
16
17
18

19 Both the treatment effect of vitamin D supplementation and the effect of potential moderators
20 will be studied in the IPD meta-analyses. The treatment effect of vitamin D will be measured
21 using the mean difference in knee pain and physical function between treatment and control
22 based on the intention-to-treat principle. The interaction between the treatment and a potential
23 moderator will be used to identify the effect of the moderator. Interaction effects with $p < 0.05$
24 will be considered statistically significant and 95% confidence intervals of the effects will be
25 provided. The IPD meta-analyses will be undertaken using both the one-stage and two-stage
26 approaches. We will use the one-stage approach as the primary analysis to avoid assumptions
27 of within-study normality and known within-study variance⁴⁴. We will and compare the results
28 to the two-stage approach to assess consistency in a sensitivity analysis.
29
30
31
32
33
34
35
36

37 ***One-stage modelling***

38 The one-stage mixed-effects IPD meta-analysis approach will take into account both study
39 level and subject-level covariates. Subject -level covariates will be centred to the mean of the
40 covariate in each trial to avoid ecological bias. Three multilevel regression models will be built,
41 the first to examine the summary treatment effect (difference between vitamin D and control),
42 the second to evaluate each of the mentioned moderators on treatment effect, and the third to
43 assess the true effect of one moderator independent of other moderators.
44
45
46
47
48

49 The first model will include outcome measure (e.g. pain score at follow-up) as a dependent
50 variable, treatment (vitamin D or control), baseline subject-level covariate (e.g. pain score) and
51 confounders (age, gender and BMI) as fixed-effect independent variables, adjusted for study
52 identifier (random intercept). The partial regression coefficient of the treatment will be used to
53 compare to the conventional meta-analysis.
54
55
56
57

58 The second model will further add the moderator of interest (e.g. radiographic stage of the
59 disease) and interaction term between the treatment and study-centred values of the moderator
60

1
2
3 in the fixed-effect of the first model. The regression coefficient of the interaction term will be
4 used to quantify the impact of the moderator on treatment effect.
5
6

7 If there are two or more moderators that have a statistically significant interaction with the
8 treatment effect, these moderators will be incorporated in the third model. Multicollinearity
9 between moderators will be tested before building the third model. A correlation coefficient
10 $r > 0.80$ will indicate that multiple collinearity exists between the two moderators, of which the
11 one that has less measurement error will be included in the model.
12
13
14
15

16 ***Two-stage modelling***

17 In the first stage, treatment effect and variance are derived from separate analysis in each study.
18 An analysis of covariance (ANCOVA) model adjusted for baseline covariates (age, gender,
19 BMI, as well as knee pain or function), will be used to obtain the treatment effect and variance
20 within each study separately. The effect of a moderator and its variance within each study will
21 be obtained by adding the interaction term between treatment effect and the moderator into the
22 model. In the second stage, the treatment effect and its variances obtained from the first stage
23 will be pooled across studies using a random-effects model³⁹. The result of this model is a
24 summary estimate of the treatment effect of vitamin D versus control. The effect of a moderator
25 will be calculated by pooling the regression coefficient and variance of the interaction term
26 between the treatment and the moderator using a similar model. If two or more interaction
27 terms are statistically significant, these moderators will be incorporated in a further model to
28 evaluate the independent effect of these moderators
29
30
31
32
33
34
35
36
37
38

39 **Discussion**

40 Vitamin D supplementation may improve pain and function in patients with knee OA; however,
41 the evidence from observational studies and RCTs are controversial^{7,18}. In a few existing RCTs
42 in patients with symptomatic knee OA^{27,14,16,17}, small to modest improvement in knee pain and
43 physical function were observed in participants receiving vitamin D supplementation, but the
44 treatment response varies considerably and the effects were not statistically significant when
45 compared to placebo. The broad variation in treatment response could be a result of the fact
46 that knee OA is a highly heterogenous disease with multiple aetiologies⁴⁵. Vitamin D may
47 therefore be more effective in a subset of patients with specific characteristics than others. The
48 purpose of the proposed IPD meta-analysis is to evaluate the treatment response of vitamin D
49 supplementation on pain and physical function for knee OA in specific subsets of patients
50 according to disease severity, vitamin D levels, presence of BMLs, inflammatory signs and
51 depressive symptoms, over both short- and long-term follow-up.
52
53
54
55
56
57
58
59
60

1
2
3 An IPD meta-analysis is the grandmother of ‘big data’⁴⁶ and an integrated part of precision
4 medicine⁴⁷. It is a cost-effective approach to identify potential moderators of treatment
5 response at a patient level, which is not possible with subgroup analyses in a single trial or
6 conventional meta-analysis with aggregate data⁴⁸. Subgroup analyses within individual trials
7 are often underpowered to generate reliable findings. In contrast, IPD meta-analysis techniques
8 increase the statistical power of the study by combining individual observation data from
9 multiple trials with the same treatment²². This offers greater precision in analysing moderators
10 of treatment response and offers the potential to analyse a greater number of moderators. In
11 conventional meta-analysis, meta-regression analysis may be used to examine differences in
12 the types of patients enrolled in individual trials, but is potentially problematic. Meta-
13 regression analysis may make incorrect inferences about individual characteristics based upon
14 aggregate baseline statistics reported in trial publications⁴⁹. This is also known as ecological
15 fallacy⁵⁰, where the relationship between the effect estimate and average patient characteristics
16 across trials may not be the same as the relationship within individual trials.

17
18 Identifying different phenotypes of knee OA is currently a popular subject of research in the
19 field. Different phenotyping strategies have been proposed based on risk factors from
20 epidemiological studies⁵¹, anatomical abnormalities on modern imaging⁵², or molecular
21 abnormalities related to pathological mechanisms⁵³. While there is currently no standardised
22 classification system for knee OA phenotypes⁵, we believe that disease phenotypes are most
23 meaningful when they reflect differential treatment effects. IPD meta-analysis provides an
24 opportunity to assess the effect of treatments on subtypes or phenotypes of patients with knee
25 OA according to predefined set of characteristics. The current proposed IPD meta-analysis
26 attempts to differentiate subgroups by identifying subtypes of patients that respond better to
27 vitamin D supplementation on pain and physical function.

28 **Strengths and limitations**

29 Several challenges may present when conducting an IPD meta-analysis. First, although IPD
30 meta-analyses usually offer sufficient statistical power to examine moderators of treatment
31 response, not all RCTs measure potential moderators of interest or measure them in the same
32 way. This may limit the analysis to only exploring moderators that have been collected across
33 studies. The current protocol attempts to minimise this risk by including moderators that are
34 commonly reported in OA research. In addition, there are expected barriers to accessing data,
35 such as the authors of included trials not being able to be contacted, or the authors losing access
36 to raw data or not choosing to collaborate, may introduce selection bias into the IPD meta-
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 analysis. However, this could be examined in sensitivity analyses by comparing the results to
4 the conventional meta-analysis or be addressed using frameworks that combine IPD and
5 aggregate data in a meta-analysis⁵⁴.
6
7

8
9 The benefits of using IPD meta-analysis techniques greatly outweigh the challenges of using
10 this intensive method. Previous RCTs and systematic reviews have not had sufficient power to
11 thoroughly examine the differential treatment response of vitamin D supplementation in
12 different subsets of patients with knee OA.
13
14

15
16 The results of this project have a high potential to provide important evidence to guide
17 subgroup-specific treatment decisions in clinical practice to improve therapeutic effectiveness.
18
19

20 **Status of project**

21 Currently, literature search in the electronic databases has been commenced.
22
23

24 **Abbreviations**

25 OA: osteoarthritis; IPD: individual patient data; RCT: randomised controlled trial; BMI: body
26 mass index; MRI: magnetic resonance imaging; BMLs: bone marrow lesions; JSN: joint space
27 narrowing; OARSI: Osteoarthritis Research Society International.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Additional Information

Acknowledgement

We acknowledge the University of Sydney China Study Centre for providing short-term travel support to establish international collaboration for this project.

Ethics approval and consent to participate

Research ethical or governance approval is exempt for this study as no new data are being collected.

Availability of data and material

Data are available upon reasonable request.

Authors contributions

All authors were involved in the study design and all will contribute to the interpretation of the results. CD, BA and XJ conceived this study. WZ and MP provided methodological support for statistical analysis. XJ and BA will contact the potential data deliverers and will coordinate the project. CD, FC, TM, NA, RNS and SRS will deliver relevant data from their completed trials. SBZ and MM will facilitate legal agreement for data transfer and provide database management at the OA Trial Bank. XJ, BA and XW will perform the study selection, risk of bias assessment, data collection and analysis. All authors contributed to writing of this manuscript and approved the final submission.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors declare that they have no competing interests.

Patient and public involvement

We do not directly include patient and public involvement in this study, but the design of included randomised controlled trials may involve patients.

Word count

Abstract: 298

Main text: 3911

References: 54

References

1. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* 2016;388(10053):1545–602.
2. Australian Bureau of Statistics. 2014-15 National Health Survey. Canberra: Australian Bureau of Statistics; 2017.
3. Ackerman IN, Pratt C, Gorelik A, Liew D. Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population-Level Analysis. *Arthritis Care Res* 2018;70(6):877–83.
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012;380(9859):2163–96.
5. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for Standardized Definitions of Osteoarthritis and Risk Stratification for Clinical Trials and Clinical Use. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2015;23(8):1233–41.
6. Australian Orthopaedic Association National Joint Replacement Registry. Annual Report 2012. Adelaide, Australia: AOA; 2012.
7. Cao Y, Winzenberg T, Nguo K, Lin J, Jones G, Ding C. Association between serum levels of 25-hydroxyvitamin D and osteoarthritis: a systematic review. *Rheumatology* 2013;ket132.
8. Garfinkel RJ, Dilisio MF, Agrawal DK. Vitamin D and Its Effects on Articular Cartilage and Osteoarthritis. *Orthop J Sports Med* [Internet] 2017 [cited 2018 Oct 12];5(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480771/>
9. Zhang FF, Drihan JB, Lo GH, et al. Vitamin D Deficiency Is Associated with Progression of Knee Osteoarthritis. *J Nutr* 2014;144(12):2002–8.
10. Bellido M, Lugo L, Roman-Blas JA, et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. *Osteoarthritis Cartilage* 2011;19(10):1228–36.
11. Wang X, Cicutinni F, Jin X, et al. Effect of vitamin D on effusion-synovitis in knee osteoarthritis: a randomized controlled trial. *Arthritis Rheumatol* 2015;67:439–40.
12. Sharma A, Kudesia P, Shi Q, Gandhi R. Anxiety and depression in patients with osteoarthritis: impact and management challenges. *Open Access Rheumatol Res Rev* 2016;8:103–13.
13. Zheng S, Tu L, Cicutinni F, et al. Effect of Vitamin D Supplementation on Depressive Symptoms in Patients With Knee Osteoarthritis. *J Am Med Dir Assoc* 2018;
14. Arden NK, Cro S, Sheard S, et al. The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial. *Osteoarthritis Cartilage* 2016;24(11):1858–66.

15. McAlindon T, LaValley M, Schneider E, et al. Effect Of Vitamin D Supplementation On Progression Of Knee Pain And Cartilage Volume Loss In Patients With Symptomatic Osteoarthritis. A Randomized Controlled Trial. *JAMA J Am Med Assoc* 2013;309(2):155–62.
16. Sanghi D, Mishra A, Sharma AC, et al. Does Vitamin D Improve Osteoarthritis of the Knee: A Randomized Controlled Pilot Trial. *Clin Orthop Relat Res* 2013;471(11):3556–62.
17. Jin X, X J, G J, et al. Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial. 2016; Available from: <http://doi.org/10.1001/jama.2016.1961>
18. Hussain S, Singh A, Akhtar M, Najmi AK. Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials. *Rheumatol Int* 2017;37(9):1489–98.
19. Diao N, Yang B, Yu F. Effect of vitamin D supplementation on knee osteoarthritis: A systematic review and meta-analysis of randomized clinical trials. *Clin Biochem* 2017;50(18):1312–6.
20. Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. *Radiol Clin* 2004;42(1):1–9.
21. Wang X, Cicuttini F, Jin X, et al. Knee effusion-synovitis volume measurement and effects of vitamin D supplementation in patients with knee osteoarthritis. *Osteoarthritis Cartilage* 2017;25(8):1304–1312.
22. Groenwold RHH, Donders ART, Heijden GJMG van der, Hoes AW, Rovers MM. Confounding of Subgroup Analyses in Randomized Data. *Arch Intern Med* 2009;169(16):1532–4.
23. Jørgensen L, Paludan-Müller AS, Laursen DRT, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. *Syst Rev [Internet]* 2016 [cited 2018 Oct 11];5. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862216/>
24. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. *Arthritis Care Res* 2001;45(5):453–61.
25. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) - validation and comparison to the WOMAC in total knee replacement. *Health Qual Life Outcomes* 2003;1:17.
26. Bellamy N. WOMAC osteoarthritis index: user guide IV. 2000.
27. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2004;12(5):389–99.

- 1
- 2
- 3
- 4 28. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L
- 5 compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life*
- 6 *Res* 2013;22(7):1717–27.
- 7
- 8 29. Rat A-C, Coste J, Pouchot J, et al. OAKHQOL: a new instrument to measure quality of
- 9 life in knee and hip osteoarthritis. *J Clin Epidemiol* 2005;58(1):47–55.
- 10
- 11 30. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. *Ann Rheum Dis*
- 12 1957;16(4):494–502.
- 13
- 14 31. Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised.
- 15 *Osteoarthritis Cartilage* 2007;15 Suppl A:A1-56.
- 16
- 17 32. Gudbergsen H, Lohmander LS, Jones G, et al. Correlations between radiographic
- 18 assessments and MRI features of knee osteoarthritis – a cross-sectional study.
- 19 *Osteoarthritis Cartilage* 2013;21(4):535–43.
- 20
- 21 33. Scragg R. Emerging Evidence of Thresholds for Beneficial Effects from Vitamin D
- 22 Supplementation. *Nutrients* 2018;10(5).
- 23
- 24 34. Hunter DJ, Lo GH, Gale D, Grainger AJ, Guermazi A, Conaghan PG. The reliability of a
- 25 new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion
- 26 assessment: BLOKS (Boston Leeds Osteoarthritis Knee Score). *Ann Rheum Dis*
- 27 2008;67(2):206–11.
- 28
- 29 35. Peterfy CG, Guermazi A, Zaim S, et al. Whole-Organ Magnetic Resonance Imaging
- 30 Score (WORMS) of the knee in osteoarthritis. *Osteoarthritis Cartilage* 2004;12(3):177–
- 31 90.
- 32
- 33 36. Kornaat PR, Ceulemans RYT, Kroon HM, et al. MRI assessment of knee osteoarthritis:
- 34 Knee Osteoarthritis Scoring System (KOSS)--inter-observer and intra-observer
- 35 reproducibility of a compartment-based scoring system. *Skeletal Radiol* 2005;34(2):95–
- 36 102.
- 37
- 38 37. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med* 2001;16(9):606–
- 39 13.
- 40
- 41 38. Montorio I, Izal M. The Geriatric Depression Scale: a review of its development and
- 42 utility. *Int Psychogeriatr* 1996;8(1):103–12.
- 43
- 44 39. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*
- 45 1986;7(3):177–88.
- 46
- 47 40. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
- 48 analyses. *BMJ* 2003;327(7414):557–60.
- 49
- 50 41. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews*
- 51 *of Interventions* version 6.0 (updated July 2019) [Internet]. Cochrane; 2019. Available
- 52 from: www.training.cochrane.org/handbook
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 42. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative
- 5 method for detecting bias in meta-analysis. *Int J Evid Based Healthc* 2018;16(4):195–
- 6 203.
- 7
- 8 43. Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained
- 9 Equations in R. *J Stat Softw* 2011;45(3).
- 10
- 11 44. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage
- 12 and two-stage approaches, and why they may differ. *Stat Med* 2017;36(5):855–75.
- 13
- 14 45. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and
- 15 reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and
- 16 Therapeutic Criteria Committee of the American Rheumatism Association. *Arthritis*
- 17 *Rheum* 1986;29(8):1039–49.
- 18
- 19 46. Gurevitch J, Koricheva J, Nakagawa S, Stewart G. Meta-analysis and the science of
- 20 research synthesis. *Nature* 2018;555(7695):175–82.
- 21
- 22 47. Cahan A, Cimino JJ. Improving precision medicine using individual patient data from
- 23 trials. *CMAJ Can Med Assoc J* 2017;189(5):E204–7.
- 24
- 25 48. Stewart LA, Tierney JF. To IPD or not to IPD?: Advantages and Disadvantages of
- 26 Systematic Reviews Using Individual Patient Data. *Eval Health Prof* 2002;25(1):76–97.
- 27
- 28 49. Reade MC, Delaney A, Bailey MJ, Angus DC. Bench-to-bedside review: Avoiding
- 29 pitfalls in critical care meta-analysis – funnel plots, risk estimates, types of heterogeneity,
- 30 baseline risk and the ecologic fallacy. *Crit Care* 2008;12(4):220.
- 31
- 32 50. Idrovo AJ. Three Criteria for Ecological Fallacy. *Environ Health Perspect*
- 33 2011;119(8):a332.
- 34
- 35 51. Felson DT. Identifying Different Osteoarthritis Phenotypes through Epidemiology.
- 36 *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2010;18(5):601–4.
- 37
- 38 52. Deveza LA, Melo L, Yamato TP, Mills K, Ravi V, Hunter DJ. Knee osteoarthritis
- 39 phenotypes and their relevance for outcomes: a systematic review. *Osteoarthritis*
- 40 *Cartilage* 2017;25(12):1926–41.
- 41
- 42 53. van Spil WE, Jansen NWD, Bijlsma JWJ, et al. Clusters within a wide spectrum of
- 43 biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals
- 44 with very early symptomatic osteoarthritis. *Osteoarthritis Cartilage* 2012;20(7):745–54.
- 45
- 46 54. Riley RD, Lambert PC, Staessen JA, et al. Meta-analysis of continuous outcomes
- 47 combining individual patient data and aggregate data. *Stat Med* 2008;27(11):1870–93.
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Appendix 1. Search strategy

Cochrane CENTRAL

- #1. MeSH descriptor Osteoarthritis explode all trees
- #2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*):ti,ab,kw
- #3. (degenerative near/2 arthritis):ti,ab,kw
- #4. coxarthrosis:ti,ab,kw
- #5. (#1 OR #2 OR #3 OR #4)
- #6. MeSH descriptor vitamin D explode all trees
- #7. (vitamin D):ti,ab,kw
- #8. (vitamin D2):ti,ab,kw
- #9. (vitamin D3):ti,ab,kw
- #10. (1-alpha hydroxyvitamin D3):ti,ab,kw
- #11. (1-alpha-hydroxy-vitamin D3):ti,ab,kw
- #12. (1-alpha hydroxycalciferol):ti,ab,kw
- #13. (1-alpha-hydroxy-calciferol):ti,ab,kw
- #14. (1,25 dihydroxyvitamin D3):ti,ab,kw
- #15. (1,25-dihydroxy-vitamin D3):ti,ab,kw
- #16. (1,25 dihydroxycholecalciferol):ti,ab,kw
- #17. (1,25-dihydroxycholecalciferol):ti,ab,kw
- #18. (25-hydroxycholecalciferol):ti,ab,kw
- #19. (25 hydroxycholecalciferol):ti,ab,kw
- #20. (25 hydroxyvitamin D):ti,ab,kw
- #21. (25-hydroxy-vitamin D):ti,ab,kw
- #22. (alfacalcidol):ti,ab,kw
- #23. (calcidiol):ti,ab,kw
- #24. (calcitriol):ti,ab,kw
- #25. (calcifediol):ti,ab,kw
- #26. (calciferol):ti,ab,kw
- #27. (ergocalciferol):ti,ab,kw
- #28. (cholecalciferol):ti,ab,kw
- #29. (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)
- #30. #5 AND #29

MEDLINE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. randomized controlled trial.pt.
31. controlled clinical trial.pt.
32. randomized controlled trials.sh.
33. random allocation.sh.
34. double blind method.sh.

- 1
- 2
- 3 35. single-blind method.sh.
- 4
- 5 36. clinical trial.pt.
- 6
- 7 37. clinical trials.sh.
- 8
- 9 38. clinical trial.tw.
- 10 39. ((singl\$ or doubl\$ or treb1\$ or tripl\$) and (mask\$ or blind\$)).tw.
- 11
- 12 40. placebos.sh.
- 13
- 14 41. placebo\$.tw.
- 15
- 16 42. random\$.tw.
- 17 43. Research Design/
- 18 44. comparative study.sh.
- 19
- 20 45. evaluation studies.sh.
- 21
- 22 46. follow-up studies.sh.
- 23
- 24 47. prospective studies.sh.
- 25
- 26 48. control\$.tw.
- 27 49. prospectiv\$.tw.
- 28
- 29 50. volunteer\$.tw.
- 30
- 31 51. or/30-50
- 32 52. (animal not human).mp.
- 33
- 34 53. 46 not 47
- 35 54. 5 and 29 and 53
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

EMBASE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. random\$.tw.
31. factorial\$.tw.
32. crossover\$.tw.
33. cross over\$.tw.
34. cross-over\$.tw.

- 1
- 2
- 3 35. placebo\$.tw.
- 4
- 5 36. (doubl\$ adj blind\$.tw.
- 6
- 7 37. (singl\$ adj blind\$.tw.
- 8
- 9 38. assign\$.tw.
- 10
- 11 39. allocat\$.tw.
- 12
- 13 40. volunteer\$.tw.
- 14
- 15 41. Crossover Procedure/
- 16
- 17 42. double-blind procedure.tw.
- 18
- 19 43. Randomized Controlled Trial/
- 20
- 21 44. Single Blind Procedure/
- 22
- 23 45. or/30-44
- 24
- 25 46. (animal/ or nonhuman/) not human/
- 26
- 27 47. 45 not 46
- 28
- 29 48. 5 and 29 and 47
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 2. Modified Cochrane's risk of bias tool.

| Source of bias [#] | Low risk | High risk | Unclear | Comments |
|-------------------------------------|--------------------------|--------------------------|--------------------------|----------|
| 1. Random sequence generation | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Allocation concealment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 3. Blinding of participants | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 4. Blinding of key study personnel | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 5. Blinding of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 6. Incomplete outcome data | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 7. Selective outcome reporting | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 8. Imbalance in baseline covariates | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 9. Treatment compliance | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 10. Timing of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Overall risk of bias | Low | Moderate | High | |
| | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |

[#]See *Appendix 2* for criteria for different levels of risk.

Appendix 3. Criteria for risk of bias assessment

1. Random sequence generation

Criteria for a judgement of “Low risk”:

The investigators describe a random component in the sequence generation process such as:

- Referring to a random number table;
- Using a computer random number generator;
- Coin tossing;
- Shuffling cards or envelopes;
- Throwing dice;
- Drawing of lots;
- Minimisation. ^*Minimization may be implemented without a random element, and this is considered to be equivalent to being random.

Criteria for a judgement of “High risk”:

Sequence generation process involves some systematic, non-random approach, for example:

- sequence generated by odd or even date of birth;
- sequence generated by some rule based on date (or day) of admission;
- sequence generated by some rule based on hospital or clinic record number.

Sequence generation process involves judgement or some method of non-random categorisation of participants, for example:

- Allocation by judgement of the clinician;
- Allocation by preference of the participant;
- Allocation based on the results of a laboratory test or a series of tests;
- Allocation by availability of the intervention.

Criteria for a judgement of “Unclear risk”:

Insufficient information about sequence generation process

2. Allocation concealment

Criteria for a judgement of “Low risk”:

Participants and investigators enrolling participants could not foresee assignment because a successful method of allocation concealment, for example:

- Central allocation (including telephone, web-based, and pharmacy-controlled, randomisation);
- Sequentially numbered drug containers of identical appearance;
- Sequentially numbered, opaque, sealed envelopes.

Criteria for a judgement of “High risk”:

Participants and investigator enrolling participants could possibly foresee assignments and thus introduce selection bias, for example:

- Using an open random allocation schedule (e.g. a list of random numbers);
- Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered);
- Alternation or rotation;
- Date of birth;
- Case record number;
- Any other explicitly unconcealed procedure.

Criteria for a judgement of “Unclear risk”:

Insufficient detail to permit judgement of “Low risk” or “High risk”.

3. Blinding of participants**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of participants ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”,
- The study did not address this outcome.

4. Blinding of key study personnel**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of key study personnel (physicians/pharmacists/care givers/trial coordinators) ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

5. Blinding of outcome assessment

Criteria for a judgement of “Low risk”:

Any one of the following:

- No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;
- Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcome assessment is likely to be influenced by lack of blinding;
- Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Criteria for a judgement of “Unclear”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

6. Incomplete outcome data

Criteria for a judgement of “Low risk”:

Any one of the following:

- No missing outcome data;
- Reasons for missing outcome data unlikely to be related to true outcome;
- Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;
- The percentage of withdrawal and drop-outs does not exceed 20% with reasons documented and missing data have been imputed using appropriate methods.

Criteria for a judgement of “High risk”:

Any one of the following:

- Reason for missing outcome data is likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;
- ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation;

- Potentially inappropriate application of simple imputation.

Criteria for a judgement of “Unclear”:

- Insufficient reporting of attrition/exclusions to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

7. Selective outcome reporting:**Criteria for a judgement of “Low risk”:**

Any of the following:

- The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
- The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).

Criteria for a judgement of “High risk”:

Any one of the following:

- Not all of the study’s pre-specified primary outcomes have been reported;
- One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified;
- One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);
- One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;
- The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Criteria for a judgement of “Unclear”:

Insufficient information to permit judgement of “Low risk” or “High risk”.

8. Imbalance in baseline covariates**Criteria for a judgement of “Low risk”:**

Groups are similar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “High risk”:

Groups are obviously dissimilar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “Unclear”:

If baseline characteristics are described in the text but data are not presented.

9. Treatment compliance**Criteria for a judgement of “Low risk”:**

Participants’ compliance with the treatment allocation was measured or documented. The level of treatment compliance based on reported dosage, duration and frequency is acceptable. Analyses were performed on an intention-to-treat basis.

Criteria for a judgement of “High risk”:

Any one of the following:

- Participants' compliance with the treatment allocation was not measured;
- Over 50% of participants did not comply with the allocated treatment;
- Participants were excluded from analysis for variety of reasons, or only per protocol analysis was performed as the primary analysis.

Criteria for a judgement of “Unclear”:

Insufficient reporting in treatment compliance to permit judgement of “Low risk” or “High risk”.

10. Timly outcome assessment

Criteria for a judgement of “Low risk”:

Timing of outcome assessment is identical or closely similar for all treatment groups and for all important outcomes.

Criteria for a judgement of “High risk”:

Timing of outcome assessment is obviously different among participants due to variety reasons.

Criteria for a judgement of “Unclear”:

Insufficient reporting to permit judgement of “Low risk” or “High risk”.

Overall risk of bias

A - low risk of bias:

Low risk for all sources of bias (1-10).

B - moderate risk of bias:

One of more high risk in other sources of bias (8-10). Low risk or unclear risk for key sources of bias (1-7).

C - high risk of bias:

High risk for one or more key sources of bias (1-7).

PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted – Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 5:15

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|-----------------------------------|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| ADMINISTRATIVE INFORMATION | | | | | |
| Title | | | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Registration | 2 | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 2 |
| Authors | | | | | |
| Contact | 3a | Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Support | | | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Role of sponsor/funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| INTRODUCTION | | | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 4-5 |

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|---|-----|---|-------------------------------------|-------------------------------------|---------------------|
| | | | Yes | No | |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| METHODS | | | | | |
| Eligibility criteria | 8 | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Information sources | 9 | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5, Appendix 1. |
| STUDY RECORDS | | | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7-8 |
| Selection process | 11b | State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Data collection process | 11c | Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8 |
| Data items | 12 | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-10 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-9 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7, Appendix 2 |
| DATA | | | | | |
| Synthesis | 15a | Describe criteria under which study data will be quantitatively synthesized | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15c | Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|-----------------------------------|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (e.g., GRADE) | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

For peer review only

BMJ Open

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis (OA) - An OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2019-035302.R2 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 20-Jan-2020 |
| Complete List of Authors: | Jin, Xingzhong; Southern Medical University, Zhujiang Hospital; The University of Sydney, The Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders Antony, Benny; University of Tasmania, Menzies Institute for Medical Research Wang, Xia; The University of Sydney, Institute of Bone and Joint Research Persson, Monica; University of Nottingham Faculty of Medicine and Health Sciences McAlindon, Timothy; Tufts Medical Center, Arden, Nigel; Nuffield Department of Orthopaedics, ; Srivastava, Sudeepti; King George Medical College Srivastava, Rajeshwar; King George Medical University van Middelkoop, Marienke; Erasmus MC Bierma-Zeinstra, Sita; Erasmus MC Zhang, Weiya; University of Nottingham, Academic Rheumatology Cicuttini, Flavia; Monash University, Department of Epidemiology and Preventative Medicine Ding, Changhai; University of Tasmania, Menzies Institute for Medical Research |
| Primary Subject Heading: | Rheumatology |
| Secondary Subject Heading: | Complementary medicine |
| Keywords: | PREVENTIVE MEDICINE, RHEUMATOLOGY, GENERAL MEDICINE (see Internal Medicine) |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis (OA)

An OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis

Xingzhong Jin^{1,2}, Benny Antony³, Xia Wang⁴, Monica SM Persson^{5,6}, Timothy McAlindon⁷, Nigel Arden⁸, Sudeepti Ratan Srivastava⁹, Rajeshwar Nath Srivastava⁹, Marienke van Middelkoop¹⁰, Sita M.A. Biermsa-Zeinstra¹⁰, Weiya Zhang^{5,6}, Flavia Cicuttini¹¹, Changhai Ding^{1,3,11}.

Author Affiliations

¹ ZhuJiang Hospital, Southern Medical University, China

² The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, the University of Sydney, Australia.

³ Menzies Institute for Medical Research, University of Tasmania, Australia.

⁴ Institute of Bone & Joint Research, the University of Sydney, Australia.

⁵ Academic Rheumatology, Division of Rheumatology, Orthopaedics, and Dermatology, University of Nottingham, United Kingdom.

⁶ Arthritis Research UK Pain Centre, United Kingdom.

⁷ Tufts Medical Center, United States.

⁸ Nuffield Department Orthopaedic, Rheumatology and musculoskeletal sciences, University of Oxford, United Kingdom.

⁹ King George Medical University, India.

¹⁰ Erasmus MC, University Medical Center Rotterdam, Netherland.

¹¹ Department of Epidemiology and Preventive Medicine, Monash University, Australia

Correspondence to

Xingzhong Jin, The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, Level 2 Charles Perkins Centre (D17), John Hopkins Drive, The University of Sydney, NSW 2006, Australia; xingzhong.jin@sydney.edu.au.

Keywords

Systematic Review; Meta-analysis; Individual Patient Data; Osteoarthritis; Vitamin D; Knee.

Abstract

Introduction

Observational data suggest vitamin D deficiency is associated with the onset and progression of knee OA. However, randomized controlled trials (RCTs) to date investigating the efficacy of vitamin D supplementation in knee OA have reported conflicting results. Further research is needed to clarify the effects of vitamin D on patient-reported outcomes and determine whether there are patient subgroups who may benefit from the supplementation. The aim of this IPD meta-analysis is to identify patient-level predictors of treatment response to vitamin D supplementation on pain and physical function.

Methods and analysis

A systematic literature search will be conducted for RCTs of vitamin D supplementation on knee OA. Authors of original RCTs will be contacted to obtain the IPD. The primary outcomes will include long-term (≥ 12 months) pain and physical function. Secondary outcomes will include medium-term (≥ 6 months and <12 months) and short-term (<6 months) pain and physical function, as well as patient global assessment, quality of life and adverse events. Potential treatment effect modifiers to be examined in the subgroup analyses include age, gender, body mass index (BMI), baseline knee pain severity and physical function, baseline vitamin D level, radiographic stage, presence of bone marrow lesions on magnetic resonance images (MRI), presence of clinical signs of local inflammation, and concomitant depressive symptoms. Both one-step and two-step modelling methods will be used to determine the possible modifiable effect of each subgroup of interest.

Ethics and dissemination

Separate ethics committee approval because this study involves analysis of de-identified data that have already been collected in individual RCTs. This study will be the first IPD meta-analysis to clarify the effect of vitamin D supplementation on clinical symptoms in different subgroups of patients with knee OA. The findings will be disseminated through peer-review publications and conference presentations.

Systematic review registration

This systematic review is registered on PROSPERO (CRD42018107740).

Article Summary

This article is a protocol for a systematic review and IPD meta-analysis of RCTs studying the effects of vitamin D supplementation on joint pain and physical function in patients with symptomatic knee OA.

Strengths and limitations of this study

- This study protocol is endorsed by the OA Trial Bank, an international collaboration that initiates meta-analyses on predefined subgroups of OA patients.
- This study is the first IPD meta-analysis to identify OA patient subgroups that may benefit from vitamin D supplementation.
- IPD meta-analysis offer greater statistical power and precision than subgroup analysis in a single trial and conventional meta-analysis using aggregate data.
- Analysis may be limited to the variables that have been collected across included RCTs.

Introduction

OA is the most common joint disorder worldwide. OA is ranked as the 13th highest contributor of 310 diseases to global disability in 2015¹. In Australia, OA affects over 2.1 million people (9% of the population), costing the healthcare system over \$2.1 billion in 2015². This cost is forecasted to increase by 41% in 2030³.

The majority (83%) of the disease burden of OA is attributable to knee OA⁴, which is characterized by pain, gradual loss of articular cartilage, and structural changes such as subchondral remodelling and effusion-synovitis⁵. Currently, there are no effective disease-modifying treatments to reverse the progression of knee OA once the disease is established. A majority of patients with knee OA eventually progress to advanced stage and undergo total knee replacement⁶. There is clearly an urgent need for innovative and cost-effective approaches to slow the progression of knee OA.

Emerging observational data suggest that vitamin D insufficiency is associated with the onset and progression of knee OA⁷. The association between low serum vitamin D levels and knee OA symptoms may be explained by a direct effect of vitamin D on chondrocytes in osteoarthritic cartilage⁸, as well as indirect effects on subchondral bone, synovium, and periarticular muscle⁹. For example, vitamin D deficiency could impair the ability of bone to respond optimally to pathological bone marrow lesions (BMLs) and altered bone mineral density, therefore predisposing the knees to disease progression¹⁰. Vitamin D also may reduce synovitis in affected knees by regulating cytokine levels in the joint, leading to a reduction in the amount of effusion-synovitis in MRI¹¹. In addition, depressive symptoms is interrelated to joint pain in OA¹², and maintaining sufficient serum vitamin D may improve depression symptoms in patients with knee OA¹³.

However, evidence from RCTs have been conflicting¹⁴⁻¹⁷. A pilot RCT in India found a small but statistically significant clinical benefit for 12-month vitamin D treatment on pain and function in patients with knee OA, compared with placebo³⁹¹⁶. In contrast, a subsequent RCT from the US showed that vitamin D supplementation did not reduce knee pain or cartilage volume loss over 24 months¹⁵. Subsequently, data from RCTs in Australia¹⁷ and UK¹⁴ did not find significant clinical benefits of vitamin D supplementation for knee OA. However, there was a non-significant trend for symptom reduction (e.g. knee pain and physical function) in these RCTs. Two systematic reviews using aggregate data from these RCTs concluded that, although current evidence does not support vitamin D supplementation for reducing structural

1
2
3 disease progression, further research is needed to clarify the effects on patient-reported
4 outcomes^{18,19}. There are no systematic reviews of previous systematic reviews on this topic.

7 The null results of these RCTs could be due to a low prevalence of vitamin D deficiency in the
8 study subjects or low statistical power secondary to small sample sizes. Another possible
9 reason is that vitamin D may have an effect only in some OA phenotypes, such as those with
10 BMLs (predominant bone abnormality)²⁰, effusion-synovitis (inflammatory)²¹ or depressive
11 symptoms (psychological distress)¹³. Post hoc analyses within these RCTs^{15,21} were frequently
12 underpowered, and hence unreliable to determine the effect of vitamin D treatment on
13 subgroups of knee OA patients. A meta-analysis using IPD can increase the power of subgroup
14 analysis by combining individual data from included trials²² and therefore can quantify
15 potential effect modifier of vitamin D treatment in subgroups.
16
17
18
19
20
21
22

23 **Methods and analysis**

24 We will conduct a systematic review and IPD meta-analysis of RCTs studying the effects of
25 vitamin D supplementation in patients with symptomatic knee OA. The primary aim is to
26 identify patient-level predictors of treatment response to vitamin D supplementation, including
27 the status of vitamin D deficiency, MRI-detected bone marrow abnormalities and effusion-
28 synovitis, and clinical signs of local inflammation. The protocol of this review is registered on
29 the PROSPERO database (CRD42018107740).
30
31
32
33
34
35

36 **Study eligibility**

37 This systematic review will include studies that meet the following inclusion criteria:

38 **Type of studies**

39 RCTs that have been published in journals and reported the efficacy of vitamin D in participants
40 with knee OA will be included. Cross-over design will also be eligible and only the first phase
41 data will be included in the analysis. Both individually randomised trials and cluster
42 randomised trials will be eligible. Both open-labelled and blinded studies will be eligible. There
43 will be no language or geographical restrictions applied to study selection.
44
45
46
47
48

49 **Participants**

50 Men and women who have a diagnosis of knee OA, either according to the American College
51 of Rheumatology criteria, or on the basis of detailed clinical and/or radiographic information,
52 will be included. Studies with a subgroup of knee OA patients will also be included, provided
53 that IPD can be collected separately for the OA subgroup. Although most patients with knee
54 OA defined by the American College of Rheumatology are usually over 50 years of age, the
55
56
57
58
59
60

1
2
3 disease can occur as early as 20 years old, therefore studies with adults at 18 years of age and
4 older will be included.
5

6 7 **Interventions**

8 Only studies investigating oral supplementation of vitamin D will be included. Vitamin D
9 treatments administered subcutaneously, intraperitoneally or intravenously will not be
10 included. Both ergocalciferol (vitamin D₂) and cholecalciferol (vitamin D₃) will be eligible,
11 irrespective of preparations (tablet or capsule), dosage, regimen, and length of treatment.
12
13
14

15 16 **Comparators**

17 Oral vitamin D supplementation will be compared with control treatment including placebo or
18 usual conservative care (pain medication and/or exercise therapy if they are used in both
19 treatment and control groups).
20
21
22

23 24 **Outcomes**

25 The minimum criterion for inclusion is reporting pain or physical function as either primary or
26 secondary outcomes. There will be no restrictions on the duration of follow-up. Data on other
27 outcomes (e.g. patient's global assessment, quality of life, and adverse events) will be analysed
28 when feasible but will not be required for study selection.
29
30
31

32 33 **Baseline assessments**

34 As a minimum, included studies should have measured knee pain, physical function, serum
35 levels of vitamin D at baseline, and included basic patient characteristics such as age, gender,
36 and BMI.
37
38

39 40 **Literature search**

41 A systematic literature search for articles published from 1 January 1990 until 31 December
42 2019 will be performed by a trained review author (XJ) in the following electronic databases:
43

- 44 • Cochrane Central Register of Controlled Trials (CENTRAL);
- 45 • MEDLINE (Ovid);
- 46 • EMBASE;
- 47
- 48

49 A previous systematic review⁷ has showed that no major RCTs were conducted for vitamin D
50 and osteoarthritis by the year 1990, therefore we choose 1 January 1990 as the start date of the
51 literature search. The search strategies used for each database are listed in *Appendix 1*. All
52 retrieved articles will be exported to the reference manager *EndNote*, in which duplicates will
53 be removed electronically and manually. The remaining records will be exported to an online
54 systematic review management tool *Covidence* (Veritas Health Innovation, Melbourne,
55 Australia) and the articles will be assessed for eligibility for inclusion. In addition to the
56
57
58
59
60

1
2
3 electronic search, we will check the reference lists of included trials and previous systematic
4 reviews to identify any trials that are not retrieved from the electronic search. Review authors
5 and collaborating authors will be asked if they are aware of further relevant studies not yet
6 included. We will also search the WHO International Clinical Trial Registration Platform
7 Search Portal (www.who.int/trialsearch) to identify any relevant trials that are completed but
8 did not published the results.
9

14 **Study selection**

15 Two review authors (XJ, BA) will independently conduct study screening by assessing the
16 article titles and abstracts. Full texts of the articles will be further assessed if the information
17 from the abstract suggests that a study is eligible for inclusion. When information contained in
18 the full text is not sufficient to make a judgement on its eligibility, we will make efforts to
19 contact the corresponding authors to obtain further details. If a corresponding author is not
20 contactable after two email attempts and one phone call, the study will be deemed ineligible.
21 Any disagreement regarding the inclusion of a study will be discussed between the two review
22 authors (XJ, BA). If no consensus can be reached, a third review author will be consulted (XW)
23 to make a final decision.
24
25
26
27
28
29

31 **Extraction of aggregate data**

32 Study data extraction will be performed independently by two review authors (BA, XW).
33 Discrepancies will be resolved by a third reviewer (XJ). We will extract the following study
34 data from the included studies:
35
36
37

- 38 • General information: article title, bibliographic details, published language, and
39 funding source.
- 40 • Participants: inclusion criteria, exclusion criteria, number of participants in total and in
41 each study arm, study settings, and baseline participant characteristics (e.g. age, gender,
42 BMI).
- 43 • Intervention: type of vitamin D preparation, dose, regimen, treatment duration, type of
44 control, and co-interventions (if any).
- 45 • Outcomes: primary and secondary outcomes at the end of treatment and/or the end of
46 follow-up. Number of withdrawals and loss to follow-up. Adverse events recorded.
- 47 • Data analysis: statistical models used for data analysis, confounding factors adjusted in
48 the models, and methods used for addressing missing values.
49
50
51
52
53
54
55
56
57
58
59
60

Risk of bias assessment

The methodological quality of the included studies will be assessed using a modified version of the Cochrane's risk of bias tool²³. The modified version includes all the seven domains of the original tool, but further separates performance bias assessment into 'blinding of participants' and 'blinding of study personnel', as well as pre-specifies other sources of bias as 'balance in baseline covariates', 'treatment compliance', and 'timely outcome assessment' (*Appendix 2*). Each domain will be scored as 'low risk', 'high risk' or 'unclear' according to the criteria described in the *Appendix 3*. The overall rating of risk of bias is based on the number of domains with a 'high-risk' score. The overall rating is intended to inform readers of the risk of bias across individual studies and will not be used to weight the studies in the meta-analysis. Two review authors (XJ, XW) will independently evaluate the quality of an individual study. Any disagreement will be settled by further discussion until a consensus is reached between the two review authors.

IPD collection and transfer

The primary or corresponding authors of included trials will be invited to collaborate on the project and contribute their raw data. When we cannot reach a corresponding author after sending two emails and making two telephone calls, we will contact the co-authors listed in the article. If none of the co-authors can be contacted, we will approach the institutes, in which the trial has been conducted. All data custodians will be asked to sign a data delivery agreement, which includes items regarding IPD delivery, obligations, ownership of data, terms and conditions of the use of the data, authorship, and publications. If needed, the project coordinator (XJ) will visit the institutes of the data deliverers to retrieve the data and to sign the data delivery agreement on behalf of the OA Trial Bank (the detailed procedures of data delivery and an example of the data delivery agreement can be found on the OA Trial Bank website <https://www.oatrialbank.com/procedures/>). De-identified datasets will be accepted in any electronic format (for example, SPSS, Stata, SAS, Excel) or in paper form, provided that variables and categories are adequately labelled within the dataset or within a separate codebook. The IPD files received by the coordinator will be kept in their original version and saved on a secured password-protected server at Erasmus MC Medical University in Rotterdam. The datasets will not be used for any other research apart from that described in the license agreement.

To ensure the quality of the data, the coordinator will independently check for data consistency by comparing the summary statistics derived from the IPD received against the summary

1
2
3 results reported in the published articles. In the case of differences, the project coordinator will
4 communicate with the data deliverer via email or teleconference to resolve the discrepancy.
5
6

7 **Variables of interest**

8 The following IPD variables will be obtained (where available):
9

10 **Primary outcome variables**

11 The primary outcomes for this meta-analysis will be pain and physical function at long-term
12 follow-up (12 months or more). This definition of 'long-term effect' for knee OA treatment
13 was used in previous systematic reviews of knee OA research^{24,25}.
14
15

- 16 • Knee pain will be evaluated using visual analogue scale (VAS) if available, otherwise the
17 pain subscales of the Western Ontario and McMaster Universities Osteoarthritis Index
18 (WOMAC)²⁶ or the Knee injury and Osteoarthritis Outcome Score (KOOS)²⁷ will be used.
19 The pain data will be converted into a 0-100 common scale as recommended by the
20 WOMAC manual²⁸.
21
22 • Physical function will be evaluated using a validated instrument specific to knee OA, such
23 as the physical function subscales of the WOMAC or the KOOS subscales. The scores will
24 be standardised into a 0-100 scale.
25
26
27
28
29
30
31

32 **Secondary outcome variables**

33 Secondary outcomes will include:
34

- 35 • Medium-term (more than 6 months but less than 12 months) pain and physical function;
- 36 • Short-term (less than 6 months) pain and physical function;
- 37 • Patient global assessment at the end of study follow-up, as recommended by the
38 OMERACT-OARSI Initiative²⁹.
39
40 • Quality of life evaluated using a validated instrument, such as EQ-5D³⁰, osteoarthritis Knee
41 and Hip Quality of Life (OAKHQOL)³¹, or original instrument used in the included studies;
- 42 • Adverse events if reported, including all major and minor events such as hypocalcaemia,
43 fractures, and depression.
44
45
46
47
48
49
50
51

52 **Potential treatment effect moderators**

53 If data are available, we will analyse potential treatment effect modification for the following
54 variables measured at baseline:
55
56

- 57 • Radiographic stage of knee OA (mild/moderate or severe). Radiographic knee OA should
58 be staged at baseline using either the Kellgren-Lawrence (KL)³² or Osteoarthritis Research
59
60

Society International (OARSI) joint space narrowing (JSN) grading system³³. The results from the two grading systems have been shown to be highly correlated³⁴. Mild to moderate disease will be defined as a KL score ≤ 3 or an OARSI JSN score ≤ 2 , and severe disease will be a KL score of 4, or an OARSI score of 3.

- Vitamin D level (deficiency, insufficiency, or sufficiency). Vitamin D deficiency is defined as serum levels of 25(OH)D less than 30 nmol/L at baseline. Insufficiency is defined as serum 25(OH)D levels from 30 to <50 nmol/L. Serum 25(OH)D levels ≥ 50 nmol/L is considered as vitamin D sufficiency³⁵.
- Presence of BMLs (yes or no). BMLs at the patella-femoral and femoro-tibial joints should be measured by MRI using a validated scoring system, such as BLOKS (Boston Leeds Osteoarthritis Knee Score)³⁶, WORMS (Whole-Organ Magnetic Resonance Imaging Score)³⁷, or KOSS (Knee Osteoarthritis Scoring System)³⁸.
- Clinical signs of local inflammation or the presence of effusion-synovitis (yes or no). Clinical signs of local inflammation should be assessed by physical examination - tumor (swelling), dolor (pain), rubor (redness), calor (heat), and functio laesa (disturbance of function) - or by additional laboratory testing (e.g. serum c-reactive protein and erythrocyte sedimentation rate). Effusion-synovitis should be measured on either ultrasound or MRI.
- Presence of depressive symptoms or comorbid depression. Depressive symptoms are measured using a validated questionnaire, such as the Patient Health Questionnaire (PHQ-9)³⁹ and the Geriatric Depression Scale (GDS)⁴⁰.

Data synthesis and statistical methods

All statistical analysis will be conducted using R version 3.5.0 and RStudio (version 1.0.136, RStudio, Inc., Boston, MA), with R extension package ‘metafor’ for the conventional meta-analysis and two-stage IPD meta-analysis, and ‘lme4’ for the one-stage IPD meta-analysis.

Conventional meta-analysis

An aggregate data meta-analysis, using a random-effects model based on the ‘DerSimonian and Laird’ method⁴¹, will be performed to estimate the treatment effect of vitamin D over control. If an included study is a cluster RCT, an approximately correct analysis will be performed to account for the effect of clustering⁴². The results will be compared with the IPD meta-analysis findings as sensitivity analyses.

Heterogeneity will be assessed by inspecting the forest plots and tested by χ^2 test. A result of $p < 0.10$ will be defined as evidence of significant heterogeneity across studies. I^2 test will be

1
2
3 used to estimate the extent of inconsistency across studies that is due to heterogeneity⁴³. A
4 result of over 30% and 50% represents moderate and substantial heterogeneity, respectively⁴².
5 Sources of heterogeneity will be explored by excluding individual trials causing an I^2 score
6 below 50%.
7
8
9

10 If 10 trials or more trials are available, we will use a Doi plot (normal quantile versus effect
11 size plot) explore publication bias and ‘small-study effects’⁴⁴. Asymmetry in the Doi plot will
12 be detected and quantified by the LFK index. A value beyond +/- 1 will be deemed consistent
13 with asymmetry, thus having considerable small-study effects⁴⁴.
14
15
16

17 **IPD meta-analysis**

18 IPD from included trials will be recoded and formatted in a consistent way to permit re-
19 analysis. A new variable will be created to indicate the trial in which the IPD are collected.
20 The method used to handle missing data will depend on the mechanism causing the
21 missingness. If no explanation is known for the reason of missing data, they will be assumed
22 to be missing at random. We will use the R MICE package⁴⁵ for multiple imputation and the
23 imputation model will include all available patient variables to help predict missing data for
24 the variables of interest within each study dataset. The imputation procedure will use 20
25 imputed datasets. A sensitivity analyses will be performed restricting to participants without
26 missing data (complete case analysis).
27
28
29
30
31
32
33
34

35 Both the treatment effect of vitamin D supplementation and the effect of potential moderators
36 will be studied in the IPD meta-analyses. The treatment effect of vitamin D will be measured
37 using the mean difference in knee pain and physical function between treatment and control
38 based on the intention-to-treat principle. The interaction between the treatment and a potential
39 moderator will be used to identify the effect of the moderator. Interaction effects with $p < 0.05$
40 will be considered statistically significant and 95% confidence intervals of the effects will be
41 provided. The IPD meta-analyses will be undertaken using both the one-stage and two-stage
42 approaches. We will use the one-stage approach as the primary analysis to avoid assumptions
43 of within-study normality and known within-study variance⁴⁶. We will and compare the results
44 to the two-stage approach to assess consistency in a sensitivity analysis.
45
46
47
48
49
50
51
52

53 ***One-stage modelling***

54 The one-stage mixed-effects IPD meta-analysis approach will take into account both study
55 level and subject-level covariates. Subject -level covariates will be centred to the mean of the
56 covariate in each trial to avoid ecological bias. Three multilevel regression models will be built,
57 the first to examine the summary treatment effect (difference between vitamin D and control),
58
59
60

1
2
3 the second to evaluate each of the mentioned moderators on treatment effect, and the third to
4 assess the true effect of one moderator independent of other moderators.
5

6
7 The first model will include outcome measure (e.g. pain score at follow-up) as a dependent
8 variable, treatment (vitamin D or control), baseline subject-level covariate (e.g. pain score) and
9 confounders (age, gender and BMI) as fixed-effect independent variables, adjusted for study
10 identifier (random intercept). The partial regression coefficient of the treatment will be used to
11 compare to the conventional meta-analysis.
12
13

14
15 The second model will further add the moderator of interest (e.g. radiographic stage of the
16 disease) and interaction term between the treatment and study-centred values of the moderator
17 in the fixed-effect of the first model. The regression coefficient of the interaction term will be
18 used to quantify the impact of the moderator on treatment effect.
19
20
21

22
23 If there are two or more moderators that have a statistically significant interaction with the
24 treatment effect, these moderators will be incorporated in the third model. Multicollinearity
25 between moderators will be tested before building the third model. A correlation coefficient
26 $r > 0.80$ will indicate that multiple collinearity exists between the two moderators, of which the
27 one that has less measurement error will be included in the model.
28
29
30
31

32 ***Two-stage modelling***

33 In the first stage, treatment effect and variance are derived from separate analysis in each
34 study. An analysis of covariance (ANCOVA) model adjusted for baseline covariates (age,
35 gender, BMI, as well as knee pain or function), will be used to obtain the treatment effect and
36 variance within each study separately. The effect of a moderator and its variance within each
37 study will be obtained by adding the interaction term between treatment effect and the
38 moderator into the model. In the second stage, the treatment effect and its variances obtained
39 from the first stage will be pooled across studies using a random-effects model⁴¹. The result
40 of this model is a summary estimate of the treatment effect of vitamin D versus control. The
41 effect of a moderator will be calculated by pooling the regression coefficient and variance of
42 the interaction term between the treatment and the moderator using a similar model. If two or
43 more interaction terms are statistically significant, these moderators will be incorporated in a
44 further model to evaluate the independent effect of these moderators.
45
46
47
48
49
50
51
52
53
54

55 **Discussion**

56 Vitamin D supplementation may improve pain and function in patients with knee OA; however,
57 the evidence from observational studies and RCTs are controversial^{7,18}. In a few existing RCTs
58
59
60

1
2
3 in patients with symptomatic knee OA^{27,14,16,17}, small to modest improvement in knee pain and
4 physical function were observed in participants receiving vitamin D supplementation, but the
5 treatment response varies considerably and the effects were not statistically significant when
6 compared to placebo. The broad variation in treatment response could be a result of the fact
7 that knee OA is a highly heterogenous disease with multiple aetiologies⁴⁷. Vitamin D may
8 therefore be more effective in a subset of patients with specific characteristics than others. The
9 purpose of the proposed IPD meta-analysis is to evaluate the treatment response of vitamin D
10 supplementation on pain and physical function for knee OA in specific subsets of patients
11 according to disease severity, vitamin D levels, presence of BMLs, inflammatory signs and
12 depressive symptoms, over both short- and long-term follow-up.
13
14
15
16
17
18
19

20
21 Meta-analysis is considered by some the grandmother of ‘big data’⁴⁸ and an integrated part of
22 precision medicine⁴⁹. It is a cost-effective approach to identify potential moderators of
23 treatment response at a patient level, which is not possible with subgroup analyses in a single
24 trial or conventional meta-analysis with aggregate data⁵⁰. Subgroup analyses within individual
25 trials are often underpowered to generate reliable findings. In contrast, IPD meta-analysis
26 techniques increase the statistical power of the study by combining individual observation data
27 from multiple trials with the same treatment²². This offers greater precision in analysing
28 moderators of treatment response and offers the potential to analyse a greater number of
29 moderators. In conventional meta-analysis, meta-regression analysis may be used to examine
30 differences in the types of patients enrolled in individual trials, but is potentially problematic.
31 Meta-regression analysis may make incorrect inferences about individual characteristics based
32 upon aggregate baseline statistics reported in trial publications⁵¹. This is also known as
33 ecological fallacy⁵², where the relationship between the effect estimate and average patient
34 characteristics across trials may not be the same as the relationship within individual trials.
35
36
37
38
39
40
41
42
43
44

45
46 Identifying different phenotypes of knee OA is currently a popular subject of research in the
47 field. Different phenotyping strategies have been proposed based on risk factors from
48 epidemiological studies⁵³, anatomical abnormalities on modern imaging⁵⁴, or molecular
49 abnormalities related to pathological mechanisms⁵⁵. While there is currently no standardised
50 classification system for knee OA phenotypes⁵, we believe that disease phenotypes are most
51 meaningful when they reflect differential treatment effects. IPD meta-analysis provides an
52 opportunity to assess the effect of treatments on subtypes or phenotypes of patients with knee
53 OA according to predefined set of characteristics. The current proposed IPD meta-analysis
54
55
56
57
58
59
60

1
2
3 attempts to differentiate subgroups by identifying subtypes of patients that respond better to
4 vitamin D supplementation on pain and physical function.
5
6

7 **Strengths and limitations**

8 Several challenges may present when conducting an IPD meta-analysis. First, although IPD
9 meta-analyses usually offer sufficient statistical power to examine moderators of treatment
10 response, not all RCTs measure potential moderators of interest or measure them in the same
11 way. This may limit the analysis to only exploring moderators that have been collected across
12 studies. The current protocol attempts to minimise this risk by including moderators that are
13 commonly reported in OA research. In addition, there are expected barriers to accessing data,
14 such as the authors of included trials not being able to be contacted, or the authors losing access
15 to raw data or not choosing to collaborate, may introduce selection bias into the IPD meta-
16 analysis. However, this could be examined in sensitivity analyses by comparing the results to
17 the conventional meta-analysis or be addressed using frameworks that combine IPD and
18 aggregate data in a meta-analysis⁵⁶.
19
20
21
22
23
24
25
26
27

28 The benefits of using IPD meta-analysis techniques greatly outweigh the challenges of using
29 this intensive method. Previous RCTs and systematic reviews have not had sufficient power to
30 thoroughly examine the differential treatment response of vitamin D supplementation in
31 different subsets of patients with knee OA. The results of this project have a high potential to
32 provide important evidence to guide subgroup-specific treatment decisions in clinical practice
33 to improve therapeutic effectiveness.
34
35
36
37
38

39 **Status of project**

40 Currently, literature search in the electronic databases has been commenced.
41
42

43 **Abbreviations**

44 OA: osteoarthritis; IPD: individual patient data; RCT: randomised controlled trial; BMI: body
45 mass index; MRI: magnetic resonance imaging; BMLs: bone marrow lesions; JSN: joint space
46 narrowing; OARSI: Osteoarthritis Research Society International.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Additional Information

Acknowledgement

We acknowledge the University of Sydney China Study Centre for providing short-term travel support to establish international collaboration for this project.

Ethics approval and consent to participate

Research ethical or governance approval is exempt for this study as no new data are being collected.

Availability of data and material

Erasmus MC intends to create a central databank including data from several randomised clinical trials evaluating one or more interventions in patients with osteoarthritis of the knee or hip (the OA Trial Bank) in order to enable researchers to perform meta-analyses on individual patient data to define sub-groups that are specifically responsive to certain treatments. Data request for future research using data deposited in the OA Trial Bank can be directed to <https://www.oatrialbank.com/contact/>

Authors contributions

All authors were involved in the study design and all will contribute to the interpretation of the results. CD, BA and XJ conceptualised this study. WZ and MP provided methodological support for statistical analysis. XJ and BA will contact the potential data deliverers and will coordinate the project. CD, FC, TM, NA, RNS and SRS will deliver relevant data from their completed trials. SBZ and MM will facilitate legal agreement for data transfer and provide database management at the OA Trial Bank. XJ, BA and XW will perform the study selection, risk of bias assessment, data collection and analysis. All authors contributed to writing of this manuscript and approved the final submission.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors declare that they have no competing interests.

Patient and public involvement

We do not directly include patient and public involvement in this study, but the design of included randomised controlled trials may involve patients.

Word count

Abstract: 297

Main text: 4068

References: 56

References

1. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* 2016;388(10053):1545–602.
2. Australian Bureau of Statistics. 2014-15 National Health Survey. Canberra: Australian Bureau of Statistics; 2017.
3. Ackerman IN, Pratt C, Gorelik A, Liew D. Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population-Level Analysis. *Arthritis Care Res* 2018;70(6):877–83.
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012;380(9859):2163–96.
5. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for Standardized Definitions of Osteoarthritis and Risk Stratification for Clinical Trials and Clinical Use. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2015;23(8):1233–41.
6. Australian Orthopaedic Association National Joint Replacement Registry. Annual Report 2012. Adelaide, Australia: AOA; 2012.
7. Cao Y, Winzenberg T, Nguo K, Lin J, Jones G, Ding C. Association between serum levels of 25-hydroxyvitamin D and osteoarthritis: a systematic review. *Rheumatology* 2013;ket132.
8. Garfinkel RJ, Dilisio MF, Agrawal DK. Vitamin D and Its Effects on Articular Cartilage and Osteoarthritis. *Orthop J Sports Med* [Internet] 2017 [cited 2018 Oct 12];5(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480771/>
9. Zhang FF, Driban JB, Lo GH, et al. Vitamin D Deficiency Is Associated with Progression of Knee Osteoarthritis. *J Nutr* 2014;144(12):2002–8.
10. Bellido M, Lugo L, Roman-Blas JA, et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. *Osteoarthritis Cartilage* 2011;19(10):1228–36.
11. Wang X, Cicutinni F, Jin X, et al. Effect of vitamin D on effusion-synovitis in knee osteoarthritis: a randomized controlled trial. *Arthritis Rheumatol* 2015;67:439–40.
12. Sharma A, Kudesia P, Shi Q, Gandhi R. Anxiety and depression in patients with osteoarthritis: impact and management challenges. *Open Access Rheumatol Res Rev* 2016;8:103–13.
13. Zheng S, Tu L, Cicutinni F, et al. Effect of Vitamin D Supplementation on Depressive Symptoms in Patients With Knee Osteoarthritis. *J Am Med Dir Assoc* 2018;
14. Arden NK, Cro S, Sheard S, et al. The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial. *Osteoarthritis Cartilage* 2016;24(11):1858–66.

15. McAlindon T, LaValley M, Schneider E, et al. Effect Of Vitamin D Supplementation On Progression Of Knee Pain And Cartilage Volume Loss In Patients With Symptomatic Osteoarthritis. A Randomized Controlled Trial. *JAMA J Am Med Assoc* 2013;309(2):155–62.
16. Sanghi D, Mishra A, Sharma AC, et al. Does Vitamin D Improve Osteoarthritis of the Knee: A Randomized Controlled Pilot Trial. *Clin Orthop Relat Res* 2013;471(11):3556–62.
17. Jin X, X J, G J, et al. Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial. 2016; Available from: <http://doi.org/10.1001/jama.2016.1961>
18. Hussain S, Singh A, Akhtar M, Najmi AK. Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials. *Rheumatol Int* 2017;37(9):1489–98.
19. Diao N, Yang B, Yu F. Effect of vitamin D supplementation on knee osteoarthritis: A systematic review and meta-analysis of randomized clinical trials. *Clin Biochem* 2017;50(18):1312–6.
20. Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. *Radiol Clin* 2004;42(1):1–9.
21. Wang X, Cicuttini F, Jin X, et al. Knee effusion-synovitis volume measurement and effects of vitamin D supplementation in patients with knee osteoarthritis. *Osteoarthritis Cartilage* 2017;25(8):1304–1312.
22. Groenwold RHH, Donders ART, Heijden GJMG van der, Hoes AW, Rovers MM. Confounding of Subgroup Analyses in Randomized Data. *Arch Intern Med* 2009;169(16):1532–4.
23. Jørgensen L, Paludan-Müller AS, Laursen DRT, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. *Syst Rev* [Internet] 2016 [cited 2018 Oct 11];5. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862216/>
24. Charlesworth J, Fitzpatrick J, Perera NKP, Orchard J. Osteoarthritis- a systematic review of long-term safety implications for osteoarthritis of the knee. *BMC Musculoskelet Disord* 2019;20(1):151.
25. van Middelkoop M, Arden NK, Atchia I, et al. The OA Trial Bank: meta-analysis of individual patient data from knee and hip osteoarthritis trials show that patients with severe pain exhibit greater benefit from intra-articular glucocorticoids. *Osteoarthritis Cartilage* 2016;24(7):1143–52.
26. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. *Arthritis Care Res* 2001;45(5):453–61.

- 1
- 2
- 3
- 4 27. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) -
- 5 validation and comparison to the WOMAC in total knee replacement. *Health Qual Life*
- 6 *Outcomes* 2003;1:17.
- 7
- 8 28. Bellamy N. WOMAC osteoarthritis index: user guide IV. 2000.
- 9
- 10 29. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative:
- 11 Osteoarthritis Research Society International set of responder criteria for osteoarthritis
- 12 clinical trials revisited. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2004;12(5):389–99.
- 13
- 14 30. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L
- 15 compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life*
- 16 *Res* 2013;22(7):1717–27.
- 17
- 18 31. Rat A-C, Coste J, Pouchot J, et al. OAKHQOL: a new instrument to measure quality of
- 19 life in knee and hip osteoarthritis. *J Clin Epidemiol* 2005;58(1):47–55.
- 20
- 21 32. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. *Ann Rheum Dis*
- 22 1957;16(4):494–502.
- 23
- 24 33. Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised.
- 25 *Osteoarthritis Cartilage* 2007;15 Suppl A:A1-56.
- 26
- 27 34. Gudbergesen H, Lohmander LS, Jones G, et al. Correlations between radiographic
- 28 assessments and MRI features of knee osteoarthritis – a cross-sectional study.
- 29 *Osteoarthritis Cartilage* 2013;21(4):535–43.
- 30
- 31 35. Scragg R. Emerging Evidence of Thresholds for Beneficial Effects from Vitamin D
- 32 Supplementation. *Nutrients* 2018;10(5).
- 33
- 34 36. Hunter DJ, Lo GH, Gale D, Grainger AJ, Guermazi A, Conaghan PG. The reliability of a
- 35 new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion
- 36 assessment: BLOKS (Boston Leeds Osteoarthritis Knee Score). *Ann Rheum Dis*
- 37 2008;67(2):206–11.
- 38
- 39 37. Peterfy CG, Guermazi A, Zaim S, et al. Whole-Organ Magnetic Resonance Imaging
- 40 Score (WORMS) of the knee in osteoarthritis. *Osteoarthritis Cartilage* 2004;12(3):177–
- 41 90.
- 42
- 43 38. Kornaat PR, Ceulemans RYT, Kroon HM, et al. MRI assessment of knee osteoarthritis:
- 44 Knee Osteoarthritis Scoring System (KOSS)--inter-observer and intra-observer
- 45 reproducibility of a compartment-based scoring system. *Skeletal Radiol* 2005;34(2):95–
- 46 102.
- 47
- 48 39. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med* 2001;16(9):606–
- 49 13.
- 50
- 51 40. Montorio I, Izal M. The Geriatric Depression Scale: a review of its development and
- 52 utility. *Int Psychogeriatr* 1996;8(1):103–12.
- 53
- 54 41. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*
- 55 1986;7(3):177–88.
- 56
- 57
- 58
- 59
- 60

42. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019) [Internet]. Cochrane; 2019. Available from: www.training.cochrane.org/handbook
43. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557–60.
44. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. *Int J Evid Based Healthc* 2018;16(4):195–203.
45. Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *J Stat Softw* 2011;45(3).
46. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. *Stat Med* 2017;36(5):855–75.
47. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. *Arthritis Rheum* 1986;29(8):1039–49.
48. Gurevitch J, Koricheva J, Nakagawa S, Stewart G. Meta-analysis and the science of research synthesis. *Nature* 2018;555(7695):175–82.
49. Cahan A, Cimino JJ. Improving precision medicine using individual patient data from trials. *CMAJ Can Med Assoc J* 2017;189(5):E204–7.
50. Stewart LA, Tierney JF. To IPD or not to IPD?: Advantages and Disadvantages of Systematic Reviews Using Individual Patient Data. *Eval Health Prof* 2002;25(1):76–97.
51. Reade MC, Delaney A, Bailey MJ, Angus DC. Bench-to-bedside review: Avoiding pitfalls in critical care meta-analysis – funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy. *Crit Care* 2008;12(4):220.
52. Idrovo AJ. Three Criteria for Ecological Fallacy. *Environ Health Perspect* 2011;119(8):a332.
53. Felson DT. Identifying Different Osteoarthritis Phenotypes through Epidemiology. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2010;18(5):601–4.
54. Deveza LA, Melo L, Yamato TP, Mills K, Ravi V, Hunter DJ. Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review. *Osteoarthritis Cartilage* 2017;25(12):1926–41.
55. van Spil WE, Jansen NWD, Bijlsma JWJ, et al. Clusters within a wide spectrum of biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals with very early symptomatic osteoarthritis. *Osteoarthritis Cartilage* 2012;20(7):745–54.
56. Riley RD, Lambert PC, Staessen JA, et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. *Stat Med* 2008;27(11):1870–93.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 1. Search strategy

Cochrane CENTRAL

- #1. MeSH descriptor Osteoarthritis explode all trees
- #2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*):ti,ab,kw
- #3. (degenerative near/2 arthritis):ti,ab,kw
- #4. coxarthrosis:ti,ab,kw
- #5. (#1 OR #2 OR #3 OR #4)
- #6. MeSH descriptor vitamin D explode all trees
- #7. (vitamin D):ti,ab,kw
- #8. (vitamin D2):ti,ab,kw
- #9. (vitamin D3):ti,ab,kw
- #10. (1-alpha hydroxyvitamin D3):ti,ab,kw
- #11. (1-alpha-hydroxy-vitamin D3):ti,ab,kw
- #12. (1-alpha hydroxycalciferol):ti,ab,kw
- #13. (1-alpha-hydroxy-calciferol):ti,ab,kw
- #14. (1,25 dihydroxyvitamin D3):ti,ab,kw
- #15. (1,25-dihydroxy-vitamin D3):ti,ab,kw
- #16. (1,25 dihydroxycholecalciferol):ti,ab,kw
- #17. (1,25-dihydroxycholecalciferol):ti,ab,kw
- #18. (25-hydroxycholecalciferol):ti,ab,kw
- #19. (25 hydroxycholecalciferol):ti,ab,kw
- #20. (25 hydroxyvitamin D):ti,ab,kw
- #21. (25-hydroxy-vitamin D):ti,ab,kw
- #22. (alfacalcidol):ti,ab,kw
- #23. (calcidiol):ti,ab,kw
- #24. (calcitriol):ti,ab,kw
- #25. (calcifediol):ti,ab,kw
- #26. (calciferol):ti,ab,kw
- #27. (ergocalciferol):ti,ab,kw
- #28. (cholecalciferol):ti,ab,kw
- #29. (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)
- #30. #5 AND #29

MEDLINE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. randomized controlled trial.pt.
31. controlled clinical trial.pt.
32. randomized controlled trials.sh.
33. random allocation.sh.
34. double blind method.sh.

- 1
- 2
- 3 35. single-blind method.sh.
- 4
- 5 36. clinical trial.pt.
- 6
- 7 37. clinical trials.sh.
- 8
- 9 38. clinical trial.tw.
- 10 39. ((singl\$ or doubl\$ or treb1\$ or tripl\$) and (mask\$ or blind\$)).tw.
- 11
- 12 40. placebos.sh.
- 13
- 14 41. placebo\$.tw.
- 15
- 16 42. random\$.tw.
- 17 43. Research Design/
- 18 44. comparative study.sh.
- 19
- 20 45. evaluation studies.sh.
- 21
- 22 46. follow-up studies.sh.
- 23
- 24 47. prospective studies.sh.
- 25
- 26 48. control\$.tw.
- 27 49. prospectiv\$.tw.
- 28
- 29 50. volunteer\$.tw.
- 30
- 31 51. or/30-50
- 32 52. (animal not human).mp.
- 33
- 34 53. 46 not 47
- 35 54. 5 and 29 and 53
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

EMBASE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. random\$.tw.
31. factorial\$.tw.
32. crossover\$.tw.
33. cross over\$.tw.
34. cross-over\$.tw.

- 1
- 2
- 3 35. placebo\$.tw.
- 4
- 5 36. (doubl\$ adj blind\$.tw.
- 6
- 7 37. (singl\$ adj blind\$.tw.
- 8
- 9 38. assign\$.tw.
- 10 39. allocat\$.tw.
- 11 40. volunteer\$.tw.
- 12
- 13 41. Crossover Procedure/
- 14
- 15 42. double-blind procedure.tw.
- 16
- 17 43. Randomized Controlled Trial/
- 18 44. Single Blind Procedure/
- 19
- 20 45. or/30-44
- 21 46. (animal/ or nonhuman/) not human/
- 22
- 23 47. 45 not 46
- 24
- 25 48. 5 and 29 and 47
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 2. Modified Cochrane's risk of bias tool.

| Source of bias [#] | Low risk | High risk | Unclear | Comments |
|-------------------------------------|--------------------------|--------------------------|--------------------------|----------|
| 1. Random sequence generation | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Allocation concealment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 3. Blinding of participants | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 4. Blinding of key study personnel | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 5. Blinding of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 6. Incomplete outcome data | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 7. Selective outcome reporting | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 8. Imbalance in baseline covariates | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 9. Treatment compliance | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 10. Timing of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Overall risk of bias | Low | Moderate | High | |
| | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |

[#]See *Appendix 2* for criteria for different levels of risk.

Appendix 3. Criteria for risk of bias assessment

1. Random sequence generation

Criteria for a judgement of “Low risk”:

The investigators describe a random component in the sequence generation process such as:

- Referring to a random number table;
- Using a computer random number generator;
- Coin tossing;
- Shuffling cards or envelopes;
- Throwing dice;
- Drawing of lots;
- Minimisation. ^*Minimization may be implemented without a random element, and this is considered to be equivalent to being random.

Criteria for a judgement of “High risk”:

Sequence generation process involves some systematic, non-random approach, for example:

- sequence generated by odd or even date of birth;
- sequence generated by some rule based on date (or day) of admission;
- sequence generated by some rule based on hospital or clinic record number.

Sequence generation process involves judgement or some method of non-random categorisation of participants, for example:

- Allocation by judgement of the clinician;
- Allocation by preference of the participant;
- Allocation based on the results of a laboratory test or a series of tests;
- Allocation by availability of the intervention.

Criteria for a judgement of “Unclear risk”:

Insufficient information about sequence generation process

2. Allocation concealment

Criteria for a judgement of “Low risk”:

Participants and investigators enrolling participants could not foresee assignment because a successful method of allocation concealment, for example:

- Central allocation (including telephone, web-based, and pharmacy-controlled, randomisation);
- Sequentially numbered drug containers of identical appearance;
- Sequentially numbered, opaque, sealed envelopes.

Criteria for a judgement of “High risk”:

Participants and investigator enrolling participants could possibly foresee assignments and thus introduce selection bias, for example:

- Using an open random allocation schedule (e.g. a list of random numbers);
- Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered);
- Alternation or rotation;
- Date of birth;
- Case record number;
- Any other explicitly unconcealed procedure.

Criteria for a judgement of “Unclear risk”:

Insufficient detail to permit judgement of “Low risk” or “High risk”.

3. Blinding of participants**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of participants ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”,
- The study did not address this outcome.

4. Blinding of key study personnel**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of key study personnel (physicians/pharmacists/care givers/trial coordinators) ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

5. Blinding of outcome assessment

Criteria for a judgement of “Low risk”:

Any one of the following:

- No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;
- Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcome assessment is likely to be influenced by lack of blinding;
- Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Criteria for a judgement of “Unclear”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

6. Incomplete outcome data

Criteria for a judgement of “Low risk”:

Any one of the following:

- No missing outcome data;
- Reasons for missing outcome data unlikely to be related to true outcome;
- Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;
- The percentage of withdrawal and drop-outs does not exceed 20% with reasons documented and missing data have been imputed using appropriate methods.

Criteria for a judgement of “High risk”:

Any one of the following:

- Reason for missing outcome data is likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;
- ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation;

- Potentially inappropriate application of simple imputation.

Criteria for a judgement of “Unclear”:

- Insufficient reporting of attrition/exclusions to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

7. Selective outcome reporting:

Criteria for a judgement of “Low risk”:

Any of the following:

- The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
- The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).

Criteria for a judgement of “High risk”:

Any one of the following:

- Not all of the study’s pre-specified primary outcomes have been reported;
- One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified;
- One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);
- One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;
- The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Criteria for a judgement of “Unclear”:

Insufficient information to permit judgement of “Low risk” or “High risk”.

8. Imbalance in baseline covariates

Criteria for a judgement of “Low risk”:

Groups are similar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “High risk”:

Groups are obviously dissimilar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “Unclear”:

If baseline characteristics are described in the text but data are not presented.

9. Treatment compliance

Criteria for a judgement of “Low risk”:

Participants’ compliance with the treatment allocation was measured or documented. The level of treatment compliance based on reported dosage, duration and frequency is acceptable. Analyses were performed on an intention-to-treat basis.

Criteria for a judgement of “High risk”:

Any one of the following:

- Participants' compliance with the treatment allocation was not measured;
- Over 50% of participants did not comply with the allocated treatment;
- Participants were excluded from analysis for variety of reasons, or only per protocol analysis was performed as the primary analysis.

Criteria for a judgement of “Unclear”:

Insufficient reporting in treatment compliance to permit judgement of “Low risk” or “High risk”.

10. Timly outcome assessment

Criteria for a judgement of “Low risk”:

Timing of outcome assessment is identical or closely similar for all treatment groups and for all important outcomes.

Criteria for a judgement of “High risk”:

Timing of outcome assessment is obviously different among participants due to variety reasons.

Criteria for a judgement of “Unclear”:

Insufficient reporting to permit judgement of “Low risk” or “High risk”.

Overall risk of bias

A - low risk of bias:

Low risk for all sources of bias (1-10).

B - moderate risk of bias:

One of more high risk in other sources of bias (8-10). Low risk or unclear risk for key sources of bias (1-7).

C - high risk of bias:

High risk for one or more key sources of bias (1-7).

PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted – Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 5:15

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|-----------------------------------|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| ADMINISTRATIVE INFORMATION | | | | | |
| Title | | | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Registration | 2 | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 2 |
| Authors | | | | | |
| Contact | 3a | Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Support | | | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Role of sponsor/funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| INTRODUCTION | | | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 4-5 |

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|---|-----|---|-------------------------------------|-------------------------------------|---------------------|
| | | | Yes | No | |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| METHODS | | | | | |
| Eligibility criteria | 8 | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Information sources | 9 | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5, Appendix 1. |
| STUDY RECORDS | | | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7-8 |
| Selection process | 11b | State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Data collection process | 11c | Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8 |
| Data items | 12 | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-10 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-9 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7, Appendix 2 |
| DATA | | | | | |
| Synthesis | 15a | Describe criteria under which study data will be quantitatively synthesized | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15c | Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|--|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (e.g., GRADE) | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

For peer review only

BMJ Open

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis (OA) - An OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2019-035302.R3 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 12-Feb-2020 |
| Complete List of Authors: | Jin, Xingzhong; Southern Medical University, Zhujiang Hospital; The University of Sydney, The Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders Antony, Benny; University of Tasmania, Menzies Institute for Medical Research Wang, Xia; The University of Sydney, Institute of Bone and Joint Research Persson, Monica; University of Nottingham Faculty of Medicine and Health Sciences McAlindon, Timothy; Tufts Medical Center, Arden, Nigel; Nuffield Department of Orthopaedics, ; Srivastava, Sudeepti; King George Medical College Srivastava, Rajeshwar; King George Medical University van Middelkoop, Marienke; Erasmus MC Bierma-Zeinstra, Sita; Erasmus MC Zhang, Weiya; University of Nottingham, Academic Rheumatology Cicuttini, Flavia; Monash University, Department of Epidemiology and Preventative Medicine Ding, Changhai; University of Tasmania, Menzies Institute for Medical Research |
| Primary Subject Heading: | Rheumatology |
| Secondary Subject Heading: | Complementary medicine |
| Keywords: | PREVENTIVE MEDICINE, RHEUMATOLOGY, GENERAL MEDICINE (see Internal Medicine) |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis (OA)

An OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis

Xingzhong Jin^{1,2}, Benny Antony³, Xia Wang⁴, Monica SM Persson^{5,6}, Timothy McAlindon⁷, Nigel Arden⁸, Sudeepti Ratan Srivastava⁹, Rajeshwar Nath Srivastava⁹, Marienke van Middelkoop¹⁰, Sita M.A. Bierma-Zeinstra¹⁰, Weiya Zhang^{5,6}, Flavia Cicuttini¹¹, Changhai Ding^{1,3,11}.

Author Affiliations

¹ ZhuJiang Hospital, Southern Medical University, China

² The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, the University of Sydney, Australia.

³ Menzies Institute for Medical Research, University of Tasmania, Australia.

⁴ Institute of Bone & Joint Research, the University of Sydney, Australia.

⁵ Academic Rheumatology, Division of Rheumatology, Orthopaedics, and Dermatology, University of Nottingham, United Kingdom.

⁶ Arthritis Research UK Pain Centre, United Kingdom.

⁷ Tufts Medical Center, United States.

⁸ Nuffield Department Orthopaedic, Rheumatology and musculoskeletal sciences, University of Oxford, United Kingdom.

⁹ King George Medical University, India.

¹⁰ Erasmus MC, University Medical Center Rotterdam, Netherland.

¹¹ Department of Epidemiology and Preventive Medicine, Monash University, Australia

Correspondence to

Xingzhong Jin, The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, Level 2 Charles Perkins Centre (D17), John Hopkins Drive, The University of Sydney, NSW 2006, Australia; xingzhong.jin@sydney.edu.au.

Keywords

Systematic Review; Meta-analysis; Individual Patient Data; Osteoarthritis; Vitamin D; Knee.

Abstract

Introduction

Observational data suggest vitamin D deficiency is associated with the onset and progression of knee OA. However, randomized controlled trials (RCTs) to date investigating the efficacy of vitamin D supplementation in knee OA have reported conflicting results. Further research is needed to clarify the effects of vitamin D on patient-reported outcomes and determine whether there are patient subgroups who may benefit from the supplementation. The aim of this IPD meta-analysis is to identify patient-level predictors of treatment response to vitamin D supplementation on pain and physical function.

Methods and analysis

A systematic literature search will be conducted for RCTs of vitamin D supplementation on knee OA. Authors of original RCTs will be contacted to obtain the IPD. The primary outcomes will include long-term (≥ 12 months) pain and physical function. Secondary outcomes will include medium-term (≥ 6 months and <12 months) and short-term (<6 months) pain and physical function, as well as patient global assessment, quality of life and adverse events. Potential treatment effect modifiers to be examined in the subgroup analyses include age, gender, body mass index (BMI), baseline knee pain severity and physical function, baseline vitamin D level, radiographic stage, presence of bone marrow lesions on magnetic resonance images (MRI), presence of clinical signs of local inflammation, and concomitant depressive symptoms. Both one-step and two-step modelling methods will be used to determine the possible modifiable effect of each subgroup of interest.

Ethics and dissemination

Separate ethics committee approval because this study involves analysis of de-identified data that have already been collected in individual RCTs. This study will be the first IPD meta-analysis to clarify the effect of vitamin D supplementation on clinical symptoms in different subgroups of patients with knee OA. The findings will be disseminated through peer-review publications and conference presentations.

Systematic review registration

This systematic review is registered on PROSPERO (CRD42018107740).

Article Summary

This article is a protocol for a systematic review and IPD meta-analysis of RCTs studying the effects of vitamin D supplementation on joint pain and physical function in patients with symptomatic knee OA.

Strengths and limitations of this study

- This study protocol is endorsed by the OA Trial Bank, an international collaboration that initiates meta-analyses on predefined subgroups of OA patients.
- This study is the first IPD meta-analysis to identify OA patient subgroups that may benefit from vitamin D supplementation.
- IPD meta-analysis offer greater statistical power and precision than subgroup analysis in a single trial and conventional meta-analysis using aggregate data.
- Analysis may be limited to the variables that have been collected across included RCTs.

Introduction

OA is the most common joint disorder worldwide. OA is ranked as the 13th highest contributor of 310 diseases to global disability in 2015¹. In Australia, OA affects over 2.1 million people (9% of the population), costing the healthcare system over \$2.1 billion in 2015². This cost is forecasted to increase by 41% in 2030³.

The majority (83%) of the disease burden of OA is attributable to knee OA⁴, which is characterized by pain, gradual loss of articular cartilage, and structural changes such as subchondral remodelling and effusion-synovitis⁵. Currently, there are no effective disease-modifying treatments to reverse the progression of knee OA once the disease is established. A majority of patients with knee OA eventually progress to advanced stage and undergo total knee replacement⁶. There is clearly an urgent need for innovative and cost-effective approaches to slow the progression of knee OA.

Emerging observational data suggest that vitamin D insufficiency is associated with the onset and progression of knee OA⁷. The association between low serum vitamin D levels and knee OA symptoms may be explained by a direct effect of vitamin D on chondrocytes in osteoarthritic cartilage⁸, as well as indirect effects on subchondral bone, synovium, and periarticular muscle⁹. For example, vitamin D deficiency could impair the ability of bone to respond optimally to pathological bone marrow lesions (BMLs) and altered bone mineral density, therefore predisposing the knees to disease progression¹⁰. Vitamin D also may reduce synovitis in affected knees by regulating cytokine levels in the joint, leading to a reduction in the amount of effusion-synovitis in MRI¹¹. In addition, depressive symptoms is interrelated to joint pain in OA¹², and maintaining sufficient serum vitamin D may improve depression symptoms in patients with knee OA¹³.

However, evidence from RCTs have been conflicting¹⁴⁻¹⁷. A pilot RCT in India found a small but statistically significant clinical benefit for 12-month vitamin D treatment on pain and function in patients with knee OA, compared with placebo³⁹¹⁶. In contrast, a subsequent RCT from the US showed that vitamin D supplementation did not reduce knee pain or cartilage volume loss over 24 months¹⁵. Subsequently, data from RCTs in Australia¹⁷ and UK¹⁴ did not find significant clinical benefits of vitamin D supplementation for knee OA. However, there was a non-significant trend for symptom reduction (e.g. knee pain and physical function) in these RCTs. Two systematic reviews using aggregate data from these RCTs concluded that, although current evidence does not support vitamin D supplementation for reducing structural disease progression, further research is needed to clarify the effects on patient-reported

1
2
3 outcomes^{18,19}. In addition, to the best of our knowledge, no previous systematic reviews of
4 previous systematic reviews exist.
5
6

7 The null results of these RCTs could be due to a low prevalence of vitamin D deficiency in the
8 study subjects or low statistical power secondary to small sample sizes. Another possible
9 reason is that vitamin D may have an effect only in some OA phenotypes, such as those with
10 BMLs (predominant bone abnormality)²⁰, effusion-synovitis (inflammatory)²¹ or depressive
11 symptoms (psychological distress)¹³. Post hoc analyses within these RCTs^{47,48,15,21} were
12 frequently underpowered, and hence unreliable to determine the effect of vitamin D treatment
13 on subgroups of knee OA patients. A meta-analysis using IPD can increase the power of
14 subgroup analysis by combining individual data from included trials²² and therefore can
15 quantify potential effect modifier of vitamin D treatment in subgroups.
16
17
18
19
20
21
22

23 **Methods and analysis**

24 We will conduct a systematic review and IPD meta-analysis of RCTs studying the effects of
25 vitamin D supplementation in patients with symptomatic knee OA. The primary aim is to
26 identify patient-level predictors of treatment response to vitamin D supplementation, including
27 the status of vitamin D deficiency, MRI-detected bone marrow abnormalities and effusion-
28 synovitis, and clinical signs of local inflammation. The protocol of this review is registered on
29 the PROSPERO database (CRD42018107740).
30
31
32
33
34
35

36 **Study eligibility**

37 This systematic review will include studies that meet the following inclusion criteria:

38 **Type of studies**

39 RCTs that have been published in journals and reported the efficacy of vitamin D in participants
40 with knee OA will be included. Cross-over design will also be eligible and only the first phase
41 data will be included in the analysis. Both individually randomised trials and cluster
42 randomised trials will be eligible. Both open-labelled and blinded studies will be eligible. There
43 will be no language or geographical restrictions applied to study selection.
44
45
46
47
48

49 **Participants**

50 Men and women who have a diagnosis of knee OA, either according to the American College
51 of Rheumatology criteria, or on the basis of detailed clinical and/or radiographic information,
52 will be included. Studies with a subgroup of knee OA patients will also be included, provided
53 that IPD can be collected separately for the OA subgroup. Although most patients with knee
54 OA defined by the American College of Rheumatology are usually over 50 years of age, the
55
56
57
58
59
60

1
2
3 disease can occur as early as 20 years old, therefore studies with adults at 18 years of age and
4 older will be included.
5

6 7 **Interventions**

8 Only studies investigating oral supplementation of vitamin D will be included. Vitamin D
9 treatments administered subcutaneously, intraperitoneally or intravenously will not be
10 included. Both ergocalciferol (vitamin D₂) and cholecalciferol (vitamin D₃) will be eligible,
11 irrespective of preparations (tablet or capsule), dosage, regimen, and length of treatment.
12
13
14

15 16 **Comparators**

17 Oral vitamin D supplementation will be compared with control treatment including placebo or
18 usual conservative care (pain medication and/or exercise therapy if they are used in both
19 treatment and control groups).
20
21
22

23 24 **Outcomes**

25 The minimum criterion for inclusion is reporting pain or physical function as either primary or
26 secondary outcomes. There will be no restrictions on the duration of follow-up. Data on other
27 outcomes (e.g. patient's global assessment, quality of life, and adverse events) will be analysed
28 when feasible but will not be required for study selection.
29
30
31

32 33 **Baseline assessments**

34 As a minimum, included studies should have measured knee pain, physical function, serum
35 levels of vitamin D at baseline, and included basic patient characteristics such as age, gender,
36 and BMI.
37
38

39 40 **Literature search**

41 A systematic literature search for articles published from 1 January 1990 until 31 December
42 2019 will be performed by a trained review author (XJ) in the following electronic databases:
43

- 44 • Cochrane Central Register of Controlled Trials (CENTRAL);
- 45 • MEDLINE (Ovid);
- 46 • EMBASE;
- 47
- 48

49 A previous systematic review⁷ has showed that no major RCTs were conducted for vitamin D
50 and osteoarthritis by the year 1990, therefore we chose 1 January 1990 as the start date of the
51 literature search. The search strategies used for each database are listed in *Appendix 1*. All
52 retrieved articles will be exported to the reference manager *EndNote*, in which duplicates will
53 be removed electronically and manually. The remaining records will be exported to an online
54 systematic review management tool *Covidence* (Veritas Health Innovation, Melbourne,
55 Australia) and the articles will be assessed for eligibility for inclusion. In addition to the
56
57
58
59
60

1
2
3 electronic search, we will check the reference lists of included trials and previous systematic
4 reviews to identify any trials that are not retrieved from the electronic search. Review authors
5 and collaborating authors will be asked if they are aware of further relevant studies not yet
6 included. We will also search the WHO International Clinical Trial Registration Platform
7 Search Portal (www.who.int/trialsearch) to identify any relevant trials that are completed but
8 did not published the results.
9

14 **Study selection**

15 Two review authors (XJ, BA) will independently conduct study screening by assessing the
16 article titles and abstracts. Full texts of the articles will be further assessed if the information
17 from the abstract suggests that a study is eligible for inclusion. When information contained in
18 the full text is not sufficient to make a judgement on its eligibility, we will make efforts to
19 contact the corresponding authors to obtain further details. If a corresponding author is not
20 contactable after two email attempts and one phone call, the study will be deemed ineligible.
21 Any disagreement regarding the inclusion of a study will be discussed between the two review
22 authors (XJ, BA). If no consensus can be reached, a third review author will be consulted (XW)
23 to make a final decision.
24
25
26
27
28
29

31 **Extraction of aggregate data**

32 Study data extraction will be performed independently by two review authors (BA, XW).
33 Discrepancies will be resolved by a third reviewer (XJ). We will extract the following study
34 data from the included studies:
35
36
37

- 38 • General information: article title, bibliographic details, published language, and
39 funding source.
- 40
- 41 • Participants: inclusion criteria, exclusion criteria, number of participants in total and in
42 each study arm, study settings, and baseline participant characteristics (e.g. age, gender,
43 BMI).
- 44
- 45 • Intervention: type of vitamin D preparation, dose, regimen, treatment duration, type of
46 control, and co-interventions (if any).
- 47
- 48 • Outcomes: primary and secondary outcomes at the end of treatment and/or the end of
49 follow-up. Number of withdrawals and loss to follow-up. Adverse events recorded.
- 50
- 51 • Data analysis: statistical models used for data analysis, confounding factors adjusted in
52 the models, and methods used for addressing missing values.
53
54
55
56
57
58
59
60

Risk of bias assessment

The methodological quality of the included studies will be assessed using a modified version of the Cochrane's risk of bias tool²³. The modified version includes all the seven domains of the original tool, but further separates performance bias assessment into 'blinding of participants' and 'blinding of study personnel', as well as pre-specifies other sources of bias as 'balance in baseline covariates', 'treatment compliance', and 'timely outcome assessment' (*Appendix 2*). Each domain will be scored as 'low risk', 'high risk' or 'unclear' according to the criteria described in the *Appendix 3*. The overall rating of risk of bias is based on the number of domains with a 'high-risk' score. The overall rating is intended to inform readers of the risk of bias across individual studies and will not be used to weight the studies in the meta-analysis. Two review authors (XJ, XW) will independently evaluate the quality of an individual study. Any disagreement will be settled by further discussion until a consensus is reached between the two review authors.

IPD collection and transfer

The primary or corresponding authors of included trials will be invited to collaborate on the project and contribute their raw data. When we cannot reach a corresponding author after sending two emails and making two telephone calls, we will contact the co-authors listed in the article. If none of the co-authors can be contacted, we will approach the institutes, in which the trial has been conducted. All data custodians will be asked to sign a data delivery agreement, which includes items regarding IPD delivery, obligations, ownership of data, terms and conditions of the use of the data, authorship, and publications. If needed, the project coordinator (XJ) will visit the institutes of the data deliverers to retrieve the data and to sign the data delivery agreement on behalf of the OA Trial Bank (the detailed procedures of data delivery and an example of the data delivery agreement can be found on the OA Trial Bank website <https://www.oatrialbank.com/procedures/>). De-identified datasets will be accepted in any electronic format (for example, SPSS, Stata, SAS, Excel) or in paper form, provided that variables and categories are adequately labelled within the dataset or within a separate codebook. The IPD files received by the coordinator will be kept in their original version and saved on a secured password-protected server at Erasmus MC Medical University in Rotterdam. The datasets will not be used for any other research apart from that described in the license agreement.

To ensure the quality of the data, the coordinator will independently check for data consistency by comparing the summary statistics derived from the IPD received against the summary

1
2
3 results reported in the published articles. In the case of differences, the project coordinator will
4 communicate with the data deliverer via email or teleconference to resolve the discrepancy.
5
6

7 **Variables of interest**

8 The following IPD variables will be obtained (where available):
9

10 **Primary outcome variables**

11 The primary outcomes for this meta-analysis will be pain and physical function at long-term
12 follow-up (12 months or more). This definition of 'long-term effect' for knee OA treatment
13 was used in previous systematic reviews of knee OA research^{24,25}.
14
15

- 16
17 • Knee pain will be evaluated using visual analogue scale (VAS) if available, otherwise the
18 pain subscales of the Western Ontario and McMaster Universities Osteoarthritis Index
19 (WOMAC)²⁶ or the Knee injury and Osteoarthritis Outcome Score (KOOS)²⁷ will be used.
20 The pain data will be converted into a 0-100 common scale as recommended by the
21 WOMAC manual²⁸.
22
23 • Physical function will be evaluated using a validated instrument specific to knee OA, such
24 as the physical function subscales of the WOMAC or the KOOS subscales. The scores will
25 be standardised into a 0-100 scale.
26
27
28
29
30
31

32 **Secondary outcome variables**

33 Secondary outcomes will include:
34

- 35 • Medium-term (more than 6 months but less than 12 months) pain and physical function;
36
37 • Short-term (less than 6 months) pain and physical function;
38
39 • Patient global assessment at the end of study follow-up, as recommended by the
40 OMERACT-OARSI Initiative²⁹.
41
42 • Quality of life evaluated using a validated instrument, such as EQ-5D³⁰, osteoarthritis Knee
43 and Hip Quality of Life (OAKHQOL)³¹, or original instrument used in the included studies;
44
45 • Adverse events if reported, including all major and minor events such as hypocalcaemia,
46 fractures, and depression.
47
48
49
50
51

52 **Potential treatment effect moderators**

53 If data are available, we will analyse potential treatment effect modification for the following
54 variables measured at baseline:
55
56

- 57 • Radiographic stage of knee OA (mild/moderate or severe). Radiographic knee OA should
58 be staged at baseline using either the Kellgren-Lawrence (KL)³² or Osteoarthritis Research
59
60

Society International (OARSI) joint space narrowing (JSN) grading system³³. The results from the two grading systems have been shown to be highly correlated³⁴. Mild to moderate disease will be defined as a KL score ≤ 3 or an OARSI JSN score ≤ 2 , and severe disease will be a KL score of 4, or an OARSI score of 3.

- Vitamin D level (deficiency, insufficiency, or sufficiency). Vitamin D deficiency is defined as serum levels of 25(OH)D less than 30 nmol/L at baseline. Insufficiency is defined as serum 25(OH)D levels from 30 to <50 nmol/L. Serum 25(OH)D levels ≥ 50 nmol/L is considered as vitamin D sufficiency³⁵.
- Presence of BMLs (yes or no). BMLs at the patella-femoral and femoro-tibial joints should be measured by MRI using a validated scoring system, such as BLOKS (Boston Leeds Osteoarthritis Knee Score)³⁶, WORMS (Whole-Organ Magnetic Resonance Imaging Score)³⁷, or KOSS (Knee Osteoarthritis Scoring System)³⁸.
- Clinical signs of local inflammation or the presence of effusion-synovitis (yes or no). Clinical signs of local inflammation should be assessed by physical examination - tumor (swelling), dolor (pain), rubor (redness), calor (heat), and functio laesa (disturbance of function) - or by additional laboratory testing (e.g. serum c-reactive protein and erythrocyte sedimentation rate). Effusion-synovitis should be measured on either ultrasound or MRI.
- Presence of depressive symptoms or comorbid depression. Depressive symptoms are measured using a validated questionnaire, such as the Patient Health Questionnaire (PHQ-9)³⁹ and the Geriatric Depression Scale (GDS)⁴⁰.

Data synthesis and statistical methods

All statistical analysis will be conducted using R version 3.5.0 and RStudio (version 1.0.136, RStudio, Inc., Boston, MA), with R extension package ‘metafor’ for the conventional meta-analysis and two-stage IPD meta-analysis, and ‘lme4’ for the one-stage IPD meta-analysis.

Conventional meta-analysis

An aggregate data meta-analysis, using a random-effects model based on the ‘Hartung-Knapp-Sidik-Jonkman (HKSJ)’ method⁴¹, will be performed to estimate the treatment effect of vitamin D over control. If an included study is a cluster RCT, results will be corrected using previously established procedures⁴². The results will be compared with the IPD meta-analysis findings as sensitivity analyses.

Heterogeneity will be assessed by inspecting the forest plots and tested by χ^2 test. A result of $p < 0.10$ will be defined as evidence of significant heterogeneity across studies. I^2 test will be

1
2
3 used to estimate the extent of inconsistency across studies that is due to heterogeneity⁴³. A
4 result of over 30% and 50% represents moderate and substantial heterogeneity, respectively.
5 Sources of heterogeneity will be explored by excluding individual trials causing an I² score
6 below 50%.
7
8
9

10 If 10 trials or more trials are available, we will use a Doi plot (normal quantile versus effect
11 size plot) explore publication bias and ‘small-study effects’⁴⁴. Asymmetry in the Doi plot will
12 be detected and quantified by the LFK index. A value beyond +/- 1 will be deemed consistent
13 with asymmetry, thus having considerable small-study effects⁴⁴.
14
15
16

17 **IPD meta-analysis**

18 IPD from included trials will be recoded and formatted in a consistent way to permit re-
19 analysis. A new variable will be created to indicate the trial in which the IPD are collected.
20 The method used to handle missing data will depend on the mechanism causing the
21 missingness. If no explanation is known for the reason of missing data, they will be assumed
22 to be missing at random. We will use the R MICE package⁴⁵ for multiple imputation and the
23 imputation model will include all available patient variables to help predict missing data for
24 the variables of interest within each study dataset. The imputation procedure will use 20
25 imputed datasets. A sensitivity analyses will be performed restricting to participants without
26 missing data (complete case analysis).
27
28
29
30
31
32
33
34

35 Both the treatment effect of vitamin D supplementation and the effect of potential moderators
36 will be studied in the IPD meta-analyses. The treatment effect of vitamin D will be measured
37 using the mean difference in knee pain and physical function between treatment and control
38 based on the intention-to-treat principle. The interaction between the treatment and a potential
39 moderator will be used to identify the effect of the moderator. Interaction effects with p<0.05
40 will be considered statistically significant and 95% confidence intervals of the effects will be
41 provided. The IPD meta-analyses will be undertaken using both the one-stage and two-stage
42 approaches. We will use the one-stage approach as the primary analysis to avoid assumptions
43 of within-study normality and known within-study variance⁴⁶. We will and compare the results
44 to the two-stage approach to assess consistency in a sensitivity analysis.
45
46
47
48
49
50
51
52

53 ***One-stage modelling***

54 The one-stage mixed-effects IPD meta-analysis approach will take into account both study
55 level and subject-level covariates. Subject -level covariates will be centred to the mean of the
56 covariate in each trial to avoid ecological bias. Three multilevel regression models will be built,
57 the first to examine the summary treatment effect (difference between vitamin D and control),
58
59
60

1
2
3 the second to evaluate each of the mentioned moderators on treatment effect, and the third to
4 assess the true effect of one moderator independent of other moderators.
5
6

7 The first model will include outcome measure (e.g. pain score at follow-up) as a dependent
8 variable, treatment (vitamin D or control), baseline subject-level covariate (e.g. pain score) and
9 confounders (age, gender and BMI) as fixed-effect independent variables, adjusted for study
10 identifier (random intercept). The partial regression coefficient of the treatment will be used to
11 compare to the conventional meta-analysis.
12
13
14

15
16 The second model will further add the moderator of interest (e.g. radiographic stage of the
17 disease) and interaction term between the treatment and study-centred values of the moderator
18 in the fixed-effect of the first model. The regression coefficient of the interaction term will be
19 used to quantify the impact of the moderator on treatment effect.
20
21
22

23 If there are two or more moderators that have a statistically significant interaction with the
24 treatment effect, these moderators will be incorporated in the third model. Multicollinearity
25 between moderators will be tested before building the third model. A correlation coefficient
26 $r > 0.80$ will indicate that multiple collinearity exists between the two moderators, of which the
27 one that has less measurement error will be included in the model.
28
29
30
31

32 ***Two-stage modelling***

33 In the first stage, treatment effect and variance are derived from separate analysis in each
34 study. An analysis of covariance (ANCOVA) model adjusted for baseline covariates (age,
35 gender, BMI, as well as knee pain or function), will be used to obtain the treatment effect and
36 variance within each study separately. The effect of a moderator and its variance within each
37 study will be obtained by adding the interaction term between treatment effect and the
38 moderator into the model. In the second stage, the treatment effect and its variances obtained
39 from the first stage will be pooled across studies using a random-effects model⁴¹. The result
40 of this model is a summary estimate of the treatment effect of vitamin D versus control. The
41 effect of a moderator will be calculated by pooling the regression coefficient and variance of
42 the interaction term between the treatment and the moderator using a similar model. If two or
43 more interaction terms are statistically significant, these moderators will be incorporated in a
44 further model to evaluate the independent effect of these moderators.
45
46
47
48
49
50
51
52
53
54

55 **Patient and public involvement**

56 We do not directly include patient and public involvement in this study, but the design of
57 included randomised controlled trials may involve patients.
58
59
60

Discussion

Vitamin D supplementation may improve pain and function in patients with knee OA; however, the evidence from observational studies and RCTs are controversial^{7,18}. In a few existing RCTs in patients with symptomatic knee OA^{27,14,16,17}, small to modest improvement in knee pain and physical function were observed in participants receiving vitamin D supplementation, but the treatment response varies considerably and the effects were not statistically significant when compared to placebo. The broad variation in treatment response could be a result of the fact that knee OA is a highly heterogenous disease with multiple aetiologies⁴⁷. Vitamin D may therefore be more effective in a subset of patients with specific characteristics than others. The purpose of the proposed IPD meta-analysis is to evaluate the treatment response of vitamin D supplementation on pain and physical function for knee OA in specific subsets of patients according to disease severity, vitamin D levels, presence of BMLs, inflammatory signs and depressive symptoms, over both short- and long-term follow-up.

Meta-analysis is considered by some to be the grandmother of ‘big data’⁴⁸ and an integrated part of precision medicine⁴⁹. It is a cost-effective approach to identify potential moderators of treatment response at a patient level, which is not possible with subgroup analyses in a single trial or conventional meta-analysis with aggregate data⁵⁰. Subgroup analyses within individual trials are often underpowered to generate reliable findings. In contrast, IPD meta-analysis techniques increase the statistical power of the study by combining individual observation data from multiple trials with the same treatment²². This offers greater precision in analysing moderators of treatment response and offers the potential to analyse a greater number of moderators. In conventional meta-analysis, meta-regression analysis may be used to examine differences in the types of patients enrolled in individual trials, but is potentially problematic. Meta-regression analysis may make incorrect inferences about individual characteristics based upon aggregate baseline statistics reported in trial publications⁵¹. This is also known as ecological fallacy⁵², where the relationship between the effect estimate and average patient characteristics across trials may not be the same as the relationship within individual trials.

Identifying different phenotypes of knee OA is currently a popular subject of research in the field. Different phenotyping strategies have been proposed based on risk factors from epidemiological studies⁵³, anatomical abnormalities on modern imaging⁵⁴, or molecular abnormalities related to pathological mechanisms⁵⁵. While there is currently no standardised classification system for knee OA phenotypes⁵, we believe that disease phenotypes are most meaningful when they reflect differential treatment effects. IPD meta-analysis provides an

1
2
3 opportunity to assess the effect of treatments on subtypes or phenotypes of patients with knee
4 OA according to predefined set of characteristics. The current proposed IPD meta-analysis
5 attempts to differentiate subgroups by identifying subtypes of patients that respond better to
6 vitamin D supplementation on pain and physical function.
7
8
9

10 **Strengths and limitations**

11 Several challenges may present when conducting an IPD meta-analysis. First, although IPD
12 meta-analyses usually offer sufficient statistical power to examine moderators of treatment
13 response, not all RCTs measure potential moderators of interest or measure them in the same
14 way. This may limit the analysis to only exploring moderators that have been collected across
15 studies. The current protocol attempts to minimise this risk by including moderators that are
16 commonly reported in OA research. In addition, there are expected barriers to accessing data,
17 such as the authors of included trials not being able to be contacted, or the authors losing access
18 to raw data or not choosing to collaborate, may introduce selection bias into the IPD meta-
19 analysis. However, this could be examined in sensitivity analyses by comparing the results to
20 the conventional meta-analysis or be addressed using frameworks that combine IPD and
21 aggregate data in a meta-analysis⁵⁶.
22
23
24
25
26
27
28
29
30

31 The benefits of using IPD meta-analysis techniques greatly outweigh the challenges of using
32 this intensive method. Previous RCTs and systematic reviews have not had sufficient power to
33 thoroughly examine the differential treatment response of vitamin D supplementation in
34 different subsets of patients with knee OA. The results of this project have a high potential to
35 provide important evidence to guide subgroup-specific treatment decisions in clinical practice
36 to improve therapeutic effectiveness.
37
38
39
40
41

42 **Status of project**

43 Currently, literature search in the electronic databases has been commenced.
44
45

46 **Abbreviations**

47 OA: osteoarthritis; IPD: individual patient data; RCT: randomised controlled trial; BMI: body
48 mass index; MRI: magnetic resonance imaging; BMLs: bone marrow lesions; JSN: joint space
49 narrowing; OARSI: Osteoarthritis Research Society International.
50
51
52
53
54
55
56
57
58
59
60

Additional Information

Acknowledgement

We acknowledge the University of Sydney China Study Centre for providing short-term travel support to establish international collaboration for this project.

Ethics approval and consent to participate

Research ethical or governance approval is exempt for this study as no new data are being collected.

Availability of data and material

Erasmus MC intends to create a central databank including data from several randomised clinical trials evaluating one or more interventions in patients with osteoarthritis of the knee or hip (the OA Trial Bank) in order to enable researchers to perform meta-analyses on individual patient data to define sub-groups that are specifically responsive to certain treatments. Data request for future research using data deposited in the OA Trial Bank can be directed to <https://www.oatrialbank.com/contact/>

Authors contributions

All authors were involved in the study design and all will contribute to the interpretation of the results. CD, BA and XJ conceived this study. WZ and MP provided methodological support for statistical analysis. XJ and BA will contact the potential data delivers and will coordinate the project. CD, FC, TM, NA, RNS and SRS will deliver relevant data from their completed trials. SBZ and MM will facilitate legal agreement for data transfer and provide database management at the OA Trial Bank. XJ, BA and XW will perform the study selection, risk of bias assessment, data collection and analysis. All authors contributed to writing of this manuscript and approved the final submission.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors declare that they have no competing interests.

Word count

Abstract: 297, **Main text:** 4095, **References:** 56

References

1. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* 2016;388(10053):1545–602.
2. Australian Bureau of Statistics. 2014-15 National Health Survey. Canberra: Australian Bureau of Statistics; 2017.
3. Ackerman IN, Pratt C, Gorelik A, Liew D. Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population-Level Analysis. *Arthritis Care Res* 2018;70(6):877–83.
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012;380(9859):2163–96.
5. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for Standardized Definitions of Osteoarthritis and Risk Stratification for Clinical Trials and Clinical Use. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2015;23(8):1233–41.
6. Australian Orthopaedic Association National Joint Replacement Registry. Annual Report 2012. Adelaide, Australia: AOA; 2012.
7. Cao Y, Winzenberg T, Nguo K, Lin J, Jones G, Ding C. Association between serum levels of 25-hydroxyvitamin D and osteoarthritis: a systematic review. *Rheumatology* 2013;ket132.
8. Garfinkel RJ, Dilisio MF, Agrawal DK. Vitamin D and Its Effects on Articular Cartilage and Osteoarthritis. *Orthop J Sports Med* [Internet] 2017 [cited 2018 Oct 12];5(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480771/>
9. Zhang FF, Drihan JB, Lo GH, et al. Vitamin D Deficiency Is Associated with Progression of Knee Osteoarthritis. *J Nutr* 2014;144(12):2002–8.
10. Bellido M, Lugo L, Roman-Blas JA, et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. *Osteoarthritis Cartilage* 2011;19(10):1228–36.
11. Wang X, Cicutinni F, Jin X, et al. Effect of vitamin D on effusion-synovitis in knee osteoarthritis: a randomized controlled trial. *Arthritis Rheumatol* 2015;67:439–40.
12. Sharma A, Kudesia P, Shi Q, Gandhi R. Anxiety and depression in patients with osteoarthritis: impact and management challenges. *Open Access Rheumatol Res Rev* 2016;8:103–13.
13. Zheng S, Tu L, Cicutinni F, et al. Effect of Vitamin D Supplementation on Depressive Symptoms in Patients With Knee Osteoarthritis. *J Am Med Dir Assoc* 2018;
14. Arden NK, Cro S, Sheard S, et al. The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial. *Osteoarthritis Cartilage* 2016;24(11):1858–66.

15. McAlindon T, LaValley M, Schneider E, et al. Effect Of Vitamin D Supplementation On Progression Of Knee Pain And Cartilage Volume Loss In Patients With Symptomatic Osteoarthritis. A Randomized Controlled Trial. *JAMA J Am Med Assoc* 2013;309(2):155–62.
16. Sanghi D, Mishra A, Sharma AC, et al. Does Vitamin D Improve Osteoarthritis of the Knee: A Randomized Controlled Pilot Trial. *Clin Orthop Relat Res* 2013;471(11):3556–62.
17. Jin X, X J, G J, et al. Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial. 2016; Available from: <http://doi.org/10.1001/jama.2016.1961>
18. Hussain S, Singh A, Akhtar M, Najmi AK. Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials. *Rheumatol Int* 2017;37(9):1489–98.
19. Diao N, Yang B, Yu F. Effect of vitamin D supplementation on knee osteoarthritis: A systematic review and meta-analysis of randomized clinical trials. *Clin Biochem* 2017;50(18):1312–6.
20. Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. *Radiol Clin* 2004;42(1):1–9.
21. Wang X, Cicuttini F, Jin X, et al. Knee effusion-synovitis volume measurement and effects of vitamin D supplementation in patients with knee osteoarthritis. *Osteoarthritis Cartilage* 2017;25(8):1304–1312.
22. Groenwold RHH, Donders ART, Heijden GJMG van der, Hoes AW, Rovers MM. Confounding of Subgroup Analyses in Randomized Data. *Arch Intern Med* 2009;169(16):1532–4.
23. Jørgensen L, Paludan-Müller AS, Laursen DRT, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. *Syst Rev* [Internet] 2016 [cited 2018 Oct 11];5. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862216/>
24. Charlesworth J, Fitzpatrick J, Perera NKP, Orchard J. Osteoarthritis- a systematic review of long-term safety implications for osteoarthritis of the knee. *BMC Musculoskelet Disord* 2019;20(1):151.
25. van Middelkoop M, Arden NK, Atchia I, et al. The OA Trial Bank: meta-analysis of individual patient data from knee and hip osteoarthritis trials show that patients with severe pain exhibit greater benefit from intra-articular glucocorticoids. *Osteoarthritis Cartilage* 2016;24(7):1143–52.
26. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. *Arthritis Care Res* 2001;45(5):453–61.

- 1
- 2
- 3
- 4 27. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) -
- 5 validation and comparison to the WOMAC in total knee replacement. *Health Qual Life*
- 6 *Outcomes* 2003;1:17.
- 7
- 8 28. Bellamy N. WOMAC osteoarthritis index: user guide IV. 2000.
- 9
- 10 29. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative:
- 11 Osteoarthritis Research Society International set of responder criteria for osteoarthritis
- 12 clinical trials revisited. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2004;12(5):389–99.
- 13
- 14 30. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L
- 15 compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life*
- 16 *Res* 2013;22(7):1717–27.
- 17
- 18 31. Rat A-C, Coste J, Pouchot J, et al. OAKHQOL: a new instrument to measure quality of
- 19 life in knee and hip osteoarthritis. *J Clin Epidemiol* 2005;58(1):47–55.
- 20
- 21 32. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. *Ann Rheum Dis*
- 22 1957;16(4):494–502.
- 23
- 24 33. Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised.
- 25 *Osteoarthritis Cartilage* 2007;15 Suppl A:A1-56.
- 26
- 27 34. Gudbergesen H, Lohmander LS, Jones G, et al. Correlations between radiographic
- 28 assessments and MRI features of knee osteoarthritis – a cross-sectional study.
- 29 *Osteoarthritis Cartilage* 2013;21(4):535–43.
- 30
- 31 35. Scragg R. Emerging Evidence of Thresholds for Beneficial Effects from Vitamin D
- 32 Supplementation. *Nutrients* 2018;10(5).
- 33
- 34 36. Hunter DJ, Lo GH, Gale D, Grainger AJ, Guermazi A, Conaghan PG. The reliability of a
- 35 new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion
- 36 assessment: BLOKS (Boston Leeds Osteoarthritis Knee Score). *Ann Rheum Dis*
- 37 2008;67(2):206–11.
- 38
- 39 37. Peterfy CG, Guermazi A, Zaim S, et al. Whole-Organ Magnetic Resonance Imaging
- 40 Score (WORMS) of the knee in osteoarthritis. *Osteoarthritis Cartilage* 2004;12(3):177–
- 41 90.
- 42
- 43 38. Kornaat PR, Ceulemans RYT, Kroon HM, et al. MRI assessment of knee osteoarthritis:
- 44 Knee Osteoarthritis Scoring System (KOSS)--inter-observer and intra-observer
- 45 reproducibility of a compartment-based scoring system. *Skeletal Radiol* 2005;34(2):95–
- 46 102.
- 47
- 48 39. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med* 2001;16(9):606–
- 49 13.
- 50
- 51 40. Montorio I, Izal M. The Geriatric Depression Scale: a review of its development and
- 52 utility. *Int Psychogeriatr* 1996;8(1):103–12.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 41. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for
- 5 random effects meta-analysis is straightforward and considerably outperforms the
- 6 standard DerSimonian-Laird method. *BMC Med Res Methodol* 2014;14(1):25.
- 7
- 8 42. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews*
- 9 *of Interventions version 6.0 (updated July 2019)* [Internet]. Cochrane; 2019. Available
- 10 from: www.training.cochrane.org/handbook
- 11
- 12 43. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
- 13 analyses. *BMJ* 2003;327(7414):557–60.
- 14
- 15 44. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative
- 16 method for detecting bias in meta-analysis. *Int J Evid Based Healthc* 2018;16(4):195–
- 17 203.
- 18
- 19 45. Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained
- 20 Equations in R. *J Stat Softw* 2011;45(3).
- 21
- 22 46. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage
- 23 and two-stage approaches, and why they may differ. *Stat Med* 2017;36(5):855–75.
- 24
- 25 47. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and
- 26 reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and
- 27 Therapeutic Criteria Committee of the American Rheumatism Association. *Arthritis*
- 28 *Rheum* 1986;29(8):1039–49.
- 29
- 30 48. Gurevitch J, Koricheva J, Nakagawa S, Stewart G. Meta-analysis and the science of
- 31 research synthesis. *Nature* 2018;555(7695):175–82.
- 32
- 33 49. Cahan A, Cimino JJ. Improving precision medicine using individual patient data from
- 34 trials. *CMAJ Can Med Assoc J* 2017;189(5):E204–7.
- 35
- 36 50. Stewart LA, Tierney JF. To IPD or not to IPD?: Advantages and Disadvantages of
- 37 Systematic Reviews Using Individual Patient Data. *Eval Health Prof* 2002;25(1):76–97.
- 38
- 39 51. Reade MC, Delaney A, Bailey MJ, Angus DC. Bench-to-bedside review: Avoiding
- 40 pitfalls in critical care meta-analysis – funnel plots, risk estimates, types of heterogeneity,
- 41 baseline risk and the ecologic fallacy. *Crit Care* 2008;12(4):220.
- 42
- 43 52. Idrovo AJ. Three Criteria for Ecological Fallacy. *Environ Health Perspect*
- 44 2011;119(8):a332.
- 45
- 46 53. Felson DT. Identifying Different Osteoarthritis Phenotypes through Epidemiology.
- 47 *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2010;18(5):601–4.
- 48
- 49 54. Deveza LA, Melo L, Yamato TP, Mills K, Ravi V, Hunter DJ. Knee osteoarthritis
- 50 phenotypes and their relevance for outcomes: a systematic review. *Osteoarthritis*
- 51 *Cartilage* 2017;25(12):1926–41.
- 52
- 53 55. van Spil WE, Jansen NWD, Bijlsma JWJ, et al. Clusters within a wide spectrum of
- 54 biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals
- 55 with very early symptomatic osteoarthritis. *Osteoarthritis Cartilage* 2012;20(7):745–54.
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 56. Riley RD, Lambert PC, Staessen JA, et al. Meta-analysis of continuous outcomes
- 5 combining individual patient data and aggregate data. *Stat Med* 2008;27(11):1870–93.
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

Appendix 1. Search strategy

Cochrane CENTRAL

- #1. MeSH descriptor Osteoarthritis explode all trees
- #2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*):ti,ab,kw
- #3. (degenerative near/2 arthritis):ti,ab,kw
- #4. coxarthrosis:ti,ab,kw
- #5. (#1 OR #2 OR #3 OR #4)
- #6. MeSH descriptor vitamin D explode all trees
- #7. (vitamin D):ti,ab,kw
- #8. (vitamin D2):ti,ab,kw
- #9. (vitamin D3):ti,ab,kw
- #10. (1-alpha hydroxyvitamin D3):ti,ab,kw
- #11. (1-alpha-hydroxy-vitamin D3):ti,ab,kw
- #12. (1-alpha hydroxycalciferol):ti,ab,kw
- #13. (1-alpha-hydroxy-calciferol):ti,ab,kw
- #14. (1,25 dihydroxyvitamin D3):ti,ab,kw
- #15. (1,25-dihydroxy-vitamin D3):ti,ab,kw
- #16. (1,25 dihydroxycholecalciferol):ti,ab,kw
- #17. (1,25-dihydroxycholecalciferol):ti,ab,kw
- #18. (25-hydroxycholecalciferol):ti,ab,kw
- #19. (25 hydroxycholecalciferol):ti,ab,kw
- #20. (25 hydroxyvitamin D):ti,ab,kw
- #21. (25-hydroxy-vitamin D):ti,ab,kw
- #22. (alfacalcidol):ti,ab,kw
- #23. (calcidiol):ti,ab,kw
- #24. (calcitriol):ti,ab,kw
- #25. (calcifediol):ti,ab,kw
- #26. (calciferol):ti,ab,kw
- #27. (ergocalciferol):ti,ab,kw
- #28. (cholecalciferol):ti,ab,kw
- #29. (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)
- #30. #5 AND #29

MEDLINE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. randomized controlled trial.pt.
31. controlled clinical trial.pt.
32. randomized controlled trials.sh.
33. random allocation.sh.
34. double blind method.sh.

- 1
- 2
- 3 35. single-blind method.sh.
- 4
- 5 36. clinical trial.pt.
- 6
- 7 37. clinical trials.sh.
- 8
- 9 38. clinical trial.tw.
- 10 39. ((singl\$ or doubl\$ or treb1\$ or tripl\$) and (mask\$ or blind\$)).tw.
- 11
- 12 40. placebos.sh.
- 13
- 14 41. placebo\$.tw.
- 15
- 16 42. random\$.tw.
- 17 43. Research Design/
- 18 44. comparative study.sh.
- 19
- 20 45. evaluation studies.sh.
- 21
- 22 46. follow-up studies.sh.
- 23
- 24 47. prospective studies.sh.
- 25
- 26 48. control\$.tw.
- 27 49. prospectiv\$.tw.
- 28
- 29 50. volunteer\$.tw.
- 30
- 31 51. or/30-50
- 32 52. (animal not human).mp.
- 33
- 34 53. 46 not 47
- 35 54. 5 and 29 and 53
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

EMBASE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. random\$.tw.
31. factorial\$.tw.
32. crossover\$.tw.
33. cross over\$.tw.
34. cross-over\$.tw.

- 1
- 2
- 3 35. placebo\$.tw.
- 4
- 5 36. (doubl\$ adj blind\$.tw.
- 6
- 7 37. (singl\$ adj blind\$.tw.
- 8
- 9 38. assign\$.tw.
- 10 39. allocat\$.tw.
- 11 40. volunteer\$.tw.
- 12
- 13 41. Crossover Procedure/
- 14
- 15 42. double-blind procedure.tw.
- 16
- 17 43. Randomized Controlled Trial/
- 18 44. Single Blind Procedure/
- 19
- 20 45. or/30-44
- 21 46. (animal/ or nonhuman/) not human/
- 22
- 23 47. 45 not 46
- 24
- 25 48. 5 and 29 and 47
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 2. Modified Cochrane's risk of bias tool.

| Source of bias [#] | Low risk | High risk | Unclear | Comments |
|-------------------------------------|--------------------------|--------------------------|--------------------------|----------|
| 1. Random sequence generation | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Allocation concealment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 3. Blinding of participants | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 4. Blinding of key study personnel | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 5. Blinding of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 6. Incomplete outcome data | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 7. Selective outcome reporting | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 8. Imbalance in baseline covariates | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 9. Treatment compliance | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 10. Timing of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Overall risk of bias | Low | Moderate | High | |
| | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |

[#]See *Appendix 2* for criteria for different levels of risk.

Appendix 3. Criteria for risk of bias assessment

1. Random sequence generation

Criteria for a judgement of “Low risk”:

The investigators describe a random component in the sequence generation process such as:

- Referring to a random number table;
- Using a computer random number generator;
- Coin tossing;
- Shuffling cards or envelopes;
- Throwing dice;
- Drawing of lots;
- Minimisation. ^*Minimization may be implemented without a random element, and this is considered to be equivalent to being random.

Criteria for a judgement of “High risk”:

Sequence generation process involves some systematic, non-random approach, for example:

- sequence generated by odd or even date of birth;
- sequence generated by some rule based on date (or day) of admission;
- sequence generated by some rule based on hospital or clinic record number.

Sequence generation process involves judgement or some method of non-random categorisation of participants, for example:

- Allocation by judgement of the clinician;
- Allocation by preference of the participant;
- Allocation based on the results of a laboratory test or a series of tests;
- Allocation by availability of the intervention.

Criteria for a judgement of “Unclear risk”:

Insufficient information about sequence generation process

2. Allocation concealment

Criteria for a judgement of “Low risk”:

Participants and investigators enrolling participants could not foresee assignment because a successful method of allocation concealment, for example:

- Central allocation (including telephone, web-based, and pharmacy-controlled, randomisation);
- Sequentially numbered drug containers of identical appearance;
- Sequentially numbered, opaque, sealed envelopes.

Criteria for a judgement of “High risk”:

Participants and investigator enrolling participants could possibly foresee assignments and thus introduce selection bias, for example:

- Using an open random allocation schedule (e.g. a list of random numbers);
- Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered);
- Alternation or rotation;
- Date of birth;
- Case record number;
- Any other explicitly unconcealed procedure.

Criteria for a judgement of “Unclear risk”:

Insufficient detail to permit judgement of “Low risk” or “High risk”.

3. Blinding of participants**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of participants ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”,
- The study did not address this outcome.

4. Blinding of key study personnel**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of key study personnel (physicians/pharmacists/care givers/trial coordinators) ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

5. Blinding of outcome assessment

Criteria for a judgement of “Low risk”:

Any one of the following:

- No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;
- Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcome assessment is likely to be influenced by lack of blinding;
- Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Criteria for a judgement of “Unclear”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

6. Incomplete outcome data

Criteria for a judgement of “Low risk”:

Any one of the following:

- No missing outcome data;
- Reasons for missing outcome data unlikely to be related to true outcome;
- Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;
- The percentage of withdrawal and drop-outs does not exceed 20% with reasons documented and missing data have been imputed using appropriate methods.

Criteria for a judgement of “High risk”:

Any one of the following:

- Reason for missing outcome data is likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;
- ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation;

- Potentially inappropriate application of simple imputation.

Criteria for a judgement of “Unclear”:

- Insufficient reporting of attrition/exclusions to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

7. Selective outcome reporting:**Criteria for a judgement of “Low risk”:**

Any of the following:

- The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
- The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).

Criteria for a judgement of “High risk”:

Any one of the following:

- Not all of the study’s pre-specified primary outcomes have been reported;
- One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified;
- One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);
- One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;
- The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Criteria for a judgement of “Unclear”:

Insufficient information to permit judgement of “Low risk” or “High risk”.

8. Imbalance in baseline covariates**Criteria for a judgement of “Low risk”:**

Groups are similar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “High risk”:

Groups are obviously dissimilar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “Unclear”:

If baseline characteristics are described in the text but data are not presented.

9. Treatment compliance**Criteria for a judgement of “Low risk”:**

Participants’ compliance with the treatment allocation was measured or documented. The level of treatment compliance based on reported dosage, duration and frequency is acceptable. Analyses were performed on an intention-to-treat basis.

Criteria for a judgement of “High risk”:

Any one of the following:

- Participants' compliance with the treatment allocation was not measured;
- Over 50% of participants did not comply with the allocated treatment;
- Participants were excluded from analysis for variety of reasons, or only per protocol analysis was performed as the primary analysis.

Criteria for a judgement of “Unclear”:

Insufficient reporting in treatment compliance to permit judgement of “Low risk” or “High risk”.

10. Timly outcome assessment

Criteria for a judgement of “Low risk”:

Timing of outcome assessment is identical or closely similar for all treatment groups and for all important outcomes.

Criteria for a judgement of “High risk”:

Timing of outcome assessment is obviously different among participants due to variety reasons.

Criteria for a judgement of “Unclear”:

Insufficient reporting to permit judgement of “Low risk” or “High risk”.

Overall risk of bias

A - low risk of bias:

Low risk for all sources of bias (1-10).

B - moderate risk of bias:

One of more high risk in other sources of bias (8-10). Low risk or unclear risk for key sources of bias (1-7).

C - high risk of bias:

High risk for one or more key sources of bias (1-7).

PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted – Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 5:15

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|-----------------------------------|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| ADMINISTRATIVE INFORMATION | | | | | |
| Title | | | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Registration | 2 | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 2 |
| Authors | | | | | |
| Contact | 3a | Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Support | | | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Role of sponsor/funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| INTRODUCTION | | | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 4-5 |

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|---|-----|---|-------------------------------------|-------------------------------------|---------------------|
| | | | Yes | No | |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| METHODS | | | | | |
| Eligibility criteria | 8 | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Information sources | 9 | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5, Appendix 1. |
| STUDY RECORDS | | | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7-8 |
| Selection process | 11b | State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Data collection process | 11c | Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8 |
| Data items | 12 | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-10 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-9 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7, Appendix 2 |
| DATA | | | | | |
| Synthesis | 15a | Describe criteria under which study data will be quantitatively synthesized | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15c | Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|-----------------------------------|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (e.g., GRADE) | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

For peer review only

BMJ Open

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis (OA) An OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2019-035302.R4 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 06-Mar-2020 |
| Complete List of Authors: | Jin, Xingzhong; Southern Medical University, Zhujiang Hospital; The University of Sydney, The Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders Antony, Benny; University of Tasmania, Menzies Institute for Medical Research Wang, Xia; The University of Sydney, Institute of Bone and Joint Research Persson, Monica; University of Nottingham Faculty of Medicine and Health Sciences McAlindon, Timothy; Tufts Medical Center, Arden, Nigel; Nuffield Department of Orthopaedics, ; Srivastava, Sudeepti; King George Medical College Srivastava, Rajeshwar; King George Medical University van Middelkoop, Marienke; Erasmus MC Bierma-Zeinstra, Sita; Erasmus MC Zhang, Weiya; University of Nottingham, Academic Rheumatology Cicuttini, Flavia; Monash University, Department of Epidemiology and Preventative Medicine Ding, Changhai; University of Tasmania, Menzies Institute for Medical Research |
| Primary Subject Heading: | Rheumatology |
| Secondary Subject Heading: | Complementary medicine |
| Keywords: | PREVENTIVE MEDICINE, RHEUMATOLOGY, GENERAL MEDICINE (see Internal Medicine) |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The Effect of Vitamin D Supplementation on Pain and Physical Function in Patients with Knee Osteoarthritis (OA)

An OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis

Xingzhong Jin^{1,2}, Benny Antony³, Xia Wang⁴, Monica SM Persson^{5,6}, Timothy McAlindon⁷, Nigel Arden⁸, Sudeepti Ratan Srivastava⁹, Rajeshwar Nath Srivastava⁹, Marienke van Middelkoop¹⁰, Sita M.A. Bierma-Zeinstra¹⁰, Weiya Zhang^{5,6}, Flavia Cicuttini¹¹, Changhai Ding^{1,3,11}.

Author Affiliations

¹ Clinical Research Centre, ZhuJiang Hospital of Southern Medical University, China

² Centre for Big Data Research in Health, University of New South Wales, Australia.

³ Menzies Institute for Medical Research, University of Tasmania, Australia.

⁴ Institute of Bone & Joint Research, the University of Sydney, Australia.

⁵ Academic Rheumatology, Division of Rheumatology, Orthopaedics, and Dermatology, University of Nottingham, United Kingdom.

⁶ Arthritis Research UK Pain Centre, United Kingdom.

⁷ Tufts Medical Center, United States.

⁸ Nuffield Department Orthopaedic, Rheumatology and musculoskeletal sciences, University of Oxford, United Kingdom.

⁹ King George Medical University, India.

¹⁰ Erasmus MC, University Medical Center Rotterdam, Netherland.

¹¹ Department of Epidemiology and Preventive Medicine, Monash University, Australia

Correspondence to

- Xingzhong Jin, Centre for Big Data Research in Health, Level 2 AGSM Building, UNSW, NSW 2052, Australia. Email: xingzhong.jin@unsw.edu.au.
- Changhai Ding, Clinical Research Centre, ZhuJiang Hospital of Southern Medical University, Guangzhou, China. Email: changhai.ding@utas.edu.au

Keywords

Systematic Review; Meta-analysis; Individual Patient Data; Osteoarthritis; Vitamin D; Knee.

Abstract

Introduction

Observational data suggest vitamin D deficiency is associated with the onset and progression of knee OA. However, randomized controlled trials (RCTs) to date investigating the efficacy of vitamin D supplementation in knee OA have reported conflicting results. Further research is needed to clarify the effects of vitamin D on patient-reported outcomes and determine whether there are patient subgroups who may benefit from the supplementation. The aim of this IPD meta-analysis is to identify patient-level predictors of treatment response to vitamin D supplementation on pain and physical function.

Methods and analysis

A systematic literature search will be conducted for RCTs of vitamin D supplementation on knee OA. Authors of original RCTs will be contacted to obtain the IPD. The primary outcomes will include long-term (≥ 12 months) pain and physical function. Secondary outcomes will include medium-term (≥ 6 months and <12 months) and short-term (<6 months) pain and physical function, as well as patient global assessment, quality of life and adverse events. Potential treatment effect modifiers to be examined in the subgroup analyses include age, gender, body mass index (BMI), baseline knee pain severity and physical function, baseline vitamin D level, radiographic stage, presence of bone marrow lesions on magnetic resonance images (MRI), presence of clinical signs of local inflammation, and concomitant depressive symptoms. Both one-step and two-step modelling methods will be used to determine the possible modifiable effect of each subgroup of interest.

Ethics and dissemination

Research ethical or governance approval is exempt for this study as no new data are being collected. This study will be the first IPD meta-analysis to clarify the effect of vitamin D supplementation on clinical symptoms in different subgroups of patients with knee OA. The findings will be disseminated through peer-review publications and conference presentations.

Systematic review registration

This systematic review is registered on PROSPERO (CRD42018107740).

Strengths and limitations of this study

- This study protocol is endorsed by the OA Trial Bank, an international collaboration that initiates meta-analyses on predefined subgroups of OA patients.
- This study is the first IPD meta-analysis to identify OA patient subgroups that may benefit from vitamin D supplementation.
- IPD meta-analysis offer greater statistical power and precision than subgroup analysis in a single trial and conventional meta-analysis using aggregate data.
- Analysis may be limited to the variables that have been collected across included RCTs.

Introduction

OA is the most common joint disorder worldwide. OA is ranked as the 13th highest contributor of 310 diseases to global disability in 2015¹. In Australia, OA affects over 2.1 million people (9% of the population), costing the healthcare system over \$2.1 billion in 2015². This cost is forecasted to increase by 41% in 2030³.

The majority (83%) of the disease burden of OA is attributable to knee OA⁴, which is characterized by pain, gradual loss of articular cartilage, and structural changes such as subchondral remodelling and effusion-synovitis⁵. Currently, there are no effective disease-modifying treatments to reverse the progression of knee OA once the disease is established. A majority of patients with knee OA eventually progress to advanced stage and undergo total knee replacement⁶. There is clearly an urgent need for innovative and cost-effective approaches to slow the progression of knee OA.

Emerging observational data suggest that vitamin D insufficiency is associated with the onset and progression of knee OA⁷. The association between low serum vitamin D levels and knee OA symptoms may be explained by a direct effect of vitamin D on chondrocytes in osteoarthritic cartilage⁸, as well as indirect effects on subchondral bone, synovium, and periarticular muscle⁹. For example, vitamin D deficiency could impair the ability of bone to respond optimally to pathological bone marrow lesions (BMLs) and altered bone mineral density, therefore predisposing the knees to disease progression¹⁰. Vitamin D also may reduce synovitis in affected knees by regulating cytokine levels in the joint, leading to a reduction in the amount of effusion-synovitis in MRI¹¹. In addition, depressive symptoms is interrelated to joint pain in OA¹², and maintaining sufficient serum vitamin D may improve depression symptoms in patients with knee OA¹³.

However, evidence from RCTs have been conflicting¹⁴⁻¹⁷. A pilot RCT in India found a small but statistically significant clinical benefit for 12-month vitamin D treatment on pain and function in patients with knee OA, compared with placebo¹⁶. In contrast, a subsequent RCT from the US showed that vitamin D supplementation did not reduce knee pain or cartilage volume loss over 24 months¹⁵. Subsequently, data from RCTs in Australia¹⁷ and UK¹⁴ did not find significant clinical benefits of vitamin D supplementation for knee OA. However, there was a non-significant trend for symptom reduction (e.g. knee pain and physical function) in these RCTs. Two systematic reviews using aggregate data from these RCTs concluded that, although current evidence does not support vitamin D supplementation for reducing structural disease progression, further research is needed to clarify the effects on patient-reported

1
2
3 outcomes^{18,19}. In addition, to the best of our knowledge, no previous systematic reviews of
4 previous systematic reviews exist.
5
6

7 The null results of these RCTs could be due to a low prevalence of vitamin D deficiency in the
8 study subjects or low statistical power secondary to small sample sizes. Another possible
9 reason is that vitamin D may have an effect only in some OA phenotypes, such as those with
10 BMLs (predominant bone abnormality)²⁰, effusion-synovitis (inflammatory)²¹ or depressive
11 symptoms (psychological distress)¹³. Post hoc analyses within these RCTs^{15,21} were frequently
12 underpowered, and hence unreliable to determine the effect of vitamin D treatment on
13 subgroups of knee OA patients. A meta-analysis using IPD can increase the power of subgroup
14 analysis by combining individual data from included trials²² and therefore can quantify
15 potential effect modifier of vitamin D treatment in subgroups.
16
17
18
19
20
21
22

23 **Methods and analysis**

24 We will conduct a systematic review and IPD meta-analysis of RCTs studying the effects of
25 vitamin D supplementation in patients with symptomatic knee OA. The primary aim is to
26 identify patient-level predictors of treatment response to vitamin D supplementation, including
27 the status of vitamin D deficiency, MRI-detected bone marrow abnormalities and effusion-
28 synovitis, and clinical signs of local inflammation. The protocol of this review is registered on
29 the PROSPERO database (CRD42018107740).
30
31
32
33
34
35

36 **Study eligibility**

37 This systematic review will include studies that meet the following inclusion criteria:

38 **Type of studies**

39 RCTs that have been published in journals and reported the efficacy of vitamin D in participants
40 with knee OA will be included. Cross-over design will also be eligible and only the first phase
41 data will be included in the analysis. Both individually randomised trials and cluster
42 randomised trials will be eligible. Both open-labelled and blinded studies will be eligible. There
43 will be no language or geographical restrictions applied to study selection.
44
45
46
47
48

49 **Participants**

50 Men and women who have a diagnosis of knee OA, either according to the American College
51 of Rheumatology criteria, or on the basis of detailed clinical and/or radiographic information,
52 will be included. Studies with a subgroup of knee OA patients will also be included, provided
53 that IPD can be collected separately for the OA subgroup. Although most patients with knee
54 OA defined by the American College of Rheumatology are usually over 50 years of age, the
55
56
57
58
59
60

1
2
3 disease can occur as early as 20 years old, therefore studies with adults at 18 years of age and
4 older will be included.
5

6 7 **Interventions**

8 Only studies investigating oral supplementation of vitamin D will be included. Vitamin D
9 treatments administered subcutaneously, intraperitoneally or intravenously will not be
10 included. Both ergocalciferol (vitamin D₂) and cholecalciferol (vitamin D₃) will be eligible,
11 irrespective of preparations (tablet or capsule), dosage, regimen, and length of treatment.
12
13
14

15 16 **Comparators**

17 Oral vitamin D supplementation will be compared with control treatment including placebo or
18 usual conservative care (pain medication and/or exercise therapy if they are used in both
19 treatment and control groups).
20
21

22 23 **Outcomes**

24 The minimum criterion for inclusion is reporting pain or physical function as either primary or
25 secondary outcomes. There will be no restrictions on the duration of follow-up. Data on other
26 outcomes (e.g. patient's global assessment, quality of life, and adverse events) will be analysed
27 when feasible but will not be required for study selection.
28
29
30

31 32 **Baseline assessments**

33 As a minimum, included studies should have measured knee pain, physical function, serum
34 levels of vitamin D at baseline, and included basic patient characteristics such as age, gender,
35 and BMI.
36
37
38

39 40 **Literature search**

41 A systematic literature search for articles published from 1 January 1990 until 31 December
42 2019 will be performed by a trained review author (XJ) in the following electronic databases:
43

- 44 • Cochrane Central Register of Controlled Trials (CENTRAL);
- 45 • MEDLINE (Ovid);
- 46 • EMBASE;
- 47
- 48

49 A previous systematic review⁷ has showed that no major RCTs were conducted for vitamin D
50 and osteoarthritis by the year 1990, therefore we chose 1 January 1990 as the start date of the
51 literature search. The search strategies used for each database are listed in *Appendix 1*. All
52 retrieved articles will be exported to the reference manager *EndNote*, in which duplicates will
53 be removed electronically and manually. The remaining records will be exported to an online
54 systematic review management tool *Covidence* (Veritas Health Innovation, Melbourne,
55 Australia) and the articles will be assessed for eligibility for inclusion. In addition to the
56
57
58
59
60

1
2
3 electronic search, we will check the reference lists of included trials and previous systematic
4 reviews to identify any trials that are not retrieved from the electronic search. Review authors
5 and collaborating authors will be asked if they are aware of further relevant studies not yet
6 included. We will also search the WHO International Clinical Trial Registration Platform
7 Search Portal (www.who.int/trialsearch) to identify any relevant trials that are completed but
8 did not published the results.
9

14 **Study selection**

15 Two review authors (XJ, BA) will independently conduct study screening by assessing the
16 article titles and abstracts. Full texts of the articles will be further assessed if the information
17 from the abstract suggests that a study is eligible for inclusion. When information contained in
18 the full text is not sufficient to make a judgement on its eligibility, we will make efforts to
19 contact the corresponding authors to obtain further details. If a corresponding author is not
20 contactable after two email attempts and one phone call, the study will be deemed ineligible.
21 Any disagreement regarding the inclusion of a study will be discussed between the two review
22 authors (XJ, BA). If no consensus can be reached, a third review author will be consulted (XW)
23 to make a final decision.
24
25
26
27
28
29

31 **Extraction of aggregate data**

32 Study data extraction will be performed independently by two review authors (BA, XW).
33 Discrepancies will be resolved by a third reviewer (XJ). We will extract the following study
34 data from the included studies:
35
36
37

- 38 • General information: article title, bibliographic details, published language, and
39 funding source.
- 40
- 41 • Participants: inclusion criteria, exclusion criteria, number of participants in total and in
42 each study arm, study settings, and baseline participant characteristics (e.g. age, gender,
43 BMI).
- 44
- 45 • Intervention: type of vitamin D preparation, dose, regimen, treatment duration, type of
46 control, and co-interventions (if any).
- 47
- 48 • Outcomes: primary and secondary outcomes at the end of treatment and/or the end of
49 follow-up. Number of withdrawals and loss to follow-up. Adverse events recorded.
- 50
- 51 • Data analysis: statistical models used for data analysis, confounding factors adjusted in
52 the models, and methods used for addressing missing values.
53
54
55
56
57
58
59
60

Risk of bias assessment

The methodological quality of the included studies will be assessed using a modified version of the Cochrane's risk of bias tool²³. The modified version includes all the seven domains of the original tool, but further separates performance bias assessment into 'blinding of participants' and 'blinding of study personnel', as well as pre-specifies other sources of bias as 'balance in baseline covariates', 'treatment compliance', and 'timely outcome assessment' (*Appendix 2*). Each domain will be scored as 'low risk', 'high risk' or 'unclear' according to the criteria described in the *Appendix 3*. The overall rating of risk of bias is based on the number of domains with a 'high-risk' score. The overall rating is intended to inform readers of the risk of bias across individual studies and will not be used to weight the studies in the meta-analysis. Two review authors (XJ, XW) will independently evaluate the quality of an individual study. Any disagreement will be settled by further discussion until a consensus is reached between the two review authors.

IPD collection and transfer

The primary or corresponding authors of included trials will be invited to collaborate on the project and contribute their raw data. When we cannot reach a corresponding author after sending two emails and making two telephone calls, we will contact the co-authors listed in the article. If none of the co-authors can be contacted, we will approach the institutes, in which the trial has been conducted. All data custodians will be asked to sign a data delivery agreement, which includes items regarding IPD delivery, obligations, ownership of data, terms and conditions of the use of the data, authorship, and publications. If needed, the project coordinator (XJ) will visit the institutes of the data deliverers to retrieve the data and to sign the data delivery agreement on behalf of the OA Trial Bank (the detailed procedures of data delivery and an example of the data delivery agreement can be found on the OA Trial Bank website <https://www.oatrialbank.com/procedures/>). De-identified datasets will be accepted in any electronic format (for example, SPSS, Stata, SAS, Excel) or in paper form, provided that variables and categories are adequately labelled within the dataset or within a separate codebook. The IPD files received by the coordinator will be kept in their original version and saved on a secured password-protected server at Erasmus MC Medical University in Rotterdam. The datasets will not be used for any other research apart from that described in the license agreement.

To ensure the quality of the data, the coordinator will independently check for data consistency by comparing the summary statistics derived from the IPD received against the summary

1
2
3 results reported in the published articles. In the case of differences, the project coordinator will
4 communicate with the data deliverer via email or teleconference to resolve the discrepancy.
5
6

7 **Variables of interest**

8 The following IPD variables will be obtained (where available):
9

10 **Primary outcome variables**

11 The primary outcomes for this meta-analysis will be pain and physical function at long-term
12 follow-up (12 months or more). This definition of 'long-term effect' for knee OA treatment
13 was used in previous systematic reviews of knee OA research^{24,25}.
14
15

- 16
17 • Knee pain will be evaluated using visual analogue scale (VAS) if available, otherwise the
18 pain subscales of the Western Ontario and McMaster Universities Osteoarthritis Index
19 (WOMAC)²⁶ or the Knee injury and Osteoarthritis Outcome Score (KOOS)²⁷ will be used.
20 The pain data will be converted into a 0-100 common scale as recommended by the
21 WOMAC manual²⁸.
22
23 • Physical function will be evaluated using a validated instrument specific to knee OA, such
24 as the physical function subscales of the WOMAC or the KOOS subscales. The scores will
25 be standardised into a 0-100 scale.
26
27
28
29
30
31

32 **Secondary outcome variables**

33 Secondary outcomes will include:
34

- 35 • Medium-term (more than 6 months but less than 12 months) pain and physical function;
36
37 • Short-term (less than 6 months) pain and physical function;
38
39 • Patient global assessment at the end of study follow-up, as recommended by the
40 OMERACT-OARSI Initiative²⁹.
41
42 • Quality of life evaluated using a validated instrument, such as EQ-5D³⁰, osteoarthritis Knee
43 and Hip Quality of Life (OAKHQOL)³¹, or original instrument used in the included studies;
44
45 • Adverse events if reported, including all major and minor events such as hypocalcaemia,
46 fractures, and depression.
47
48
49
50
51

52 **Potential treatment effect moderators**

53 If data are available, we will analyse potential treatment effect modification for the following
54 variables measured at baseline:
55
56

- 57 • Radiographic stage of knee OA (mild/moderate or severe). Radiographic knee OA should
58 be staged at baseline using either the Kellgren-Lawrence (KL)³² or Osteoarthritis Research
59
60

Society International (OARSI) joint space narrowing (JSN) grading system³³. The results from the two grading systems have been shown to be highly correlated³⁴. Mild to moderate disease will be defined as a KL score ≤ 3 or an OARSI JSN score ≤ 2 , and severe disease will be a KL score of 4, or an OARSI score of 3.

- Vitamin D level (deficiency, insufficiency, or sufficiency). Vitamin D deficiency is defined as serum levels of 25(OH)D less than 30 nmol/L at baseline. Insufficiency is defined as serum 25(OH)D levels from 30 to <50 nmol/L. Serum 25(OH)D levels ≥ 50 nmol/L is considered as vitamin D sufficiency³⁵.
- Presence of BMLs (yes or no). BMLs at the patella-femoral and femoro-tibial joints should be measured by MRI using a validated scoring system, such as BLOKS (Boston Leeds Osteoarthritis Knee Score)³⁶, WORMS (Whole-Organ Magnetic Resonance Imaging Score)³⁷, or KOSS (Knee Osteoarthritis Scoring System)³⁸.
- Clinical signs of local inflammation or the presence of effusion-synovitis (yes or no). Clinical signs of local inflammation should be assessed by physical examination - tumor (swelling), dolor (pain), rubor (redness), calor (heat), and functio laesa (disturbance of function) - or by additional laboratory testing (e.g. serum c-reactive protein and erythrocyte sedimentation rate). Effusion-synovitis should be measured on either ultrasound or MRI.
- Presence of depressive symptoms or comorbid depression. Depressive symptoms are measured using a validated questionnaire, such as the Patient Health Questionnaire (PHQ-9)³⁹ and the Geriatric Depression Scale (GDS)⁴⁰.

Data synthesis and statistical methods

All statistical analysis will be conducted using R version 3.5.0 and RStudio (version 1.0.136, RStudio, Inc., Boston, MA), with R extension package ‘metafor’ for the conventional meta-analysis and two-stage IPD meta-analysis, and ‘lme4’ for the one-stage IPD meta-analysis.

Conventional meta-analysis

An aggregate data meta-analysis, using a random-effects model based on the ‘Hartung-Knapp-Sidik-Jonkman (HKSJ)’ method⁴¹, will be performed to estimate the treatment effect of vitamin D over control. If an included study is a cluster RCT, results will be corrected using previously established procedures⁴². The results will be compared with the IPD meta-analysis findings as sensitivity analyses.

Heterogeneity will be assessed by inspecting the forest plots and tested by χ^2 test. A result of $p < 0.10$ will be defined as evidence of significant heterogeneity across studies. I^2 test will be

1
2
3 used to estimate the extent of inconsistency across studies that is due to heterogeneity⁴³. A
4 result of over 30% and 50% represents moderate and substantial heterogeneity, respectively.
5 Sources of heterogeneity will be explored by excluding individual trials causing an I^2 score
6 below 50%.
7
8
9

10 If 10 trials or more trials are available, we will use a Doi plot (normal quantile versus effect
11 size plot) explore publication bias and ‘small-study effects’⁴⁴. Asymmetry in the Doi plot will
12 be detected and quantified by the LFK index. A value beyond +/- 1 will be deemed consistent
13 with asymmetry, thus having considerable small-study effects⁴⁴.
14
15
16

17 **IPD meta-analysis**

18 IPD from included trials will be recoded and formatted in a consistent way to permit re-
19 analysis. A new variable will be created to indicate the trial in which the IPD are collected.
20 The method used to handle missing data will depend on the mechanism causing the
21 missingness. If no explanation is known for the reason of missing data, they will be assumed
22 to be missing at random. We will use the R MICE package⁴⁵ for multiple imputation and the
23 imputation model will include all available patient variables to help predict missing data for
24 the variables of interest within each study dataset. The imputation procedure will use 20
25 imputed datasets. A sensitivity analyses will be performed restricting to participants without
26 missing data (complete case analysis).
27
28
29
30
31
32
33
34

35 Both the treatment effect of vitamin D supplementation and the effect of potential moderators
36 will be studied in the IPD meta-analyses. The treatment effect of vitamin D will be measured
37 using the mean difference in knee pain and physical function between treatment and control
38 based on the intention-to-treat principle. The interaction between the treatment and a potential
39 moderator will be used to identify the effect of the moderator. Interaction effects with $p < 0.05$
40 will be considered statistically significant and 95% confidence intervals of the effects will be
41 provided. The IPD meta-analyses will be undertaken using both the one-stage and two-stage
42 approaches. We will use the one-stage approach as the primary analysis to avoid assumptions
43 of within-study normality and known within-study variance⁴⁶. We will and compare the results
44 to the two-stage approach to assess consistency in a sensitivity analysis.
45
46
47
48
49
50
51
52

53 ***One-stage modelling***

54 The one-stage mixed-effects IPD meta-analysis approach will take into account both study
55 level and subject-level covariates. Subject -level covariates will be centred to the mean of the
56 covariate in each trial to avoid ecological bias. Three multilevel regression models will be built,
57 the first to examine the summary treatment effect (difference between vitamin D and control),
58
59
60

1
2
3 the second to evaluate each of the mentioned moderators on treatment effect, and the third to
4 assess the true effect of one moderator independent of other moderators.
5
6

7 The first model will include outcome measure (e.g. pain score at follow-up) as a dependent
8 variable, treatment (vitamin D or control), baseline subject-level covariate (e.g. pain score) and
9 confounders (age, gender and BMI) as fixed-effect independent variables, adjusted for study
10 identifier (random intercept). The partial regression coefficient of the treatment will be used to
11 compare to the conventional meta-analysis.
12
13
14

15
16 The second model will further add the moderator of interest (e.g. radiographic stage of the
17 disease) and interaction term between the treatment and study-centred values of the moderator
18 in the fixed-effect of the first model. The regression coefficient of the interaction term will be
19 used to quantify the impact of the moderator on treatment effect.
20
21
22

23 If there are two or more moderators that have a statistically significant interaction with the
24 treatment effect, these moderators will be incorporated in the third model. Multicollinearity
25 between moderators will be tested before building the third model. A correlation coefficient
26 $r > 0.80$ will indicate that multiple collinearity exists between the two moderators, of which the
27 one that has less measurement error will be included in the model.
28
29
30
31

32 ***Two-stage modelling***

33 In the first stage, treatment effect and variance are derived from separate analysis in each
34 study. An analysis of covariance (ANCOVA) model adjusted for baseline covariates (age,
35 gender, BMI, as well as knee pain or function), will be used to obtain the treatment effect and
36 variance within each study separately. The effect of a moderator and its variance within each
37 study will be obtained by adding the interaction term between treatment effect and the
38 moderator into the model. In the second stage, the treatment effect and its variances obtained
39 from the first stage will be pooled across studies using a random-effects model⁴¹. The result
40 of this model is a summary estimate of the treatment effect of vitamin D versus control. The
41 effect of a moderator will be calculated by pooling the regression coefficient and variance of
42 the interaction term between the treatment and the moderator using a similar model. If two or
43 more interaction terms are statistically significant, these moderators will be incorporated in a
44 further model to evaluate the independent effect of these moderators.
45
46
47
48
49
50
51
52
53
54

55 **Patient and public involvement**

56 We do not directly include patient and public involvement in this study, but the design of
57 included randomised controlled trials may involve patients.
58
59
60

Discussion

Vitamin D supplementation may improve pain and function in patients with knee OA; however, the evidence from observational studies and RCTs are controversial^{7,18}. In a few existing RCTs in patients with symptomatic knee OA^{14,16,17}, small to modest improvement in knee pain and physical function were observed in participants receiving vitamin D supplementation, but the treatment response varies considerably and the effects were not statistically significant when compared to placebo. The broad variation in treatment response could be a result of the fact that knee OA is a highly heterogenous disease with multiple aetiologies⁴⁷. Vitamin D may therefore be more effective in a subset of patients with specific characteristics than others. The purpose of the proposed IPD meta-analysis is to evaluate the treatment response of vitamin D supplementation on pain and physical function for knee OA in specific subsets of patients according to disease severity, vitamin D levels, presence of BMLs, inflammatory signs and depressive symptoms, over both short- and long-term follow-up.

Meta-analysis is considered by some to be the grandmother of ‘big data’⁴⁸ and an integrated part of precision medicine⁴⁹. It is a cost-effective approach to identify potential moderators of treatment response at a patient level, which is not possible with subgroup analyses in a single trial or conventional meta-analysis with aggregate data⁵⁰. Subgroup analyses within individual trials are often underpowered to generate reliable findings. In contrast, IPD meta-analysis techniques increase the statistical power of the study by combining individual observation data from multiple trials with the same treatment²². This offers greater precision in analysing moderators of treatment response and offers the potential to analyse a greater number of moderators. In conventional meta-analysis, meta-regression analysis may be used to examine differences in the types of patients enrolled in individual trials, but is potentially problematic. Meta-regression analysis may make incorrect inferences about individual characteristics based upon aggregate baseline statistics reported in trial publications⁵¹. This is also known as ecological fallacy⁵², where the relationship between the effect estimate and average patient characteristics across trials may not be the same as the relationship within individual trials.

Identifying different phenotypes of knee OA is currently a popular subject of research in the field. Different phenotyping strategies have been proposed based on risk factors from epidemiological studies⁵³, anatomical abnormalities on modern imaging⁵⁴, or molecular abnormalities related to pathological mechanisms⁵⁵. While there is currently no standardised classification system for knee OA phenotypes⁵, we believe that disease phenotypes are most meaningful when they reflect differential treatment effects. IPD meta-analysis provides an

1
2
3 opportunity to assess the effect of treatments on subtypes or phenotypes of patients with knee
4 OA according to predefined set of characteristics. The current proposed IPD meta-analysis
5 attempts to differentiate subgroups by identifying subtypes of patients that respond better to
6 vitamin D supplementation on pain and physical function.
7
8
9

10 **Strengths and limitations**

11 Several challenges may present when conducting an IPD meta-analysis. First, although IPD
12 meta-analyses usually offer sufficient statistical power to examine moderators of treatment
13 response, not all RCTs measure potential moderators of interest or measure them in the same
14 way. This may limit the analysis to only exploring moderators that have been collected across
15 studies. The current protocol attempts to minimise this risk by including moderators that are
16 commonly reported in OA research. In addition, there are expected barriers to accessing data,
17 such as the authors of included trials not being able to be contacted, or the authors losing access
18 to raw data or not choosing to collaborate, may introduce selection bias into the IPD meta-
19 analysis. However, this could be examined in sensitivity analyses by comparing the results to
20 the conventional meta-analysis or be addressed using frameworks that combine IPD and
21 aggregate data in a meta-analysis⁵⁶.
22
23
24
25
26
27
28
29
30

31 The benefits of using IPD meta-analysis techniques greatly outweigh the challenges of using
32 this intensive method. Previous RCTs and systematic reviews have not had sufficient power to
33 thoroughly examine the differential treatment response of vitamin D supplementation in
34 different subsets of patients with knee OA. The results of this project have a high potential to
35 provide important evidence to guide subgroup-specific treatment decisions in clinical practice
36 to improve therapeutic effectiveness.
37
38
39
40
41

42 **Status of project**

43 Currently, literature search in the electronic databases has been commenced.
44
45

46 **Abbreviations**

47 OA: osteoarthritis; IPD: individual patient data; RCT: randomised controlled trial; BMI: body
48 mass index; MRI: magnetic resonance imaging; BMLs: bone marrow lesions; JSN: joint space
49 narrowing; OARSI: Osteoarthritis Research Society International.
50
51
52
53
54
55
56
57
58
59
60

Additional Information

Acknowledgement

We acknowledge the University of Sydney China Study Centre for providing short-term travel support to establish international collaboration for this project.

Ethics approval and consent to participate

Research ethical or governance approval is exempt for this study as no new data are being collected.

Availability of data and material

Erasmus MC intends to create a central databank including data from several randomised clinical trials evaluating one or more interventions in patients with osteoarthritis of the knee or hip (the OA Trial Bank) in order to enable researchers to perform meta-analyses on individual patient data to define sub-groups that are specifically responsive to certain treatments. Data request for future research using data deposited in the OA Trial Bank can be directed to <https://www.oatrialbank.com/contact/>

Authors contributions

All authors were involved in the study design and all will contribute to the interpretation of the results. CD, BA and XJ conceived this study. WZ and MP provided methodological support for statistical analysis. XJ and BA will contact the potential data delivers and will coordinate the project. CD, FC, TM, NA, RNS and SRS will deliver relevant data from their completed trials. SBZ and MM will facilitate legal agreement for data transfer and provide database management at the OA Trial Bank. XJ, BA and XW will perform the study selection, risk of bias assessment, data collection and analysis. All authors contributed to writing of this manuscript and approved the final submission.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors declare that they have no competing interests.

Word count

Abstract: 294, **Main text:** 4095, **References:** 56

References

1. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* 2016;388(10053):1545–602.
2. Australian Bureau of Statistics. 2014-15 National Health Survey. Canberra: Australian Bureau of Statistics; 2017.
3. Ackerman IN, Pratt C, Gorelik A, Liew D. Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population-Level Analysis. *Arthritis Care Res* 2018;70(6):877–83.
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012;380(9859):2163–96.
5. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for Standardized Definitions of Osteoarthritis and Risk Stratification for Clinical Trials and Clinical Use. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2015;23(8):1233–41.
6. Australian Orthopaedic Association National Joint Replacement Registry. Annual Report 2012. Adelaide, Australia: AOA; 2012.
7. Cao Y, Winzenberg T, Nguo K, Lin J, Jones G, Ding C. Association between serum levels of 25-hydroxyvitamin D and osteoarthritis: a systematic review. *Rheumatology* 2013;ket132.
8. Garfinkel RJ, Dilisio MF, Agrawal DK. Vitamin D and Its Effects on Articular Cartilage and Osteoarthritis. *Orthop J Sports Med* [Internet] 2017 [cited 2018 Oct 12];5(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480771/>
9. Zhang FF, Drihan JB, Lo GH, et al. Vitamin D Deficiency Is Associated with Progression of Knee Osteoarthritis. *J Nutr* 2014;144(12):2002–8.
10. Bellido M, Lugo L, Roman-Blas JA, et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. *Osteoarthritis Cartilage* 2011;19(10):1228–36.
11. Wang X, Cicuttini F, Jin X, et al. Effect of vitamin D on effusion-synovitis in knee osteoarthritis: a randomized controlled trial. *Arthritis Rheumatol* 2015;67:439–40.
12. Sharma A, Kudesia P, Shi Q, Gandhi R. Anxiety and depression in patients with osteoarthritis: impact and management challenges. *Open Access Rheumatol Res Rev* 2016;8:103–13.
13. Zheng S, Tu L, Cicuttini F, et al. Effect of Vitamin D Supplementation on Depressive Symptoms in Patients With Knee Osteoarthritis. *J Am Med Dir Assoc* 2018;
14. Arden NK, Cro S, Sheard S, et al. The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial. *Osteoarthritis Cartilage* 2016;24(11):1858–66.

15. McAlindon T, LaValley M, Schneider E, et al. Effect Of Vitamin D Supplementation On Progression Of Knee Pain And Cartilage Volume Loss In Patients With Symptomatic Osteoarthritis. A Randomized Controlled Trial. *JAMA J Am Med Assoc* 2013;309(2):155–62.
16. Sanghi D, Mishra A, Sharma AC, et al. Does Vitamin D Improve Osteoarthritis of the Knee: A Randomized Controlled Pilot Trial. *Clin Orthop Relat Res* 2013;471(11):3556–62.
17. Jin X, X J, G J, et al. Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial. 2016; Available from: <http://doi.org/10.1001/jama.2016.1961>
18. Hussain S, Singh A, Akhtar M, Najmi AK. Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials. *Rheumatol Int* 2017;37(9):1489–98.
19. Diao N, Yang B, Yu F. Effect of vitamin D supplementation on knee osteoarthritis: A systematic review and meta-analysis of randomized clinical trials. *Clin Biochem* 2017;50(18):1312–6.
20. Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. *Radiol Clin* 2004;42(1):1–9.
21. Wang X, Cicuttini F, Jin X, et al. Knee effusion-synovitis volume measurement and effects of vitamin D supplementation in patients with knee osteoarthritis. *Osteoarthritis Cartilage* 2017;25(8):1304–1312.
22. Groenwold RHH, Donders ART, Heijden GJMG van der, Hoes AW, Rovers MM. Confounding of Subgroup Analyses in Randomized Data. *Arch Intern Med* 2009;169(16):1532–4.
23. Jørgensen L, Paludan-Müller AS, Laursen DRT, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. *Syst Rev* [Internet] 2016 [cited 2018 Oct 11];5. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862216/>
24. Charlesworth J, Fitzpatrick J, Perera NKP, Orchard J. Osteoarthritis- a systematic review of long-term safety implications for osteoarthritis of the knee. *BMC Musculoskelet Disord* 2019;20(1):151.
25. van Middelkoop M, Arden NK, Atchia I, et al. The OA Trial Bank: meta-analysis of individual patient data from knee and hip osteoarthritis trials show that patients with severe pain exhibit greater benefit from intra-articular glucocorticoids. *Osteoarthritis Cartilage* 2016;24(7):1143–52.
26. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. *Arthritis Care Res* 2001;45(5):453–61.

- 1
- 2
- 3
- 4 27. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) -
- 5 validation and comparison to the WOMAC in total knee replacement. *Health Qual Life*
- 6 *Outcomes* 2003;1:17.
- 7
- 8 28. Bellamy N. WOMAC osteoarthritis index: user guide IV. 2000.
- 9
- 10 29. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative:
- 11 Osteoarthritis Research Society International set of responder criteria for osteoarthritis
- 12 clinical trials revisited. *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2004;12(5):389–99.
- 13
- 14 30. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L
- 15 compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life*
- 16 *Res* 2013;22(7):1717–27.
- 17
- 18 31. Rat A-C, Coste J, Pouchot J, et al. OAKHQOL: a new instrument to measure quality of
- 19 life in knee and hip osteoarthritis. *J Clin Epidemiol* 2005;58(1):47–55.
- 20
- 21 32. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. *Ann Rheum Dis*
- 22 1957;16(4):494–502.
- 23
- 24 33. Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised.
- 25 *Osteoarthritis Cartilage* 2007;15 Suppl A:A1-56.
- 26
- 27 34. Gudbergesen H, Lohmander LS, Jones G, et al. Correlations between radiographic
- 28 assessments and MRI features of knee osteoarthritis – a cross-sectional study.
- 29 *Osteoarthritis Cartilage* 2013;21(4):535–43.
- 30
- 31 35. Scragg R. Emerging Evidence of Thresholds for Beneficial Effects from Vitamin D
- 32 Supplementation. *Nutrients* 2018;10(5).
- 33
- 34 36. Hunter DJ, Lo GH, Gale D, Grainger AJ, Guermazi A, Conaghan PG. The reliability of a
- 35 new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion
- 36 assessment: BLOKS (Boston Leeds Osteoarthritis Knee Score). *Ann Rheum Dis*
- 37 2008;67(2):206–11.
- 38
- 39 37. Peterfy CG, Guermazi A, Zaim S, et al. Whole-Organ Magnetic Resonance Imaging
- 40 Score (WORMS) of the knee in osteoarthritis. *Osteoarthritis Cartilage* 2004;12(3):177–
- 41 90.
- 42
- 43 38. Kornaat PR, Ceulemans RYT, Kroon HM, et al. MRI assessment of knee osteoarthritis:
- 44 Knee Osteoarthritis Scoring System (KOSS)--inter-observer and intra-observer
- 45 reproducibility of a compartment-based scoring system. *Skeletal Radiol* 2005;34(2):95–
- 46 102.
- 47
- 48 39. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med* 2001;16(9):606–
- 49 13.
- 50
- 51 40. Montorio I, Izal M. The Geriatric Depression Scale: a review of its development and
- 52 utility. *Int Psychogeriatr* 1996;8(1):103–12.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 41. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for
5 random effects meta-analysis is straightforward and considerably outperforms the
6 standard DerSimonian-Laird method. *BMC Med Res Methodol* 2014;14(1):25.
- 7
- 8 42. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews*
9 *of Interventions version 6.0 (updated July 2019)* [Internet]. Cochrane; 2019. Available
10 from: www.training.cochrane.org/handbook
- 11
- 12 43. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
13 analyses. *BMJ* 2003;327(7414):557–60.
- 14
- 15 44. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative
16 method for detecting bias in meta-analysis. *Int J Evid Based Healthc* 2018;16(4):195–
17 203.
- 18
- 19 45. Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained
20 Equations in R. *J Stat Softw* 2011;45(3).
- 21
- 22 46. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage
23 and two-stage approaches, and why they may differ. *Stat Med* 2017;36(5):855–75.
- 24
- 25 47. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and
26 reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and
27 Therapeutic Criteria Committee of the American Rheumatism Association. *Arthritis*
28 *Rheum* 1986;29(8):1039–49.
- 29
- 30 48. Gurevitch J, Koricheva J, Nakagawa S, Stewart G. Meta-analysis and the science of
31 research synthesis. *Nature* 2018;555(7695):175–82.
- 32
- 33 49. Cahan A, Cimino JJ. Improving precision medicine using individual patient data from
34 trials. *CMAJ Can Med Assoc J* 2017;189(5):E204–7.
- 35
- 36 50. Stewart LA, Tierney JF. To IPD or not to IPD?: Advantages and Disadvantages of
37 Systematic Reviews Using Individual Patient Data. *Eval Health Prof* 2002;25(1):76–97.
- 38
- 39 51. Reade MC, Delaney A, Bailey MJ, Angus DC. Bench-to-bedside review: Avoiding
40 pitfalls in critical care meta-analysis – funnel plots, risk estimates, types of heterogeneity,
41 baseline risk and the ecologic fallacy. *Crit Care* 2008;12(4):220.
- 42
- 43 52. Idrovo AJ. Three Criteria for Ecological Fallacy. *Environ Health Perspect*
44 2011;119(8):a332.
- 45
- 46 53. Felson DT. Identifying Different Osteoarthritis Phenotypes through Epidemiology.
47 *Osteoarthr Cartil OARS Osteoarthr Res Soc* 2010;18(5):601–4.
- 48
- 49 54. Deveza LA, Melo L, Yamato TP, Mills K, Ravi V, Hunter DJ. Knee osteoarthritis
50 phenotypes and their relevance for outcomes: a systematic review. *Osteoarthritis*
51 *Cartilage* 2017;25(12):1926–41.
- 52
- 53 55. van Spil WE, Jansen NWD, Bijlsma JWJ, et al. Clusters within a wide spectrum of
54 biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals
55 with very early symptomatic osteoarthritis. *Osteoarthritis Cartilage* 2012;20(7):745–54.
- 56
- 57
- 58
- 59
- 60

- 1
2
3 56. Riley RD, Lambert PC, Staessen JA, et al. Meta-analysis of continuous outcomes
4 combining individual patient data and aggregate data. Stat Med 2008;27(11):1870–93.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 1. Search strategy

Cochrane CENTRAL

- #1. MeSH descriptor Osteoarthritis explode all trees
- #2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*):ti,ab,kw
- #3. (degenerative near/2 arthritis):ti,ab,kw
- #4. coxarthrosis:ti,ab,kw
- #5. (#1 OR #2 OR #3 OR #4)
- #6. MeSH descriptor vitamin D explode all trees
- #7. (vitamin D):ti,ab,kw
- #8. (vitamin D2):ti,ab,kw
- #9. (vitamin D3):ti,ab,kw
- #10. (1-alpha hydroxyvitamin D3):ti,ab,kw
- #11. (1-alpha-hydroxy-vitamin D3):ti,ab,kw
- #12. (1-alpha hydroxycalciferol):ti,ab,kw
- #13. (1-alpha-hydroxy-calciferol):ti,ab,kw
- #14. (1,25 dihydroxyvitamin D3):ti,ab,kw
- #15. (1,25-dihydroxy-vitamin D3):ti,ab,kw
- #16. (1,25 dihydroxycholecalciferol):ti,ab,kw
- #17. (1,25-dihydroxycholecalciferol):ti,ab,kw
- #18. (25-hydroxycholecalciferol):ti,ab,kw
- #19. (25 hydroxycholecalciferol):ti,ab,kw
- #20. (25 hydroxyvitamin D):ti,ab,kw
- #21. (25-hydroxy-vitamin D):ti,ab,kw
- #22. (alfacalcidol):ti,ab,kw
- #23. (calcidiol):ti,ab,kw
- #24. (calcitriol):ti,ab,kw
- #25. (calcifediol):ti,ab,kw
- #26. (calciferol):ti,ab,kw
- #27. (ergocalciferol):ti,ab,kw
- #28. (cholecalciferol):ti,ab,kw
- #29. (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)
- #30. #5 AND #29

MEDLINE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. randomized controlled trial.pt.
31. controlled clinical trial.pt.
32. randomized controlled trials.sh.
33. random allocation.sh.
34. double blind method.sh.

- 1
- 2
- 3 35. single-blind method.sh.
- 4
- 5 36. clinical trial.pt.
- 6
- 7 37. clinical trials.sh.
- 8
- 9 38. clinical trial.tw.
- 10 39. ((singl\$ or doubl\$ or treb1\$ or tripl\$) and (mask\$ or blind\$)).tw.
- 11
- 12 40. placebos.sh.
- 13
- 14 41. placebo\$.tw.
- 15
- 16 42. random\$.tw.
- 17 43. Research Design/
- 18 44. comparative study.sh.
- 19
- 20 45. evaluation studies.sh.
- 21
- 22 46. follow-up studies.sh.
- 23
- 24 47. prospective studies.sh.
- 25
- 26 48. control\$.tw.
- 27 49. prospectiv\$.tw.
- 28
- 29 50. volunteer\$.tw.
- 30
- 31 51. or/30-50
- 32 52. (animal not human).mp.
- 33
- 34 53. 46 not 47
- 35 54. 5 and 29 and 53
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

EMBASE (via Ovid)

1. exp osteoarthritis/
2. (osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3. (degenerative adj2 arthritis).ti,ab.
4. coxarthrosis.ti,ab.
5. or/1-4
6. exp Vitamin D/
7. vitamin D.tw.
8. vitamin D2.tw.
9. vitamin D3.tw.
10. 1-alpha hydroxyvitamin D3.tw.
11. 1-alpha-hydroxy-vitamin D3.tw.
12. 1-alpha hydroxycalciferol.tw.
13. 1-alpha-hydroxy-calciferol.tw.
14. 1,25 dihydroxyvitamin D3.tw.
15. 1,25-dihydroxy-vitamin D3.tw.
16. 1,25 dihydroxycholecalciferol.tw.
17. 1,25-dihydroxycholecalciferol.tw.
18. 25-hydroxycholecalciferol.tw.
19. 25 hydroxycholecalciferol.tw.
20. 25 hydroxyvitamin D.tw.
21. 25-hydroxy-vitamin D.tw.
22. alfacalcidol.tw.
23. calcidiol.tw.
24. calcitriol.tw.
25. calcifediol.tw.
26. calciferol.tw.
27. ergocalciferol.tw.
28. cholecalciferol.tw.
29. or/6-28
30. random\$.tw.
31. factorial\$.tw.
32. crossover\$.tw.
33. cross over\$.tw.
34. cross-over\$.tw.

- 1
- 2
- 3 35. placebo\$.tw.
- 4
- 5 36. (doubl\$ adj blind\$.tw.
- 6
- 7 37. (singl\$ adj blind\$.tw.
- 8
- 9 38. assign\$.tw.
- 10 39. allocat\$.tw.
- 11 40. volunteer\$.tw.
- 12
- 13 41. Crossover Procedure/
- 14
- 15 42. double-blind procedure.tw.
- 16
- 17 43. Randomized Controlled Trial/
- 18 44. Single Blind Procedure/
- 19
- 20 45. or/30-44
- 21 46. (animal/ or nonhuman/) not human/
- 22
- 23 47. 45 not 46
- 24
- 25 48. 5 and 29 and 47
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 2. Modified Cochrane's risk of bias tool.

| Source of bias [#] | Low risk | High risk | Unclear | Comments |
|-------------------------------------|--------------------------|--------------------------|--------------------------|----------|
| 1. Random sequence generation | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Allocation concealment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 3. Blinding of participants | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 4. Blinding of key study personnel | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 5. Blinding of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 6. Incomplete outcome data | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 7. Selective outcome reporting | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 8. Imbalance in baseline covariates | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 9. Treatment compliance | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| 10. Timing of outcome assessment | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Overall risk of bias | Low | Moderate | High | |
| | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |

[#]See *Appendix 2* for criteria for different levels of risk.

Appendix 3. Criteria for risk of bias assessment

1. Random sequence generation

Criteria for a judgement of “Low risk”:

The investigators describe a random component in the sequence generation process such as:

- Referring to a random number table;
- Using a computer random number generator;
- Coin tossing;
- Shuffling cards or envelopes;
- Throwing dice;
- Drawing of lots;
- Minimisation. ^*Minimization may be implemented without a random element, and this is considered to be equivalent to being random.

Criteria for a judgement of “High risk”:

Sequence generation process involves some systematic, non-random approach, for example:

- sequence generated by odd or even date of birth;
- sequence generated by some rule based on date (or day) of admission;
- sequence generated by some rule based on hospital or clinic record number.

Sequence generation process involves judgement or some method of non-random categorisation of participants, for example:

- Allocation by judgement of the clinician;
- Allocation by preference of the participant;
- Allocation based on the results of a laboratory test or a series of tests;
- Allocation by availability of the intervention.

Criteria for a judgement of “Unclear risk”:

Insufficient information about sequence generation process

2. Allocation concealment

Criteria for a judgement of “Low risk”:

Participants and investigators enrolling participants could not foresee assignment because a successful method of allocation concealment, for example:

- Central allocation (including telephone, web-based, and pharmacy-controlled, randomisation);
- Sequentially numbered drug containers of identical appearance;
- Sequentially numbered, opaque, sealed envelopes.

Criteria for a judgement of “High risk”:

Participants and investigator enrolling participants could possibly foresee assignments and thus introduce selection bias, for example:

- Using an open random allocation schedule (e.g. a list of random numbers);
- Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered);
- Alternation or rotation;
- Date of birth;
- Case record number;
- Any other explicitly unconcealed procedure.

Criteria for a judgement of “Unclear risk”:

Insufficient detail to permit judgement of “Low risk” or “High risk”.

3. Blinding of participants**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of participants ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”,
- The study did not address this outcome.

4. Blinding of key study personnel**Criteria for a judgement of “Low risk”:**

Any one of the following:

- No blinding, but the review authors judge that the outcomes are not likely to be influenced by lack of blinding;
- Blinding of key study personnel (physicians/pharmacists/care givers/trial coordinators) ensured, and unlikely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcomes are likely to be influenced by lack of blinding;
- Blinding of key study personnel attempted, but likely that the blinding could have been broken;
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

Criteria for a judgement of “Unclear risk”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

5. Blinding of outcome assessment

Criteria for a judgement of “Low risk”:

Any one of the following:

- No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;
- Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

Criteria for a judgement of “High risk”:

Any one of the following:

- No blinding or incomplete blinding, and the outcome assessment is likely to be influenced by lack of blinding;
- Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Criteria for a judgement of “Unclear”:

Any one of the following:

- Insufficient information to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

6. Incomplete outcome data

Criteria for a judgement of “Low risk”:

Any one of the following:

- No missing outcome data;
- Reasons for missing outcome data unlikely to be related to true outcome;
- Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;
- The percentage of withdrawal and drop-outs does not exceed 20% with reasons documented and missing data have been imputed using appropriate methods.

Criteria for a judgement of “High risk”:

Any one of the following:

- Reason for missing outcome data is likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;
- For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;
- ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation;

- Potentially inappropriate application of simple imputation.

Criteria for a judgement of “Unclear”:

- Insufficient reporting of attrition/exclusions to permit judgement of “Low risk” or “High risk”;
- The study did not address this outcome.

7. Selective outcome reporting:**Criteria for a judgement of “Low risk”:**

Any of the following:

- The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
- The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).

Criteria for a judgement of “High risk”:

Any one of the following:

- Not all of the study’s pre-specified primary outcomes have been reported;
- One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified;
- One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);
- One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;
- The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Criteria for a judgement of “Unclear”:

Insufficient information to permit judgement of “Low risk” or “High risk”.

8. Imbalance in baseline covariates**Criteria for a judgement of “Low risk”:**

Groups are similar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “High risk”:

Groups are obviously dissimilar at baseline regarding demographics, severity of pain, and value of main outcome measure(s).

Criteria for a judgement of “Unclear”:

If baseline characteristics are described in the text but data are not presented.

9. Treatment compliance**Criteria for a judgement of “Low risk”:**

Participants’ compliance with the treatment allocation was measured or documented. The level of treatment compliance based on reported dosage, duration and frequency is acceptable. Analyses were performed on an intention-to-treat basis.

Criteria for a judgement of “High risk”:

Any one of the following:

- Participants' compliance with the treatment allocation was not measured;
- Over 50% of participants did not comply with the allocated treatment;
- Participants were excluded from analysis for variety of reasons, or only per protocol analysis was performed as the primary analysis.

Criteria for a judgement of “Unclear”:

Insufficient reporting in treatment compliance to permit judgement of “Low risk” or “High risk”.

10. Timly outcome assessment

Criteria for a judgement of “Low risk”:

Timing of outcome assessment is identical or closely similar for all treatment groups and for all important outcomes.

Criteria for a judgement of “High risk”:

Timing of outcome assessment is obviously different among participants due to variety reasons.

Criteria for a judgement of “Unclear”:

Insufficient reporting to permit judgement of “Low risk” or “High risk”.

Overall risk of bias

A - low risk of bias:

Low risk for all sources of bias (1-10).

B - moderate risk of bias:

One of more high risk in other sources of bias (8-10). Low risk or unclear risk for key sources of bias (1-7).

C - high risk of bias:

High risk for one or more key sources of bias (1-7).

PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted – Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 5:15

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|-----------------------------------|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| ADMINISTRATIVE INFORMATION | | | | | |
| Title | | | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Registration | 2 | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 2 |
| Authors | | | | | |
| Contact | 3a | Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |
| Support | | | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| Role of sponsor/funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 15 |
| INTRODUCTION | | | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 4-5 |

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|---|-----|---|-------------------------------------|-------------------------------------|---------------------|
| | | | Yes | No | |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| METHODS | | | | | |
| Eligibility criteria | 8 | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Information sources | 9 | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 5, Appendix 1. |
| STUDY RECORDS | | | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7-8 |
| Selection process | 11b | State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 6 |
| Data collection process | 11c | Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8 |
| Data items | 12 | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-10 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 8-9 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 7, Appendix 2 |
| DATA | | | | | |
| Synthesis | 15a | Describe criteria under which study data will be quantitatively synthesized | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10-12 |
| | 15c | Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

| Section/topic | # | Checklist item | Information reported | | Line number(s) |
|--|----|---|-------------------------------------|-------------------------------------|----------------|
| | | | Yes | No | |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Page 10 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (e.g., GRADE) | <input type="checkbox"/> | <input checked="" type="checkbox"/> | N/A |

For peer review only